





The Implementation, Impact and Effectiveness of Surveillance 


















A thesis submitted in partial fulfilment of the requirements of the University of the West of England, 










Department of Applied Sciences, Faculty of Health and Applied Sciences, Frenchay Campus, 










I can confirm that this thesis was written by me and in my own words, based on the research I have 
undertaken during the course of my Professional Doctorate in Biomedical Science. I have not 
copied from anyone else’s work and all work is referenced in accordance with the University of the 
West of England (UWE) Rules and Regulations. I have fully read and understood the assessment 




Name: Jennifer Henderson 
 
Signature:   
 
 




























Foremost, I would like to thank Dr. Holly Ciesielczuk, whose continued support and prompt 
feedback has enabled me to complete this professional doctorate in under the allocated timeframe 
set by UWE. 
I would also like to thank Dr. Mark Wilks and Dr. Shona Nelson, who have provided me with 
support and direction throughout the duration of the course. 
 
Besides my supervisors, I would like to acknowledge my friends and colleagues at Barts Health 
Trust for their encouragement and support, with a special thank you to Martina Cummins and the 
Infection and Prevention Control Department for their assistance with the point prevalence study.  
 
Thank you to the laboratories for the provision of isolates required for the evaluation of the in-house 
PCR including; The Royal Marsden NHS Foundation Trust, London, Guy’s and St Thomas’ NHS 
Foundation Trust, London, Queen Elizabeth Hospital, London, St George’s Hospital, London, HCA 
Healthcare, London and Southmead Hospital, Bristol and Dr. David Wareham for providing 
confirmatory testing of discrepant results. 
 
Finally, I would like to thank my close family and friends for always expressing an interest in my 



























Carbapenems are broad spectrum antibiotics often reserved for the critically ill. Their increased 
and, often, inappropriate use, has led to the development of resistance, through acquisition of 
carbapenemase enzymes. There are five carbapenemases that predominate worldwide (the “big 
five”): VIM, NDM, KPC, OXA-48 and IMP. However, the true prevalence of carbapenemases is 
unknown. Therefore, prompt detection, targeted screening, effective control measures and 
surveillance are required to reduce further transmission of these multi-drug resistant organisms. 
Each of these were investigated as part of this project. 
 
A systematic review was performed to determine how hospitals in England were implementing the 
Public Health England (PHE) toolkit for the detection, management and control of 
Enterobacteriaceae. Following this, carbapenemase prevalence across Barts Health NHS Trust 
(BHT) was determined by conducting a point prevalence (inpatient) study and a community study, 
using a published PCR assay that detects the “big five” enzymes.  Isolates from these studies and 
various outbreaks were then investigated by whole genome sequencing. Finally, the value of 
sequential screening was assessed by reviewing carbapenemase screening data.  
 
The systematic review identified five hospitals which had partially implemented the PHE toolkit, 
with prior hospitalisation deemed a common risk factor for carbapenemase carriage at these sites 
and at BHT. The “big five” PCR identified an inpatient carbapenemase prevalence of 3.1% and a 
community prevalence of 0.5%. Previous hospitalisation was also a notable risk factor at BHT. 
Whole genome sequencing identified an OXA-48-harbouring IncL/M plasmid among the outbreak 
isolates, with Klebsiella pneumoniae ST17 also implicated.  
 
The PHE toolkit, as it stands, is costly and impractical for full implementation. Determining the 
prevalence and high-risk groups at BHT enabled targeted screening for carbapenemase producing 
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Chapter 1: Introduction 
 
1.1 Antibiotic resistance   
The post antibiotic era is now approaching and one of the principal contributing factors is the 
overprescribing of antibiotics in healthcare and agriculture. The use of antibiotics eliminates, or 
significantly reduces, the susceptible bacteria present, while enabling any resistant bacteria to 
remain and subsequently multiply. This is referred to as selective pressure. This inappropriate use 
of antibiotics has forced the use of newer and more expensive broad-spectrum antibiotics, which 
were previously restricted to the last resort for the critically ill and difficult to treat infections caused 
by multi-drug resistant (MDR) organisms. Antibiotic resistance is also driven by inadequate dosing 
and an inappropriate antibiotic course, which can lead to the resistant bacteria remaining, upon 
completion of the course (Laxminarayan et al., 2013). 
 
The dissemination of antibiotic resistant variants, including extended spectrum beta-lactamases 
(ESBLs), AmpC producers and carbapenemases, has been reported worldwide, meaning this is 
now a global issue (Nordmann et al., 2011). As a result, infections are becoming harder to treat, 
often requiring combination therapy, and have been associated with an increased risk of morbidity 
and mortality. To tackle this global issue, policy makers are promoting the development of new 
antibiotics, together with enhanced surveillance and antibiotic stewardship (Littmann et al., 2015). 
However, the development of antibiotics is slow, due to the cost required for their development and 
the time for the new drug to become available (Ventola, 2015).  
 
1.2 Carbapenems  
The carbapenem antibiotics belong to the beta-lactam family which inhibit bacterial cell wall 
synthesis, targeting enzymes crucial to its production.  The cell wall consists mainly of 
peptidoglycan, a polymer composed of repeat disaccharide units (N-acetylglucosamine (NAG) and 
N-acetylmuramic acid (NAM) which form the backbone of the structure) and cross- linked with 
peptide chains. The synthesis of peptidoglycan begins within the bacterial cytoplasm, where 
disaccharide-oligopeptide precursors are made. These precursors are translocated across the 
cytoplasmic membrane then inserted into the cell wall (Typas et al., 2011). The mechanism of 
action of carbapenems is to permanently acylate the transpeptidases, also known as penicillin 
binding proteins (PBPs), responsible for catalysing the formation of crosslinks in peptidoglycan. 
Peptidoglycan is essential for the structure and integrity of the bacterial cell wall. When the activity 
of PBPs is inhibited, the cell wall weakens, resulting in lysis of the cell (Papp-Wallace et al., 2011). 
 
The most commonly used carbapenems in the UK are ertapenem, meropenem, imipenem and 
doripenem, which differ from one another in their spectrum of activity (Hawkey and Livermore, 
2012). 
Carbapenems were traditionally reserved for the critically ill or patients thought to have an infection 
caused by MDR bacteria. The emergence and expansion of extended spectrum beta-lactamases 
(ESBLs) over the last two decades has led to increased prescribing and inappropriate use of 
carbapenem antibiotics, resulting in development of resistance (Gharbi et al., 2015). Carbapenem 
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resistance was first described in 1993 and, since then, a variety of intrinsic and acquired resistance 
mechanisms have been identified (Nordmann et al., 2011).  
 
1.3 Carbapenemases 
A carbapenemase-producing organism (CPO) is an organism that possesses a carbapenemase 
enzyme. This is typically an acquired resistance mechanism, through possession of a mobile 
genetic element, such as a plasmid. Plasmids frequently possess multiple genes, making the 
organism resistant to more than one class of antimicrobial agent (Partridge et al., 2018). 
Organisms resistant to carbapenems are referred to as carbapenem-resistant organisms (CRO) 
(Livermore et al., 2020). This can result from carbapenemase production alone, or in combination 
with non-carbapenemase mechanisms, such as possession of AmpC or ESBL enzymes together 
with increased efflux pump expression or porin loss (Goodman et al., 2016). Acinetobacter 
baumannii can possess both intrinsic (overexpression of efflux pumps) and acquired (OXA-23 
carbapenemase) resistance (Netsvyetayeva et al., 2011).  Importantly, possession of a 
carbapenemase does not confer resistance to all carbapenems. For example, P. aeruginosa can 
appear imipenem resistant, but meropenem susceptible (Pragasam et al., 2016).  
 
There are two main systems used in the classification of carbapenemases, the Ambler 
classification and the Bush-Jacoby-Medeiros scheme. The latter differentiates between the 
functional characteristics of beta-lactamases, including substrate and inhibitor profiles and 
correlates the beta-lactamase with the phenotype in the isolate. The Bush scheme consists of 
Groups 1 to 4, each group then broken down into sub-groups. Group 1 (Ambler classification 
group C), includes the cephalosporinases which are not inhibited by clavulanic acid. Group 2 
(Ambler groups A and D), includes the penicillinases, cephalosporinases and broad-spectrum beta-
lactamases, which are inhibited by various beta lactamase inhibitors. Group 3 (Ambler group B), 
includes the metallo-beta-lactamases which are inhibited by ETDA. Group 4 does not relate to any 
Ambler class and is made up of the penicillincases (Bush et al., 2010). The Ambler system is, 
however, the most widely used classification scheme, and is based on amino acid sequences, 
dividing beta-lactamases into Groups A to D.  Some of the carbapenemases reported in literature 














Table 1: Ambler classification for carbapenemases and AmpC type beta-lactamases 
 
*Ambler class refers to the classification of beta-lactamases based on the amino acid sequences 
(Hall and Barlow, 2005). 
 
For the purpose of this project, only the big five are detailed in subsequent chapters. Class A 
carbapenemases are partially inhibited by clavulanic acid and can either be chromosome- encoded 
(NmcA, SME) or plasmid-encoded (KPC, GES). KPC-producers are the most frequently isolated 
worldwide, from this class, with the majority being nosocomial Klebsiella pneumoniae isolates. 
Specifically, K. pneumoniae sequence type 258 has been identified worldwide and is thought to be 
responsible for the spread of blaKPC genes (Espedido et al., 2013; Mathers et al., 2015; Nordmann 
et al., 2011). 
 
Class B metallo-beta lactamases (MBLs) are inhibited by EDTA, but not clavulanic acid, and have 
been reported worldwide also. They hydrolyse all beta-lactam antibiotics with the exception of 
aztreonam and are most frequently associated with K. pneumoniae. The blaNDM gene is diverse and 
found on a range of plasmids, which are also capable of carrying a number of other resistance 
genes (van Duin and Doi, 2017). Therefore, the antibiogram of NDM-producers varies greatly.  
Class C beta-lactamases are considered cephalosporinases, also referred to as AmpC beta-
lactamases. No carbapenemases have been reported in this classification group. The 
overproduction of these enzymes confers resistance to the cephalosporin group of antibiotics, with 
the exception of cefepime and cefpirome (Mammeri et al., 2006).  
 
Class D carbapenemases, such as OXA-48, are not inhibited by EDTA or clavulanic acid and are 
most frequently associated with K. pneumoniae and Escherichia coli (van Duin and Doi, 2017). 
Their genes can be located on plasmids or chromosomes and are considered to be the most 
difficult to identify in the laboratory, as isolates can appear carbapenem-susceptible (Hamprecht et 
al., 2019). 
 
CROs are made up primarily of Enterobacterales, Acinetobacter species and Pseudomonas 
species. These bacteria are frequent residents of the gut’s normal microbiome in 
immunocompetent individuals and can be present without causing infection. However, they are 
Ambler* class A: 
Serine 
carbapenemases 






Ambler class D: Serine 
carbapenemases 
NmcA VIM CMY-10 OXA-48 
SME IMP PDC OXA-23 
IMI-1 NDM  OXA-24 
SFC-1   OXA-40 
KPC   OXA-51 
IMI-2   OXA-55 
GES   OXA-58 
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also among the most common organisms causing both hospital and community acquired infections, 
such as meningitis, bacteraemia and urinary tract infections (Nordmann et al., 2011).  
Throughout the course of this project four different terminologies for bacteria resistant to 
carbapenems were used: 
 
Table 2: Definitions of the terms used for carbapenem resistant bacteria 
Abbreviation Definition of abbreviation 
CRO This is an organism which demonstrates resistance to the carbapenem class of 
antibiotics, via any resistance mechanism e.g. porin loss combined with 
ESBL/AmpC production or a carbapenemase. 
CRE Same as CRO, however, only includes organisms in the order Enterobacterales. 
CPO Any organisms which produces a carbapenemase 
CPE Any member of the Enterobacterales which is producing a carbapenemase  
 
1.4 Prevalence and epidemiology of CPOs 
The steady global increase in CPOs and the need for improved laboratory detection methods are 
the current challenges facing infection control teams, clinicians and the scientists working to 
identify them. PHE has reported a rapid increase in the number of infections involving CPOs in the 
UK since the early 2000s and now strongly recommends screening for them using either rectal 
swabs or stool samples (PHE, 2016). 
 
PHE calculated the prevalence of CPOs within the inpatient population across England, based on 
routine diagnostic samples. The CPO prevalence at Barts Health NHS Trust (BHT) was reported as 
2.2%, compared to the 0.3 – 3.8% reported at other regional hospitals (unpublished data from the 
antimicrobial resistance workbooks-PHE, 2018). This analysis of routine diagnostic samples, and 
not screens specifically targeting CPOs, has likely underestimated this prevalence. It is also 
important to recognise that CPO prevalence will vary depending on the type of hospital, as some 
are specialised centres and others are district general hospitals. Therefore, the prevalence 
reported was likely biased and not truly representative of the area the Trust serves. The majority of 
samples in this data set included those of bone and joint, the gastrointestinal tract and respiratory 
tract, as well as faeces, which likely represented CPO screening samples. The data also revealed 
that the number of cases was higher in males, regardless of age group (unpublished data from the 
antimicrobial resistant workbooks-PHE, 2018).   
 
KPC-producers are reportedly the most prevalent across the world, with only two states in the USA 
lacking any reports of KPC carriage or infection (Kelly et al., 2017). In Europe, both Greece and 
Italy have reported high rates of KPC-producing enzymes causing infection, with >50% of invasive 
infections caused by MDR isolates harbouring this enzyme noted in Greece (Galani et al., 2018). 
NDM was first reported in 2008 from a Swedish patient who had a history of foreign travel and 
hospitalisation in New Delhi, India. This blaNDM-1 has since been reported in sewage samples and 
drinking water, in addition to patient samples, across New Delhi (Dortet et al., 2014). More recently, 
NDM-producing isolates have been frequently reported across the majority of Asia and many parts 
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of Europe including Poland, Romania and Denmark (van Duin and Doi, 2017). Unlike the other 
common carbapenemase enzymes, which have typically been identified in Enterobacterales, VIM 
has frequently been documented in Pseudomonas species, primarily throughout Europe including 
Spain, Hungary and Italy. IMP, like the other carbapenemases, has been predominately reported in 
Klebsiella species, Enterobacter species, Citrobacter species and E. coli in Asia-Pacific countries 
(van Duin and Doi, 2017). The first European case of OXA-48 was reported in Turkey (Kilic and 
Baysallar, 2015). Originally OXA-48 type carbapenemases were documented in countries based in 
North Africa, India and the Middle East (Poirel et al., 2012). They are now widespread around the 
world, with a particular burden in the UK and Mediterranean  (van Duin and Doi, 2017). 
 
1.5 Outbreaks  
An outbreak is defined by the World Health Organization (WHO) as the increase of a disease 
beyond normal expectancy (World Health Organization, 2020). In relation to CPOs, an outbreak 
can be defined as the transfer of MDR bacteria between patients and the environment, resulting in 
higher numbers of patients acquiring resistant isolates. 
There have been many reported outbreaks worldwide, some linked to medical devices, such as 
endoscopy equipment, others by contamination of drains or simply transfer from patient to patient, 
with no known environmental source (Decraene et al., 2018). Slovenia reported their first OXA-48 
and NDM dual carriage outbreak in 2014. Prior to this, prevalence of CPE was described as 
sporadic (Pirs et al., 2019). Another study describing the first national outbreak of CPE, was in 
Ireland, reporting a NDM-1 producer across three separate, but affiliated hospital sites (O'Connor 
et al., 2016). In addition to countries documenting their first outbreak, there have also been many 
reports of subsequent outbreaks, across one or several linked sites. Italy has suffered several CPE 
outbreaks, including one reported by Tavoschi et al. (2020), which detailed 1,645 samples, 
collected over one year, harbouring an NDM. Initially 77.2% of the cases were considered to be 
horizontal transmission of plasmids, but further analysis revealed 90.9% to be K. pneumoniae 
ST147, suggesting clonal expansion of this strain (Tavoschi et al., 2020). An outbreak was reported 
in Greece in 2012, when a total of nine CPEs all produced an OXA-48 and were of the same clonal 
complex (ST11) (Voulgari et al., 2013). Similarly, in an outbreak described in Argentina, a Serratia 
marcescens of the same clonal complex producing a VIM carbapenemase was detected from 
several patients (Nastro et al., 2013).  
 
Within England, an outbreak of Enterobacter cloacae producing NDM-1 was reported in patients 
admitted to Nottingham University Hospital NHS Trust, over two sites, 8 km apart. As a result, 
mass screening was performed. However, no further positive cases nor environmental source was 
identified (Nastro et al., 2013). Possibly the largest known outbreak in England to date has been 
from Manchester University Hospital. Here the cases of KPC have been increasing since 2009, 
with an official outbreak declared in 2015, when cases increased rapidly (Decraene et al., 2018). In 
London, there have been a number of outbreaks relating to transmission of CPOs and BHT is 
ranked 4th for the number of CROs referred to PHE for testing (data provided by Katie Hopkins, 




In a large majority of cases, the term outbreak is used prior to any knowledge of similarity between 
these resistant strains, with the exception of the same carbapenemase. To determine if CPO cases 
can be classed as an outbreak, further analysis of strains and their genetic elements must be 
carried out.  
 
1.6 Infection prevention and control (IPC) policies 
Policies are produced at local, national and international levels to enhance IPC measures and to 
prevent further transmission of CPOs.  
 
1.6.1 International guidelines 
The Centers for Disease Control and Prevention (CDC), the WHO and the European Centre for 
Disease Prevention and Control (ECDC) have all provided expert guidance on the IPC measures to 
be implemented when dealing with MDR organisms, including CPOs. The WHO has provided 
guidelines for the prevention and control of carbapenem-resistant Enterobacterales, A. baumannii 
and P. aeruginosa in health care facilities (World Health Organization, 2017). These guidelines 
state that multimodal IPC measures should be implemented to control the transmission of CPOs, 
as follows: surveillance of patients to occur if active infection, asymptomatic colonisation, positive 
patient contacts or patients recently hospitalised within an area of known high CPO prevalence; 
hand hygiene best practises and adequate contact precautions by wearing of PPE, restricted 
movement of patients, disposable equipment to be used when possible and enhanced disinfection 
and cleaning of the environment surrounding the patient; isolation of patients in either a single 
room or cohorting of cases on the same ward whenever possible; both environmental cleaning of 
the area surrounding the patient and environmental screening is recommended depending on 
whether epidemiologically relevant; and monitoring of the implementation of the IPC strategy and 
feedback to staff is recommended to aid in learning of best practises (World Health Organization, 
2017). 
 
The ECDC have produced the document ‘Infection prevention and control measures and tools for 
the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings’ 
(Magiorakos et al., 2017). This guidance states that at-risk patient populations, which are to be 
screened, must have had at least one of the following in the last 12 months i) history of overnight 
stay in a healthcare setting, ii) cancer chemotherapy, iii) dialysis therapy, iv) previous carriage of a 
CPO, or v) contact with a previous CPO positive patient. In line with the WHO IPC 
recommendations, the ECDC states that isolation facilities should include en-suite facilities and, 
where this cannot be accommodated, a commode should be used. The ECDC also document that 
enhanced communication between the laboratory, nursing staff, noting status on laboratory 
information management system (LIMS), healthcare settings and all staff is essential. Cohorting of 
nurses should also occur, when possible, to prevent transmission of CPOs by staff. Bathing in an 
antiseptic is acknowledged, although, it is noted that this is more beneficial when dealing with 
Gram-positive organisms, which are colonisers of the skin and the limited data available  indicates 




The CDC guidance published in 2015 entitled ‘Facility Guidance for Control of Carbapenem- 
resistant Enterobacteriaceae (CRE)’ also details hand hygiene, personal protective equipment 
(PPE), cohorting of patients, environmental cleaning, screening contacts and active surveillance, 
as does the WHO and ECDC guidance. In addition, the CDC guidance also details education of 
staff to aid in the prevention of further transmission and enhanced communication between wards 
and the laboratory. Device usage was also detailed to be minimised whenever possible and 
antimicrobial stewardship tightened, to ensure use of narrow spectrum antibiotics whenever 
possible and for the correct and shortest duration. This is the only international guidance which 
recommends the use of antiseptic bathing, using chlorhexidine, on all patients who have been in 
contact with a CPO carrier. This can also be used as an intervention in at-risk patient groups.  
 
All international guidelines share the same fundamental principles, which should be applied to 
minimize the risk of transmission of CPOs and other MDR bacteria, between patients and the 
environment. These are specifically implementing best hand hygiene practises, wearing 
appropriate PPE, isolation and/or cohorting and enhanced surveillance.  
 
1.6.2 National guidance produced for the control of CPOs 
‘The Acute Trust toolkit for the early detection, management and control of carbapenemase-
producing Enterobacteriaceae’ was published by PHE in 2013. This guidance advised on the 
management of colonisation or infection, caused by CPEs, for clinicians and frontline staff in an 
acute care setting. This toolkit focuses on Enterobacterales only and, therefore, refers to CPEs 
rather than CPOs. Countries considered to be high risk are documented within this guidance, as 
well as areas in the UK reported to have a high rate of colonisation of CPEs. Risk factors include a 
patient who has been an inpatient abroad within the last 12 months or an inpatient in the UK, which 
has a known problem with CPEs, or a patient that has been previously positive for a CPE.  
 
The toolkit stipulates all patients should be assessed on admission to hospital and for those 
patients not deemed to be at risk, no screening need be performed, and no further action is 
required. However, suspected CPE carriers identified by one or more of the risk factors should 
have a rectal swab taken and be isolated with en-suite facilities. A total of three screens, 48 hours 
apart, prior to de-escalation should be performed. The IPC practises noted in this guidance share 
the same principles as the WHO and ECDC guidance.  It is advised that previous or known CPE 
positive patients should be managed as CPE positive for the duration of their admission.  
 
The guidance does not recommend antibiotic treatment for decolonisation. Treatment is only 
advised if the patient has an infection and under the advice of a microbiologist. Both monotherapy 
including polymyxins, tigecycline, fosfomycin or aminoglycosides and combination therapy options, 
which include the addition of a carbapenem, are listed if the patient goes on to develop infection 






1.6.3 Local guidance produced for the control of CPOs 
Using national and international expert guidance, each hospital or NHS trust requires their own 
policy for managing patients with MDR bacteria. The BHT policy for MDR bacteria applies to all 
health care workers employed by BHT, all of whom have a responsibility to prevent the spread of 
infection. This policy was developed in 2015 and took into account both international and national 
guidance.  Risk factors detailed in the policy include; i) overseas hospitalisation, ii) inpatient in UK 
hospital known to have increased numbers of CROs, iii) contact with a known CRO carrier, iv) 
previous CRO carrier, v) prolonged hospital stay, vi) patients on a long course of antibiotics vii) or 
admission to either the intensive care unit, renal or haematology units (Trust confidential 
document).  
 
Transmission may occur from contaminated hands of healthcare workers, surfaces or fomites. 
Environmental contamination increases if the patient has colonised skin lesions or diarrhoea.  
On admission to hospital, all patients are risk assessed for the likelihood of CRO possession. The 
patient is asked if they have received any healthcare overseas within the last 12 months and their 
notes should be checked for previous hospitalisation or CRO status. All at-risk patients should be 
notified to the IPC team. Screening should be based on risk factor analysis and either a rectal swab 
or stool sample should be sent to the laboratory for testing. Confirmed positive patients have a 
further risk assessment performed and the patient isolated in a side room with en-suite facilities for 
the duration of their stay. 
 
For at-risk patients with unknown CPO status, three negative screens taken at 48-hour intervals 
should be obtained prior to de-escalating IPC measures, as per the PHE toolkit. If a patient returns 
a positive screen, contact screening may be required if the patient spent any time on an open bay 
prior to isolation or on a Nightingale-style ward. Contacts do not need to be isolated, however, 
cohorting might be beneficial (if possible), whilst maintaining good hand hygiene. Treatment is not 
advised and should only be performed upon clinical assessment and discussion with a 
microbiologist. Weekly screening is recommended, however, it should not impact isolation, it is 
merely to assess current carriage status. If a known positive patient is admitted to hospital, de-
isolation based on subsequent negative screens should only be made based on clinical risk 
assessment by the IPC team. 
 
Hand hygiene, protective clothing, environmental cleaning, control of antimicrobial use, education 
and training are all very important in the management and reduction in spread of these MDR 
bacteria between patients and the environment. Daily audits of side rooms and annual isolated 
patient audit is performed to ensure compliance with this policy.  
 
As the policy was released in 2015, it is due for review, although this will not be performed until the 
release of the updated PHE toolkit, which was expected to be released in July 2020. However, the 





1.7 Clinical Use of Carbapenems 
The carbapenem class of antibiotics have a broad spectrum of activity, both across Gram-positive 
and Gram-negative organisms, including anaerobes. However, this class of antibiotic does not 
have activity against Enterococcus faecium and methicillin-resistant Staphylococcus aureus 
(MRSA). Imipenem is administered together with cilastatin, to reduce inactivation in the kidney 
(NICE, 2020). Imipenem has good activity against P. aeruginosa and can be used as empirical 
treatment in patients with neutropenia and hospital-acquired septicaemia although is not 
recommended as the drug of choice for infection of the central nervous system. Meropenem has a 
very similar spectrum of activity to that of imipenem. It can also be used to treat hospital-acquired 
septicaemia, in addition to infections in cystic-fibrosis patients, meningitis and in combination use 
for endocarditis. Common uses of ertapenem include community-acquired pneumonia, 
gynaecological infections and abdominal infections, such as diabetic foot infections or surgical 
prophylaxis prior to abdominal surgery (NICE, 2020; Wilson, 2017). Ertapenem has low activity 
against non-fermenters and is not commonly used to treat infections caused by Pseudomonas and 
Acinetobacter species as it has been reported to have a higher potential to select for porin loss in 
ESBL producing isolates (Codjoe and Donkor, 2017; Garcia-Fernandez et al., 2010). Carbapenems 
are administered intravenously (NICE, 2020; Wilson, 2017). 
Treatment of infections caused by CROs are limited and consist largely of colistin, polymyxin B, 
fosfomycin and tigecycline (Sheu et al., 2019; Rodriguez-Bano et al., 2018). In addition to these 
options, some infections caused by CPOs can still be treated by carbapenems, if the minimum 
inhibitory concentration (MIC) of the particular carbapenem is low, or in combination with another 
agent (Livermore et al., 2020). Ceftazidime-avibactam is a relatively new cephalosporin and  beta-
lactamase inhibitor combination which has been successfully used to treat infections caused by 
CPOs, such as those with an OXA-48-type infection (Alraddadi et al., 2019). It also has activity 
against P. aeruginosa and KPC producing Enterobacterales, but not NDM producers.  
Decolonisation of CPO carriage using antibiotics is not recommended, as it may lead to increased 
resistance. However, there have been many studies investigating the benefit of faecal microbiota 
transplantation, which have demonstrated a reduction in decolonisation (Saidani et al., 2019; 
Davido et al., 2017). This method has also been successful in treating infections caused by 
Clostridium difficile (Debast et al., 2014; Hocquart et al., 2018; Baxter and Colville, 2016). 
However, large-scale randomised controlled trials would be required before routine implementation 
(Saidani et al., 2019). 
 
1.8 Laboratory methods for detection of CPOs 
There are many in-house and commercially available tests for the detection of CPOs. In addition, 
polymerase chain reaction (PCR) can be used either following culture or direct from the sample. 
Further consideration of this technique is presented in chapter 3.2. 
 
1.8.1 Selective Culture Media 
Several companies have marketed selective media for the detection of CROs. These include 
Brilliance CRE (Oxoid, Basingstoke, UK), CHROMID CARBA (bioMérieux, Marcy-l'Étoile, France), 
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Colorex KPC (Biomed Diagnostics, Antwerp, Belgium) and Colorex mSuperCARBA (EO Labs, 
Scotland, UK). The exact composition of these media is often withheld for intellectual property 
rights reasons, however, the kit inserts and publications indicate they contain an unspecified 
carbapenem, which prevents susceptible isolates from growing, and a colorimetric biomarker, to 
allow the distinction between different bacterial species (Amar et al., 2017; Hinic et al., 2017; 
Garcia-Fernandez et al., 2017; Wilkinson et al., 2012). Despite similarities between the various 
chromogenic media, their performance can vary. One study reported CHROMID CARBA 
(bioMérieux) to have the best sensitivity and specificity (96% and 76%, respectively) when 
compared to three other types of chromogenic media (Wilkinson et al., 2012), whereas the 
sensitivity of Colorex mSuperCARBA (EO Labs) was reportedly higher for KPC detection, but low 
for OXA-48 detection when interrogated with a lower CFU per mL (Garcia-Fernandez et al., 2017). 
Therefore, it is important that each laboratory performs an appropriate verification that suits their 
needs.  
 
An alternative to selective media is the use of a non-selective medium, such as MacConkey agar, 
with a carbapenem disk to inhibit growth of any carbapenem-susceptible organisms. Laboratories 
may opt for this method if they have a low burden of CPOs, as chromogenic media are more costly 
and often have a shorter shelf life. Colonies growing up to the disk are considered resistant and 
undergo further testing to confirm the presence of the CRO (Saegeman et al., 2015; PHE, 2016; 
EUCAST, 2020). However, this method is more time consuming for a laboratory with a high 
throughput and requires a higher skill level to report the test.  
 
The majority of CPOs have been reported as those belonging to the Enterobacterales, 
pseudomonads and Acinetobacter species (Bonomo et al., 2018). Therefore, if any of these 
organisms are recovered on either the chromogenic or non-selective media, they then need their 
identification confirmed and to undergo further antimicrobial sensitivity testing, to determine the 
mechanism conferring carbapenem resistance. 
 
1.8.2 Antimicrobial susceptibility of isolates displaying carbapenem resistance 
Antibiograms of CPOs can vary, with some appearing relatively susceptible to carbapenems in 
laboratory testing, while others can appear highly resistant. OXA-48-producers in particular can be 
difficult to detect using phenotypic testing methods, as they can demonstrate in vitro susceptibility 
to both carbapenems and cephalosporins (Tadros et al., 2018). To overcome this, the combination 
of temocillin and piperacillin-tazobactam antibiotic susceptibility testing (AST) has been a useful 
tool for the detection of OXA-48 producers (Huang et al., 2014; Ciesielczuk et al., 2018). For the 
non-OXA-48-like CPOs, resistance to imipenem has frequently been documented, alongside 
cefotaxime. However, there are cases where susceptibility to cefotaxime has been described 
(Hrabak et al., 2014; Tadros et al., 2018). Organisms with class A carbapenemases often 
demonstrate resistance to penicillin, cephalothin, cefuroxime and aztreonam, with elevated MICs to 
a broader range of cephalosporins, including cefotaxime, ceftriaxone, ceftazidime and cefepime 
(Lamoureaux et al., 2012).  Organisms producing class B metallo-beta-lactamases, have 
demonstrated resistance to penicillins, cephalosporins and carbapenems, but are typically 




Following recovery of a presumptive CRO, AST needs to be performed in order to confirm the 
organism is carbapenem resistant, but also to infer the causative resistance mechanism (Hsu et al., 
2015). This is especially important for CROs, where resistance may be conferred by a 
carbapenemase, up-regulation of efflux pumps or expression of an ESBL in conjunction with porin 
loss (Maurya et al., 2019). Another issue is that it can be difficult to determine the presence of a 
CPO from this technique alone, as some bacteria have carbapenem MICs lower than the 
breakpoint (Hrabak et al., 2014). To overcome this limitation, EUCAST recommend using the 
epidemiological cut-off values to presumptively identify CPOs. However, as these are lower, this 
can result in an increased proportion of false positives (EUCAST, 2020).  
 
Currently at BHT, screening of CPOs is performed using an AST-based algorithm. Resistance to 
temocillin (TEM) and piperacillin-tazobactam (TAZ) alongside meropenem (MER) susceptibility is 
indicative of an OXA-48 producer, while resistance to ertapenem (ERT) and meropenem (MER) is 
indicative of a CPO other than OXA-48 (Ciesielczuk et al., 2018). For Acinetobacter, 
Stenotrophomonas and Pseudomonas species, PHE guidelines are followed due to the presence 
of alternative mechanisms, which are responsible for intrinsic resistance to some carbapenems 
(PHE, 2016). For example, Acinetobacter species can routinely demonstrate resistance to the 
carbapenems and cephalosporins, in addition to ciprofloxacin, levofloxacin, cotrimoxazole, 
ampicillin-sulbactam and piperacillin, but by intrinsic resistance mechanisms such as possession of 
low outer membrane proteins with or without efflux pumps, and not possess a carbapenemase 
(Zeighami et al., 2019).  
 
Once a presumptive CRO has been recovered using appropriate media and carbapenem 
resistance confirmed, the detection of a carbapenemase can then be performed and identified, if 
applicable. Several carbapenemase screening tests are discussed below. 
 
1.8.3 Modified Hodge test (MHT) 
The Modified Hodge Test was one of the first tests introduced to identify carbapenemase 
resistance. On a lawn of a carbapenem-susceptible organism (e.g. E. coli ATCC 25922), test 
isolates are streaked from the edge of the plate to the centre, where a carbapenem disk is placed. 
If one or more of the test isolates are carbapenemase-producers, the round zone of inhibition 






Figure 1:  Modified Hodge Test  
Isolate 1 is positive for the possession of a CPO, whereas isolates 2-5 are negative. 
 
Despite its simplicity, this method is no longer employed in diagnostic laboratories as it has been 
reported to produce a high number of false positives, as it cannot always differentiate between a 
CPO and a CRO (Hrabak et al., 2014; Tamma and Simner, 2018). In addition, although it has 
demonstrated excellent sensitivity for detection of both KPC and OXA-48 producers (93-98%), it 
has demonstrated low sensitivity for NDM producers (50%), despite the addition of zinc improving 
CPO detection rates (Girlich et al., 2012; Tamma and Simner, 2018). 
 
1.8.4 Synergy testing 
A commercial alternative to the MHT is the use of indicator disks, similar to those employed for 
ESBL and AmpC detection (Ingram et al., 2011).  These tests aim to detect synergy between a 
carbapenem disk and a disk containing the carbapenem plus an inhibitory agent (Hrabak et al., 
2014). Examples of these tests include the Carbapenemase Detection SetTM (MAST-CDS, 
Merseyside, UK) and KPC/Metallo-B-Lactamase Confirm Kit (ROSCO, Taastrupgardsvej, 
Denmark). Though not specified, reports indicate the inhibitory disks contain 
Ethylenediaminetetraacetic acid (EDTA) or dipicolinic acid (DPA), cloxacillin and boronic acid, to 
differentiate between metallo-beta-lactamases, AmpC beta-lactamases and KPC, respectively 
(Osei Sekyere et al., 2015; Giske et al., 2011). This method of detecting CPOs has demonstrated 
high sensitivity and specificity for both E. coli and K. pneumoniae, however, data has not been 
deemed sufficient for other members of the Enterobacterales order (Hrabak et al., 2014; Chu et al., 
2005; Ratkai et al., 2009). 
 
1.8.5 Colorimetric tests 
RAPIDEC Carba NP I, Carba NP II (Biomerieux, Marcy-l'Étoile, France), and CarbAcineto NP tests 
(bioMérieux, Marcy-l'Étoile, France) work by the hydrolysis of imipenem, resulting in a colour 
change from red to yellow. The Carba NP II is also able to differentiate between class A and B 
carbapenemases, by the addition of EDTA, which inhibits growth of class B, and the addition of 
tazobactam, which inhibits class A carbapenemases (Osei Sekyere et al., 2015). Class D 
carbapenemases are identified as they are not inhibited by either EDTA or tazobactam. This test 
has a reported sensitivity and specificity ranging between 91-100% (Osei Sekyere et al., 2015). 
However, an evaluation of the RAPIDEC CarbaNP I demonstrated sensitivity of only 49% for the 
Clover leaf shaped 
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detection of OXA-48-like enzymes. To overcome this, the researchers increased both the inoculum 
and incubation time, which increased the sensitivity to 100% (Hombach et al., 2015).  
 
1.8.6 Screening of CPOs using Matrix Associated Laser Desorption/Ionisation-Time of Flight 
Mass Spectrometry (MALDI-TOF MS) 
MALDI-TOF MS is an instrument used in many UK diagnostic microbiology laboratories to identify 
bacteria and fungi recovered from patient samples (Bizzini et al., 2010). However, it has also been 
employed to identify CPOs. The test bacterium is incubated with a carbapenem disk in broth for 1-4 
hours. Following incubation, the charge to mass ratio of the degradation products and a control 
carbapenem are compared. The absence of the ‘carbapenem’ peak in the test suspension 
identifies the bacterium as producing a carbapenemase. This method can determine the presence 
of a carbapenemase with a reported sensitivity and specificity of 100% (Osei Sekyere et al., 2015; 
Kempf et al., 2012; Lartigue, 2013). 
 
1.8.7 Lateral flow assays 
Relatively new tests for rapid confirmation and identification of specific carbapenemase enzymes 
include the Coris lateral flow immunoassays (BioConcept, Gembloux, Belgium) and the CARBA5 
lateral flow device (NG Biotech, Guipry, France). These devices can either be for single 
carbapenemase identification or multiple enzymes, such as the “big five” carbapenemases. As the 
isolate suspension passes along a nitrocellulose membrane it encounters immobilized antibodies, 
specific to various alleles of each carbapenemase enzyme. If the carbapenemase is present in the 
sample, it binds to the antibodies, resulting in the appearance of a coloured line. Lateral flow 
devices are highly sensitive and specific  with a reported sensitivity of 96% and specificity of 100% 
(Fauconnier et al., 2019; Boutal et al., 2018; Fauconnier et al., 2019; Wareham et al., 2016). 
However, these devices are unable to detect all alleles of existing carbapenemases or new 
variants. For example, the Coris lateral flow device can detect KPC variants including KPC-1, KPC- 
2, KPC- 3, KPC- 4 and KPC- 9 only. Therefore, testing of an isolate with an alternative KPC variant 
would result in a false negative (Coris BioConcept, 2017).  
 
1.8.8 Carbapenem inactivation method (CIM) 
In the carbapenem inactivation method, a suspension of the test isolate containing a meropenem 
disk, is incubated for a minimum of two hours. Following incubation, the disk is removed and 
placed on a Mueller-Hinton plate streaked with a carbapenem-susceptible E. coli (e.g. ATCC 
25922) and incubated. If the test isolate produces a carbapenemase, the meropenem in the disk 
will have been hydrolysed, allowing the susceptible E. coli strain to grow up to the disk (van der 
Zwaluw et al., 2015). This test has demonstrated a high sensitivity and specificity of 100% in 
comparison to PCR (van der Zwaluw et al., 2015; Gauthier et al., 2017). However, it should be 
noted that this test, while simple and easy to perform in a diagnostic laboratory, does not identify 
the specific enzyme causing the carbapenem inactivation. Therefore, further testing on a positive 
isolate would need to be performed. However, a modification of this method, to include the addition 
of EDTA, has been evaluated and demonstrated the ability to differentiate between class A and 




1.9 Aim and Objectives 
 
The overall aim of this project was to gain a better understanding of CPOs at BHT to inform best 
practice on patient screening. This was achieved through the following objectives: review of 
published engagement with the PHE toolkit for managing CPEs, optimising detection of the “big 
five” carbapenemases, evaluation of CPO prevalence in different patient populations across BHT, 
determination of the value of sequential screening and carrying out phylogenetic analyses of 



































Chapter 2: A Systematic Review Evaluating Surveillance Systems 




2.1.1 Infection Prevention and Control (IPC) 
IPC is an approach to minimise the risk of infection to patients by the implementation of a practical 
solution. In addition to good hand hygiene and injection safety, IPC teams play a large role in the 
prevention and combating of catheter associated urinary tract and bloodstream infections, 
sepsis, healthcare associated infections, antimicrobial resistance and surgical site infection (PHE, 
2016). 
 
Evidence based guidelines on management of MDR bacteria are produced worldwide and 
implemented by IPC teams (CDC, 2006; ECDC, 2011; PHE, 2013). These guidelines provide 
recommendations based on best practise and are relevant to specific regions and practise. These 
guidelines can then be adapted at a local level, to produce policies within hospitals. They are 
produced by a systematic review of evidence, which assesses the benefits and value of specific 
protocols and procedures (CDC, 2006).   
 
Surveillance systems are used to monitor the IPC measures put in place to prevent further 
transmission of infection or carriage of microorganisms. By monitoring this data, the IPC team are 
able to determine whether the controls that have been put in place are working effectively. It allows 
a constant review of practises and enables continuing improvement (Infection Control Today, 
2017).  
 
2.1.2 Surveillance systems 
There are three main types of surveillance system, as defined by the WHO, including sentinel 
surveillance, national active and national passive (WHO, 2020). Sentinel surveillance utilises a 
limited network of reporting sites, such as a study which only includes data from a defined number 
of selected sites, whereas, passive surveillance involves the regular reporting of all networks, for 
example, all hospital trusts who report antimicrobial susceptibility results to PHE. Active 
surveillance does not rely on the routine reporting, but the active searching for cases (e.g. by 
screening all patients upon admission for a CPE) (WHO, 2020). In England, surveillance for CPOs 
routinely utilises i) passive surveillance - the routine detection of CPOs from all samples, which are 
automatically reported to PHE as part of this process; and ii) active screening - enhanced 
screening for CPOs on a particular ward (i.e. during an outbreak or patient group). 
 
It is imperative that surveillance is performed to identify and analyse the distribution of MDR 
bacteria, to monitor transmission and implement IPC measures to prevent further transmission. 
Effective surveillance allows us to directly improve patients’ health by allowing clinicians to make 
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an informed decision about treatment options, which also improves antimicrobial stewardship. 
Awareness of the prevalence and epidemiology at a national level can also improve the policies 
and guidelines produced. Effective surveillance over time will also enhance knowledge of 
antimicrobial resistance, transmission routes, prevalence and epidemiology, which can be used to 
inform future strategies (Review on Antimicrobial Resistance, 2016). 
 
2.1.3 Aim 
Despite the publication and implementation of the Acute Trust toolkit for early detection, 
management and control of carbapenemase-producing Enterobacteriaceae across the UK, CPO 
surveillance practices vary from hospital to hospital. Therefore, a systematic review was performed 
to determine the CPO protocols in place, within England, following the publication of this guidance. 
This review is based on published literature and is not an audit of practice, as many hospitals have 
not published their protocols. 
 
2.2 Systematic review: The implementation of surveillance 
systems in the prevention of CPO transmission in a hospital 
setting within England  
 
2.2.1 Background 
Carbapenemase enzymes, harboured by many Gram-negative bacteria, confer resistance to the 
carbapenems. The first UK CPO, identified in 2003, was a KPC-producing Enterobacter cloacae 
isolated from a blood culture (Findlay et al., 2016). Since then, PHE has reported the increasing 
prevalence of CPOs and now strongly recommends screening using either a rectal swab or stool 
sample (PHE, 2016). A number of UK CPO outbreaks have also been reported (Martin et al., 2017; 
Breathnach et al., 2012; Gharbi et al., 2015). KPC was recently ranked the most prevalent 
carbapenemase in the UK (44%), followed by OXA-48-like carbapenemases (38%) (Trepanier et 
al., 2017). Identification and surveillance of these organisms is extremely important, as infection 
with a CPO increases both morbidity and mortality, due to the limited treatment options (Sekirov et 
al., 2016). Therefore, identification of CPO carriers needs to be prioritised to prevent further 
transmission of these highly MDR organisms. Appropriate measures to prevent CPO transmission 
and control outbreaks, such as evaluation of high-risk patients, sampling frequency and appropriate 
time-frame, vary.    
The PHE toolkit was first published in December 2013 and was written to disseminate expert 
advice, on a national level, to front-line staff in acute healthcare settings, on the control and 
management of CPE. According to the ‘Acute trust toolkit for early detection, management and 
control of carbapenemase-producing Enterobacteriaceae (CPE)’ (PHE, 2013), on admission to 
hospital a number of tasks need to be completed and the carrier state of the patient needs to be 
determined, as detailed in Table 3. A CPE carrier should remain in isolation for the duration of their 
hospital stay, despite subsequently testing negative. This calls into question the necessity of 
sequential screening if the results will not affect patient cohorting or isolation (PHE, 2013; 
Mookerjee et al., 2018). In addition, isolation in hospital can have a detrimental effect on a patient’s 
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well-being, as does having frequently repeated rectal swabs  (Tran et al., 2017).  Many hospitals 
have a limited number of side rooms available or, in some instances, no side rooms, adding 
another disadvantage to isolation. Despite the recommended screening for the detection of CPOs, 
antibiotic treatment is not advised, unless the patient develops an infection (PHE, 2013)  
 
Table 3: Factors defining CPE carrier status and steps required on admission 
Suspected CPE carriers 
include a patient who in 
the last 12 months has 
been: 
An inpatient in a hospital abroad 
An inpatient in a UK hospital known to have had outbreaks or sporadic 
cases with CPEs 
Previously colonised or had an infection with a CPE. 
 
Course of action if 
positive: 
Patient to be isolated 
Strict infection control procedures enforced 
Contacts identified and screened 
CPE status recorded on patient’s notes 
Discharge summary to GP 
The patient themselves should be notified of their status 
Good communication used throughout with all healthcare staff and 




Early detection and management of patients with suspected or confirmed CPOs, through 
appropriate IPC measures and antibiotic therapy, is key to preventing the uncontrolled spread of 
CPOs between patients and wards. Early detection can decrease the use of unnecessary 
antibiotics, if used, while implementing appropriate treatment. A timely negative result, on newly 
screened patients, also has the advantage to de-isolate patients, reduce costs associated with 
isolation and barrier nursing, as well as improve patient well-being.  
 
2.2.2 Method 
This systematic review was performed using the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). This method was chosen as this 
research focused on the evaluation of interventions used across England.   
 
2.2.3.1 Eligibility criteria  
Studies were eligible for this review if the following inclusion criteria were met: 1) study patients 
were inpatients, 2) study described screening to detect CPOs, 3) screening was part of active 
surveillance e.g. routine screening as part of trust policy, enhanced screening and screening based 
on risk factors, 4) study was performed within England, 5) study was conducted between January 




The PICO (patient/population, intervention, control and outcome) for this study is set out in figure 1. 
This method was used to frame the question. No control group was included as this review 
determined screening practices, not direct interventions. Both randomised and non-randomised 
control trials were included. This ensured the inclusion of both targeted screening and non-targeted 
screening of CPOs. Controlled before and after studies were also included to allow collection of 
data prior to active surveillance screening of CPOs and post- implementation of screening.  
 
Exclusion criteria eliminated inpatient surveillance during outbreak settings only, as this was not 
considered routine screening. Studies conducted prior to 2014, when PHE launched the screening 
toolkit, were also excluded, as were studies performed outside of England, outpatient/community 
studies and papers detailing diagnostic methods to detect CPOs in a laboratory setting rather than 
active surveillance.  Duplicate studies were also removed and papers with insufficient data for 
analysis, alongside letters to editors, were excluded. 
 
2.2.2.2 Literature search 
Medline and EMBASE were searched for papers between 2014 and 2018. This took place on 
17/07/2018 for human studies and was based on free-text key words (carbapenemase AND 
screening OR surveillance AND carbapenemase) and written using the English language. All 
records from the searches were imported into RefWorks for analysis.  
 
2.2.2.3 Data extraction 
Data extraction was performed by two independent reviewers (Jennifer Henderson and Dr. Holly 
Ciesielczuk, Clinical Scientist, Barts Health Trust), who reviewed the title and abstract against the 
eligibility criteria (Figures 2 and 3). All subsequent work was performed by Jennifer Henderson. 
Studies that passed the first stage of data extraction were then reviewed against the full eligibility 
criteria as follows; population screened, specimen type used for screening, study population size 
and risk factors. Reviewers resolved any disagreement through discussion. The papers selected 
for inclusion are tabulated in the results. 
 
2.2.2.4 Data synthesis and analysis 
A meta-analysis was not performed, as the outcomes of the included studies were qualitative and 
results descriptive. Data was analysed using a narrative synthesis against the intervention criteria 
(Timulak., 2009). 
 
2.2.2.5 Risk of bias 
Assessment was performed using the Cochrane Collaboration’s tool for assessing risk of bias 
(Higgins, 2011), in which the risk was determined as low, medium or high for each eligible study. 
The questions asked determined any selection bias (screening of targeted groups), detection bias 
(outcome assessment), reporting bias (interpretation of incomplete data and selective reporting) 
and attrition bias (refusal to participate). Each study was assessed by two reviewers and all 





























Figure 2: PICO flowchart determining inclusion criteria (systematic review). No control 



















Active surveillance  
May include any of the 
following: 
• Who to screen 
• When to screen 
• Risk factor-based 
screening 
• Frequency of 
screening 
• Specimen type 
used 













for CPOs in England 
between 2014-2018 
from randomised and 
Outcome 
May include any of the following: 





























































Records identified through other 
sources (conferences) (n=1) 
Titles and abstract screened against inclusion criteria (n=1,051) 
Removal of duplicates (n=201) 
Records eligible for full screening 
(n=22) 
Records included in this review (n= 5) 
Records excluded after title and 
abstract screening (n=1,029) 
Excluded reports (n= 17) 
Letters to editors (n=3) 
Not a surveillance study (n=13) 




2.2.4.1 Included studies 
A total of 1,252 papers were returned via the MEDLINE and EMBASE searches. Results from this 
search were exported into RefWorks and duplicate papers removed. A total of 22 from 1,051 were 
taken forward for full eligibility review based on the initial screening process. Excluded studies 
involved those conducted outside England, detailed outbreak management or laboratory screening 
methods. From the remaining papers, 17 were excluded due to lack of study information (including 
letters to editors) or because they were not part of active surveillance (Figure 3). The remaining 5 
studies focused on the surveillance and screening practises of inpatients, therefore fulfilling the 
























Screening protocol Sample size Risk factors identified 
1 Carter (2015) All inpatients 2013: CCU, renal, 
haematology and patients 
having dialysis abroad, 
admission and weekly screens 
 
2015: Rectal/wound/skin 
swabs alongside risk factor 
data 
551 Number of positive cases not 
documented, therefore no 










stay in the past 12 





2015: Risk-factor based 
screening, including sequential 
screens 48 hours apart 
 
2018: Two screening 
scenarios A) Three sequential 
screens received at specific 
times B) If additional screens 
were received <12 hours 
apart, all additional swabs 
were excluded from the study 
 
9,514 Increased hospital stay increases 
number of Gram-negative bacteria, 
however this was not found to 

























AMU, acute medical unit; AAU, acute assessment unit; ITU, intensive care unit; CPE, carbapenemase-producing Enterobacterales; CCU, critical care unit; 













Rectal swab alongside risk-
factor based demographic 
questions 
 
4,006 Hospitalisation abroad 
4 Poole (2016) All inpatients not 
previously known 
to be a CPE 
carrier 
 
2013: PHE toolkit risk-factor 
based protocol implemented 
 
2016: Rectal swab alongside 
patient demographics 
 
618 Increased age and being prescribed 
antibiotics on the day of surgery 
 
5 Wilson (2018) All adult inpatients Rectal swab or stool over a 3-
day period 
 
577 No positive cases of CPE, therefore 




2.2.4.2 Patient population groups 
The majority of studies (4/5) included all adult inpatients, with little exclusion. The remaining study 
screened specific areas/specialities which were considered at higher risk of CPE carriage specific 
to that Trust (Table 4). Studies 1 and 5 detailed that all adult inpatients were screened, regardless 
of any other factor (Carter et al., 2015; Wilson et al., 2018). Study 4 screened all inpatients with 
unknown CPE status (Poole et al., 2016). The emergency department, day unit and maternity 
wards were excluded from the screening in study 3, however, these specialities were classified as 
outpatient wards, meaning inpatient data was not lost (Otter et al., 2016). Finally, study 2 included 
risk factors of overseas residents, patients with a history of overnight hospitalisation and 
specialities which had been deemed high risk. Therefore, patients fitting one or more of these 
criteria were screened (Mookerjee et al., 2018).   
 
2.2.4.3 Screening protocol 
Rectal swabs were the main sample type for the recovery of CPEs in all studies. Perineal swabs 
were submitted for study 2, but later excluded), the reason for this not being documented 
(Mookerjee et al., 2018). Additional sample types included in other studies werewound and skin 
swabs and stool samples (Wilson et al., 2018; Carter et al., 2015). All studies asked risk factor-
based questions or gathered patient demographics with the potential to contain risk factors (e.g. 
age). Study 2 performed sequential screening to determine whether the PHE toolkit sampling 
recommendation was justified and whether there was a need (Mookerjee et al., 2018). 
 
2.2.4.4 Risk factors 
Study 1 initially only included patients the authors deemed high risk, such as travellers receiving 
dialysis abroad, haematology and renal patients; it then expanded to encompass a broader 
inpatient demographic and a trust-wide point prevalence study (PPS) was conducted (Carter et al., 
2015). Risk factors obtained during this PPS included any previous healthcare or admission to 
hospital and treatment overseas, in the UK, or at their hospital. This study conducted a CPO risk 
assessment for the hospital based on these factors and linked them to speciality (e.g. cardiology, 
oncology, renal). However, it cannot be determined whether the risk factors included had an impact 
on CPO carriage, as the study results (i.e. number of positive cases) were not included in the 
report.  
 
Study 2 limited the population sampled and only included those deemed to be at higher risk of 
carriage. These included all inpatients that were overseas residents, those who had a history of an 
overnight stay in a hospital in the past 12 months and all those from high-risk wards, including ITU, 
renal, vascular and haematology (Mookerjee et al., 2018). As this study only included groups with 
specified risk factors and the number of positive cases was low (0.5%), no link can be determined 
between risk factors and patient population from this data. The focus of this study was the value of 





Study 3 concluded that CPO prevalence was associated with hospitalisation abroad, despite only a 
small proportion of patients being reported as hospitalised in an overseas hospital (Otter et al., 
2016).  Of note, 41.9% of patients had an overnight stay in a UK hospital within the past 12 
months, 31.1% of these were re-admissions and 37% were from Greater London. Only 1% had an 
overnight stay in a hospital abroad and 1.3% were from overseas. Of all the risk factors identified, 
64.5% of all admissions had at least one risk factor. This, according to the PHE toolkit, would be 
sufficient to start isolation and IPC precautions. This study (study 3) revealed overseas 
hospitalisation abroad was an associated risk factor of CPE carriage, with 2/5 positive cases 
having been hospitalised in any country and 1/5 linked to a high-risk country as determined by the 
PHE. A further 4/5 of these positive cases were also associated with UK hospitalisation, not limited 
to hospitals based within London (1/5). This indicates that other UK-wide hospitalisations may also 
be a risk factor. Interestingly, there were no positive cases identified from hospitalisations 
associated with the North West, where there is known to be a high prevalence of CPEs (Poole et 
al., 2016). 
 
Age, sex, ethnicity and date of birth, alongside medical history information (including previous 
antibiotic use or proton pump inhibitors, endoscopy, previous admission and length of stay) were 
not found to be associated with CPE carriage in study 4 (Poole et al., 2016). This study used 
logistic regression to determine that age, alongside antibiotic use, was associated with a higher 
rate of CPE carriage. Due to the high number of positive cases detected at this trust (11% 
prevalence), it is a valuable study with which to determine risk factors. However, due to the 
outbreaks of KPC within this trust and known high burden, it may be possible that this high 
prevalence is due to factors other than patient-associated risk factors, such as an environmental 
reservoir.   
 
Study 5 identified the risk factors as previous hospitalisation in the UK, including London and 
Manchester, and any previous hospitalisation abroad (Wilson et al., 2018). Patients were also 
asked if they recalled any questions similar to this on admission, as per the PHE toolkit guidance. A 
total of 509/595 provided this risk factor information. From this questioning, 62.5% documented 
previous hospitalisation in the UK and a further 0.6% stated hospitalisation abroad. No positive 
CPE cases were found, despite a significant number (63.1%) having been deemed high risk 




From the studies which reported prevalence (n=4) ranged between 0% to 11%, with 50% of the 
studies typically reporting a prevalence of <0.5%, indicating an extremely low burden of CPE (Otter 
et al., 2016; Mookerjee et al., 2018; Poole et al., 2016).  The high CPE prevalence (11%) noted in 
study 4 is likely skewed, as it included known positive CPE cases identified throughout the trust 
(Poole et al., 2016). For studies 1 and 5, the former does not detail the number of CPEs, meaning 





2.2.4.6 Routine surveillance 
In July 2013, study 1 implemented admission screening and weekly screening of their high-risk 
patients, though the at-risk category expanded over the following months (Carter et al., 2015).   
Study 2 also performed admission screening, but just on those meeting the PHE toolkit criteria. 
These patients then received the recommended three sequential screens also (Mookerjee et al., 
2018). Between 2011 and 2013, 25 CREs were detected in study 3, even though it was 
documented that no screening protocol was in place at this time, then the PHE toolkit risk factor 
protocol was implemented (Otter et al., 2016). Study 4 conducted risk-based admission screening, 
however, the authors did not state what these risk factors were (Poole et al., 2016). 
 
2.2.5 Discussion 
An effective surveillance program is the continuous gathering of data and interpretation to enable 
the implementation and evaluation of best practice (WHO, Immunization, Vaccines and Biologicals, 
2020). Active surveillance provides an early indication of potential threats, in this instance the 
increased burden of CPOs. Surveillance informs IPC practices and guidelines and monitors CPO 
epidemiology and prevalence, within the UK, to provide guidance on best practice relating to their 
control.  
 
2.2.5.1 Population tested 
Targeted screening is recommended by PHE, as blanket screening of the entire inpatient 
population would be costly, time consuming and impractical for most hospitals in England. 
However, if targeted screening was to be implemented, it would be important to identify the patient 
groups most at risk for each hospital. Point prevalence and large-scale studies provide an ideal 
platform with which to identify these patient groups and can be utilised to allow implementation of 
more focused active surveillance, as performed in 4/5 hospitals included in this review. The 
majority of studies (4/5) included here sampled all inpatients, regardless of risk factors, with the aim 
of determining the overall CPE prevalence and potential at-risk patient groups (Carter et al., 2015; 
Otter et al., 2016; Poole et al., 2016; Wilson et al., 2018). The remaining study (study 2) focused on 
testing patients with risk factors listed in the PHE toolkit, excluding a large portion of the inpatient 
population, thus targeted screening in line with published guidelines (Mookerjee et al., 2018).  
 
2.2.5.2 Sample type 
PHE have recommend rectal swabs for CPO screening, with CPO recovery increased when visible 
faecal matter is present (PHE, 2013). However, one study has contradicted this suggestion on 
faecal matter (Otter et al., 2016). Stool samples can also be used, although results may be delayed 
as nurses wait for the patient to produce the sample, which likely explains why just one study 
accepted this sample type (PHE, 2013). Of note, study 1 was the only one to include wound and 
skin swabs from around medical devices in addition to rectal swabs and the remaining studies (5/6) 
tested rectal swabs only, with one study accepting stool samples in place of rectal swabs where 
needed (Carter et al., 2015; Mookerjee et al., 2018; Otter et al., 2016; Poole et al., 2016; Wilson et 
al., 2018).  The testing of wound and skin swabs is important to identify colonisation and infection; 
however, as no CPO positive results were obtained, the value of this screening is unclear. 
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Study 2 specifically excluded perineal swabs, for unknown reasons, though it may have been due 
to lack of guidance or perhaps this sample was collected in error, as MRSA screening typically 
employs this sample type (Mookerjee et al., 2018; Department of Health, 2014). A published study, 
not included here, compared recovery rates of ESBL and carbapenemase producers, using 
perineal and rectal swabs. It was demonstrated that rectal swabs were over two times more 
sensitive than a perineal swab, indicating why this sample type is not recommended (Dyakova et 
al., 2017).  
 
2.2.5.3 Risk factors 
Study 3 reported hospitalisation abroad and any previous hospitalisation in the UK to be risk-
factors (Otter et al., 2016). This partially contradicts the PHE toolkit, which states UK hospitalisation 
is a risk factor if the hospital has a known CPE problem. A national surveillance study, EuSCAPE-
UK, identified Greater London and Manchester as areas of the UK with the highest CPE 
prevalence (Trepanier et al., 2017). However, only one of five CPE positive patients from study 3 
were hospitalised in Greater London (Otter et al., 2016). This demonstrates the importance of all 
UK hospitals performing large scale surveillance studies, in order to determine their own CPE 
prevalence for hospital-specific IPC measures to be implemented.  
 
Previous use of antibiotics was not found to be a significant risk factor, despite 54.1% of the patient 
group fitting into this risk category defined by study 3 (Otter et al., 2016). However, study 4, where 
there is a well-established high burden of CPE (11%), reported that age, alongside the use of 
antibiotics, was associated with CPE carriage, but due to sporadic cases and outbreaks within this 
trust, it may be possible that this high prevalence was due to non-patient-specific risk factors 
(Poole et al., 2016). Other risk factors reported outside of this review included  mechanical 
ventilation, presence of indwelling devices, severity of illness, history of stay on ITU, prior 
antimicrobial use, immunosuppression, patient mobility and corticosteroid use (ECDC, 2011; 
Madueno et al., 2017; Mariappan et al., 2017). 
 
Studies 5 did not have any positive cases of CPE, therefore, risk factors could not be identified, 
while study 2 did not identify any CPE-associated risk factors, however, increased hospital stay 
was associated with increased number of MDR bacteria. In study 5, patients were asked if they 
recalled being asked risk factor-based questions previously (i.e. on admission), as per PHE toolkit 
recommendation, but 94.5% did not recall ever having been asked these questions. It is possible 
that failed recall was due to being unwell upon admission to hospital. However, the authors 
suggested that the PHE toolkit had not been implemented efficiently (Wilson et al., 2018).  
 
 2.2.5.4 Prevalence 
Low CPE carriage rates of 0.1% and 0.5% were reported in studies 2 and 4, respectively 
(Mookerjee et al., 2018; Otter et al., 2016). However, a PPS conducted in London, but excluded 
from this review due to lack of information, documented a CPO prevalence of 4.6% (Draz et al., 
2018). This indicates that the true burden of CPOs may be higher than some studies suggest.  
Study 4, conducted in Manchester, reported a much higher prevalence (11%), but this is a location 
known to have a high KPC carbapenemase burden and has been associated with a large-scale 
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outbreak (Decraene et al., 2018; Poole et al., 2016). It is clear from the few studies included in this 
review that CPE prevalence in England is varied and influenced by hospital-specific factors, as well 
as some universal risk factors detailed in the PHE toolkit. Given the range in CPE prevalence 
reported by these studies, it is imperative that more hospitals report their rates to truly understand 
the national CPE prevalence. 
 
Within Greater London, data provided by PHE (AmSurv) was used to determine the prevalence of 
CPOs across a variety of hospitals. The carbapenemase prevalence at BHT in 2017 was 2.2%, 
compared to Croydon (0.3%), Great Ormond Street Hospital (GOSH) (1.7%), Homerton (0.9%), 
Imperial College (3.8%), Kingston (0.3%) and Romford (0.9%), the majority of which are higher 
than that reported in this systematic review (Unpublished data from: antimicrobial resistant 
workbooks-PHE, 2018). However, this data was acquired from all routine diagnostic samples and 
not just CPO screens. In addition, CPO cases were notably higher in males, regardless of age 
group. However, not all laboratories routinely identify CPOs, therefore, this data has a degree of 
bias, potentially causing an under-reporting of CPO prevalence, as isolates have not been detected 
from targeted screening (Trepanier et al., 2017; Woodford et al., 2018). The data published by PHE 
reports prevalence slightly higher than that reported in the studies included here. This could be due 
to the location of the trusts (North Middlesex, Cambridge, West London and North London), with 
London-based hospitals having a higher burden of CPOs compared to Cambridge (0%).  
 
2.2.5.5 Number of screens 
Study 2 assessed the value of sequential screening on the recovery of CPEs over two scenarios. 
The first scenario included the recommendation of three sequential screening samples taken at 
designated time points 48 hours apart, as per PHE toolkit guidelines (Mookerjee et al., 2018). 
However, they found that samples were often not collected, due to staffing levels, movement of the 
patient and reluctance to send a repeat rectal swab. The second scenario included serial sample 
collection at unspecified time points. They found one patient to have a positive carrier status at 
both the first and third screening, but negative for the second. Transient CPE carriage has been 
reported previously, with studies indicating that a patient with a subsequent negative screen can 
revert back to positive carrier status, particularly after completion of a course of antibiotics (PHE, 
2013).  The study authors suggested that serial screening should be discontinued and replaced 
with regular screening of long-term patients. This is due to the increased carriage rate of MDR 
bacteria detected the longer the patient is hospitalised (Mookerjee et al., 2018). Based on this 
study, further work should be performed to determine the benefit of sequential screening compared 
to the screening of long-term hospitalised patients. If the carriage of CPOs is indeed transient, 
there is limited benefit from three negative follow-up screens when the patient has the potential to 
revert back to positive status following this. As patients are hospitalised for longer periods of time, it 
is increasingly likely that MDR bacteria will be selected for and dominate in the gut, due to the 
prescribing of antibiotics (Mookerjee et al., 2018). This group of patients are, therefore, more likely 
to suffer treatment failure if carriage leads to infection caused by an MDR organism or a potential 
CPO. 
The remaining four studies included in this review did not perform or did not detail serial screening. 
More evidence would, therefore, be required to draw conclusions on the benefit of sequential 
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screening. Transient carriage is possible and the requirement to remove patients from isolation and 
de-escalate infection prevention control measures would be advantageous to both the patient and 
the hospital.  
 
2.2.5.6 Uptake and awareness of the PHE toolkit 
A survey was conducted in 2016, following the implementation of the PHE toolkit, to assess the 
uptake and awareness of the guidance by acute trusts. A total of 99 out of 151 (65.6 %) trusts 
complied with the survey and provided data for analysis. Findings suggested awareness of the 
toolkit was high (99%), however, familiarity with the specific contents of the toolkit was much lower 
(75%). Uptake of the toolkit occurred in 13/99 (13.13%) trusts prior to the release of PHE guidance. 
In 2014, a further 47 trusts had issued a screening plan for CPE, though unpublished. Between 
2015 and 2016 a further 25 trusts implemented the guidance. Of the remaining 14 trusts (14.14%), 
6 had no immediate intention to adopt a CPE protocol and 8 did not state future plans. This same 
survey tried to identify the usefulness of the toolkit, determining whether it met specific needs of the 
trust and whether the information was practical. It was reported that overall users did not have 
confidence in the toolkit, however, all used the toolkit to develop their own local plan (Coope et al., 
2018). 
 
The majority of studies (3/5) included in this review state that the PHE toolkit, or a screening policy 
based on the toolkit, was implemented between 2013 - 2015 (Mookerjee et al., 2018; Otter et al., 
2016; Wilson et al., 2018). Of the remaining two, study 1 only screened patients for CPE who were 
admitted to one of their ‘high risk’ wards, while study 4 performed risk-based admission screening 
in August 2014, but did not state whether these were the toolkit risk factors or their hospital-specific 
risk factors (Carter et al., 2015; Poole et al., 2016). Study 3 stated that the PHE risk factors were 
not based on evidence and, therefore, their study was designed to implement a cost effective 
screening protocol based on their own patient population (Otter et al., 2016). They indicated that 
outcomes would be different if this study was performed elsewhere in the country, such as a site 
with a higher CPO burden. This same study demonstrated that hospitalisation was associated with 
CPO carriage, this being partially in line with the PHE toolkit guidance (PHE, 2013). 
 
Taken together, the studies reviewed here suggest that the PHE toolkit has a place in some 
hospitals in England, where all stated risk factors are relevant, while at other sites the toolkit can 
only be partially implemented, due to population-specific risk factors that were identified. In 
addition, if the PHE toolkit were to be implemented fully, it would mean the unnecessary isolation of 
approximately 40% of patients, due to the low CPO prevalence, and this would be very costly 
(Vella et al., 2016). 
 
Unpublished data obtained from the BHT IPC team allowed the determination of the screening 
practises performed at three other large London-based hospitals. One central London trust 
screened all patients who have had an overnight stay in any hospital, including the UK and abroad, 
within the last 12 months. The same trust performed contact screening of confirmed positive cases, 
screened the renal and transplant unit and all renal inpatients. Another London- based hospital 
screened 1) all previously confirmed positive patients, 2) all patients with overnight hospital stay 
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within the last 12 months, 3) all patients admitted to critical care wards and 4) all patients on renal 
haemodialysis. A third hospital separated the screening of adults and children. All children were 
screened on admission, then weekly, when transferred between wards and upon discharge. Adult 
screening practises resembled that of the PHE toolkit and consisted of 1) history of CPE 
colonisation, 2) hospitalisation abroad within the last 12 months, 3) admission to hospital in a high-
risk area, including North West England and London and 4) all private patients. Risk factors for all 
included those determined by the PHE toolkit, but also some speciality groups, such as renal and 
transplant patients. This demonstrates that these sites utilised the toolkit in the development of 
local policies, however, they also took into account local factors.   
 
2.2.5.7 Limitations 
The number of studies included in this review was low, which limits the interpretation and 
conclusions that can be made. By including studies which did not meet the inclusion criteria, such 
as one conducted in Ireland which reported a prevalence of 1.38% and a survey conducted over a 
6 month period estimating an overall prevalence of 0.02% within the United Kingdom, the 
understanding of screening practices could be increased (Cafferkey et al., 2019; Trepanier et al., 
2017).  
 
The studies reviewed here either excluded children or did not specify their participation. Presence 
of CPOs in children has the same clinical significance as in adults and, therefore, excluding them 
from research is a limitation and will have affected the results. There are few studies identifying the 
geographical distribution of carbapenemases within neonates; reports having largely been case 
reports, outbreaks or small case series. It has been estimated that 30% of all global neonatal 
deaths caused by sepsis can be attributed to antimicrobial resistance (Folgori et al., 2017).  There 
is also a comparable lack of data from the paediatric population, however, a study by Chiotos et al. 
(2016), demonstrated there to be a similar prevalence to that in adults. This study reported CPEs in 
0.47% of all Enterobacterales recovered from children, of which 4.5% of these had risk factors 
associated with previous admission to ITU (Chiotos et al., 2016). There are restrictions and 
debates in the literature regarding inclusion of children in research, as ethical approval, when 
required, can prove difficult. As several of these studies required verbal consent this would need to 
be ascertained from the gatekeepers (Collings et al., 2016). The main sample type submitted in 
these studies was a rectal swab which, for a small child, would not be favourable. However, a stool 
sample which, according to the PHE guidelines, is an acceptable sample type, could have been 
submitted from this group of patients (PHE, 2013).  
 
This review only included studies of inpatients, not capturing data from the community. This could 
potentially exclude a CPE reservoir, although this was not the focus of the review. Community 
prevalence is largely unknown as research tends to be based on hospitalised patients or 
outbreaks. However, a relatively recent review on community CPE prevalence noted that five 
studies reported no CPE-associated carriage, while for 10 studies the prevalence ranged from 
0.04% to 29.5%. Studies performed in the USA reported a higher prevalence ranging from 5.6-





Based on the studies included in this review, previous hospitalisation is demonstrated to be the 
most frequent risk factor associated with CPE carriage, which is in line with the PHE toolkit (PHE, 
2013). Whether this is caused by previous administration of antibiotics selecting for these MDR 
bacteria or environmental exposure to CPOs, remains unknown.  
 
Findings from these studies demonstrated that it would be beneficial for all hospitals to perform a 
large-scale study to determine their own patient prevalence and hospital-specific risk factors 
associated with CPO carriage. This would allow for more specific screening. Detection of CPOs 
from targeted screening upon admission allows for the prompt implementation of IPC measures to 
prevent onward transmission of CPEs between patients and within the environment, but in a more 
practical and economical way, that is manageable for the hospital.  As it stands, the PHE toolkit is 
costly and not practical to implement and could benefit from being updated to allow for a more 
practical form of guidance. Since its publication, a number of CPE studies have been reported that 
could be adopted into the new version of the toolkit.  
 
As with some of the studies discussed here, BHT adopted parts of the PHE toolkit, including 
screening of at-risk groups and isolation of a confirmed positive patient. However, as side rooms 
are both costly and not always available, it was not possible to isolate every high-risk patient. 
Based on findings from this systematic review, two prevalence studies were conducted at BHT, 
which are discussed in more detail in chapter 4. Additional risk-factors have since been added to 
























Chapter 3: Evaluation and Optimisation of a Real-Time PCR 
Assay for the Detection of VIM, NDM, KPC, IMP and OXA-48-like 
Carbapenemases 
 
3.1 Introduction  
 
Detection of CPOs in the diagnostic laboratory typically involves testing of clinical samples, to 
detect an infection, or testing of screening samples, to determine if the patient is colonised with one 
or more CPOs in their gastrointestinal tract. The recommended sample type for CPO screening in 
England, Wales and Northern Ireland is either a rectal swab or a stool sample (PHE, 2013). Testing 
guidance from EUCAST and PHE recommends the use of meropenem as an initial indicator for the 
presence of a CPO (EUCAST, 2017; PHE, 2013). It has been reported that ertapenem 
demonstrates a high sensitivity, but low specificity for the detection of carbapenemases, and may 
not always reliably differentiate between carbapenem resistance and carbapenemase production. 
Use of meropenem is viewed as a compromise between both sensitivity and specificity (Codjoe 
and Donkor, 2017). Another complication in identifying CPOs is that some strains appear 
carbapenem- susceptible in laboratory tests, specifically OXA-48-producers which have 
demonstrated low-level carbapenem resistance and so appear susceptible to meropenem  and 
also cephalosporins (Ciesielczuk et al., 2018; PHE, 2016). This makes interpretation of traditional 
laboratory tests difficult, with many isolates sent to the reference laboratory unnecessarily for 
confirmation. Therefore, with the rapid emergence and increase in CPOs there is a need for prompt 
and accurate detection methods.  
 
The standard for microbiology investigations (SMI) for the detection of CPOs states there is no gold 
standard method for their detection, as there are many different test methods and varieties of 
media available with a similar reported sensitivity and specificity (PHE, 2016). Further details of 
methods to detect CPOs are documented in section 1.8. 
 
3.2 PCR for the detection of CPOs 
There are many methods available for the detection of CPOs. PCR is a technique used to amplify 
small amounts of genetic material to detectable levels. PCR for the detection of carbapenemases 
has frequently been described and, in the last 10 years, various commercial real-time PCR assays 
have been released, including Check-Points CPO, BD Max (BD, New Jersey, USA), Xpert Carba-R 
(Cepheid, California, USA) and EntericBio CPE screen (Serosep, Crawley, UK) (Antonelli et al., 
2016; Ellington et al., 2016; Hrabak et al., 2014;  Pasanen et al., 2014; Woodford et al., 2006; Kazi 
et al., 2018).  There are also many published in-house PCRs that have been developed for  
carbapenemase detection, the majority focusing on the ‘big five’, but others have been designed to 
target the most common resistance mechanisms in that given geographical area (Boo et al., 2016; 
La et al., 2014; Smiljanic et al., 2017). However, PHE do not recommend in-house methods and 
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encourage laboratories to use commercial methods wherever possible, due to the high degree of 




As part of this study, an assay developed by van der Zee et al. (2014) was selected, as it met the 
criteria of detecting the ‘big five’, but it had also been validated across multiple laboratories and 
thermocyclers, across Europe, suggesting a robust performance (van der Zee et al., 2014). 
The aim of this study was to evaluate and optimise this RT-PCR assay for the detection of KPC, 
NDM, OXA-48, VIM and IMP-type carbapenemases, using control strains possessing at least one 




3.4.1 Barts Health Trust CPO detection method at time of evaluation 
The routine method at Barts Health Trust for carbapenemase detection was use of an antibiogram-
based algorithm, following culture and identification by MALDI-TOF MS (Ciesielczuk et al., 2018). 
Isolates resistant to ertapenem and meropenem were considered presumptive CPOs, other than 
OXA-48-producers, and referred to the reference laboratory for confirmation. Piperacillin-
tazobactam and temocillin resistance, in conjunction with meropenem susceptibility, was indicative 
of an OXA-48 producer, with final confirmation following receipt of the report from the reference 
laboratory. The time-frame from referral to confirmation of carbapenemase production was 
approximately 2 weeks.  
 
3.4.2 Positive control strains 
Sixty four isolates, possessing at least one of the big five carbapenemases, were supplied from the 
following laboratories; The Royal Marsden NHS Foundation Trust, London (n = 5), Guy’s and St. 
Thomas’ NHS Foundation Trust, London (n = 4), Queen Elizabeth Hospital, Romford (n = 4), St. 
George’s Hospital, London (n = 6), HCA Healthcare, London (n = 3) and Southmead Hospital, 
Bristol (n = 4).  The remaining 38 isolates were from BHT. Isolate identification and corresponding 
carbapenemase enzyme are detailed in appendices 2-6. Three of the 64 positive isolates were 
reported to possess more than one carbapenemase gene. 
 
3.4.3 Negative control strains 
To calculate the specificity of the optimised in-house PCR, 31 isolates negative for one or more of 
the big five carbapenemases were tested. These included isolates producing ESBLs (n = 9), OXA-
23 (n = 1), OXA-51 (n = 1) and 20 isolates with no detected resistance mechanisms (Appendix 1). 
 
3.4.4 DNA Extraction: Automated method 
An automated extraction method was used initially in this project, as it is the routine extraction 
method employed by the Infection Department in the Trust. In preparation for automated extraction, 
a 1 µl loop (Starstedt, Leicester, UK) of pure bacterial isolate was transferred to a 2 ml tube (Fisher 
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Scientific, Loughborough, UK) containing 400 µl of ATL buffer (Qiagen, Hilden, Germany) and 
emulsified. Automated DNA extraction was performed on the QIAsymphony (Qiagen) using the 
QIAsymphony DSP virus/pathogen kit (Qiagen), according to the manufacturer’s instructions. 
Extracted DNA was eluted into a 1.5 ml tube (Starlab, Milton Keynes, UK) and stored at 4°C until 
testing. 
 
3.4.5 DNA Extraction: Boil method 
A boil extraction method was trialled to reduce the overall cost and time constraints associated with 
the automated extraction method. A 10 µl loop (Starstedt) was used to transfer approximately 3-5 
single isolated colonies to 200 µl sterile water (Oxoid). This suspension was vortexed briefly using 
a Vortex Genie (Fisher Scientific) and transferred to a Techne hot block (Fisher Scientific) at 95°C 
for ≥10 minutes. Once cooled to room temperature, tubes were centrifuged at 13,000 rpm for 1 
minute using a Sigma centrifuge (SciQuip, Shropshire, UK). The supernatant was transferred to a 
new 1.5 ml tube (Starlab) and saved at -80°C for testing at a later date. 
 
3.4.6 Preparation of Primers and Probes 
Primers and probes were as published, but with the addition of distinct reporter/quencher dyes for 
each of the probes (van der Zee et al., 2014). Primers and probes were supplied by Sigma-Aldrich 
(Basingstoke, UK) at a concentration of 100 µMand rehydrated in accordance with the 
manufacturer’s instructions (Table 5). The primers and probes were combined into 3 separate 

























Table 5: Real-time PCR primer and probe sequences taken from a published study (van der 
Zee et al., 2014).  
Primer/Probe 
name 
5’ – 3’ Sequence Amplicon 
size (bp) 
Reporter/quencher 
dye (probes only) 
OXA48-F GCGTGGTTAAGGATGAACAC 239 - 
OXA48 R CATCAAGTTCAACCCAACCG - 
OXA48-Pr AGCCATGCTGACCGAAGCCAATG Cy5/BHQ1 
VIM-F GAGATTCCCACGCACTCTCTAGA 390 - 
VIM-R AATGCGCAGCACCAGGATAG - 
VIM-Pr ACGCAGTGCGCTTCGGTCCAGT JOE 
IMP-F GGCGGAATAGAGTGGCTTAATTCTC 188 - 
IMP-R1 GAATTTTTAGCTTGTACTTTACCGTCTTT - 
IMP-R2 ATTTTTAGCTTGTACCTTACCGTATT - 
IMP-R3 TTTGTAGCTTGCACCTTATTGTCTTT - 
IMP-Pr1 ATGCATCTGAATTAAC CY5.5 
IMP-Pr2 TAT*GCATCT*GAAT*TAA*CAaAT*GA  
NDM-F CATTAGCCGCTGCATTGATG 83 - 
NDM-R GTCGCCAGTTTCCATTTGCT - 
NDM-Pr CATGCCCGGTGAAATCCGCC TAM, later changed 
to TEXAS RED 
KPC-F TGCAGAGCCCAGTGTCAGTTT   138 - 
KPC-R CGCTCTATCGGCGATACCA - 
KPC-Pr TTCCGTCACGGCGCGCG FAM 
F, forward primer; R, reverse primer; Pr, probe; bp, base pairs 



















Table 6: Primer and probe mix components 
Mix name Primer/Probe 
components 
Volume of 100 µM 
stock required 
Volume of water 
added to mix (total 
mix volume) 






45 µl  30 µl (300 µl) 










75 µl (300 µl) 
IMP (R1+R2) 
 
22.5 µl  
Probe mix OXA-48 11.25 µl 223.5 µl (300 µl) 
VIM 11.25 µl 
IMP1 12 µl 
IMP2 12 µl 
NDM 15 µl 
KPC 15 µl 
 
3.4.7 Master Mix 
The PCR master mix was prepared according to the volumes in Table 7.  
 
Table 7: Real-time PCR Master mix components  
Reagent Volume per reaction (µl) 
iTaq universal probes supermix* 10 
Primer mix 1 1 
Primer mix 2 1 
Probe mix 1 
Molecular-grade water^ 2 
DNA extract 5 
Total  20 




3.4.8 Real-Time PCR 
RT-PCR was performed on the CFX96 thermocycler (Bio-Rad), using the cycling conditions 
described by the manufacturer for the iTaq universal probes supermix (Bio-Rad) and the published 
annealing temperature of 60°C  (van der Zee et al., 2014). The protocol was set to run for 40 
cycles, under the following conditions: initial iTaq activation and denaturation at 95°C for 4 minutes, 
then annealing/elongation at 60°C for 30 seconds; followed by 15 seconds denaturation step for 
each subsequent cycle with a total run time of approximately 1 hour. 
 
3.4.9 Gel electrophoresis 
During evaluation/optimisation of the PCR, all PCR products were resolved by gel electrophoresis 
to confirm the presence or absence of the 5 carbapenemase targets. Briefly, a 2% w/v gel was 
prepared using 2 g agarose (Bioline, London, UK), 100 ml 1X TBE buffer (Sigma-Aldrich) and 
ethidium bromide solution (Sigma-Aldrich) at a dilution of 1/20,000 (5 µl). Products were resolved in 
a Sub-cell GT Cell (Bio-Rad) for 20 minutes at 150 V, alongside a 100 bp hyperladderTM (Bioline). 
Gels were visualised under UV light using a G: Box Imager (Syngene, Cambridge, UK). 
 
3.4.10 Discrepant results 
Where a negative result was reported from the in-house PCR, compared to a positive result from 
the referring laboratory, gel electrophoresis was first performed. If a band was not detected, 
isolates were then referred to Dr David Wareham (Queen Mary College, University of London, UK) 
for further testing. If the in-house PCR detected a target which was not reported from the referring 
laboratory, this was confirmed by a lateral flow device, according to the manufacturer’s instructions 





3.5.1 Positive and negative control strains 
Ten positive control isolates, consisting of two of each target, were initially tested to verify the PCR 
was fit for purpose. All 10 were correctly identified by PCR, an example of a RT-PCR curve is 
illustrated in Figure 4. Once the carbapenemase presence was confirmed by PCR, all remaining 






Figure 4: Example of a real-time curve for the RT-PCR 
 
Testing of subsequent control isolates revealed all NDM-containing isolates were positive for VIM 
also. However, when resolved by gel electrophoresis, only the NDM bands were present. All NDM 
isolates were re-tested using VIM-only primers and probes and gave a negative result. This 
indicated that there was an issue with probe detection, with the TAM (NDM) probe (wavelength 555 
nm-576 nm) potentially being detected in the same channel as JOE (VIM) (wavelength 520 nm-548 
nm) on the thermocycler. To test this theory, the TAM dye was changed to TEXAS RED 
(wavelength 583 nm-603 nm) on the NDM probe and the isolates were re-tested.   
All NDM control isolates were positive for NDM only on re-testing, therefore, for all further testing 
the TEXAS RED probe was used. 







Figure 5: Agarose gel confirming presence of OXA-48 and NDM targets 
 
Once the NDM-probe issue was resolved, it was revealed that all 64 positive and 31 negative 
controls were correctly amplified and detected by the in-house PCR. An additional NDM was 
detected using the in-house PCR and a KPC that was initially reported by the reference laboratory 
was not detected by the in-house PCR. Following confirmation by gel electrophoresis (Figure 5) 
and an external laboratory, KPC was confirmed to be absent in this isolate. Results are displayed 
in Table 8.  
 
Table 8: RT-PCR results for the positive control strains  
PCR target KPC VIM IMP OXA-48 NDM 
Total number tested 12 20 6 16 11 
Number positive by PCR 11 16 6 16 12 
Number negative by 
PCR 
1 4 0 0 0 
 
The optimised RT-PCR demonstrated a sensitivity, specificity, PPV and NPV of 100%. 
 
3.5.2 Automated versus boil extraction 
Twenty of the positive control isolates underwent successful DNA extraction using both methods, 
with all 20 extracts generating the same qualitative result (positive or negative for carbapenemase). 
However, lower Cq values were observed with the boil method (8.56 – 22.78), compared to the 






Figure 6: Demonstrating the variations in boil versus automated extraction methods 
 
3.5.3 Optimised RT-PCR 
Following the successful evaluation of this PCR, the OXA-48 and IMP targets started to fail 
amplification. The following steps were taken to identify the cause of this issue: 1) Samples were 
repeated using freshly prepared Taq polymerase, primers and probes, 2) products were run with 
primers only and on a gel to determine whether it was a problem with the probes and 3) contact 
was made with the suppliers to ascertain whether there had been any change to the Taq 
polymerase, the primers or probes.  
 
Use of fresh reagents, including new primer batches, did not resolve the detection issue, nor did 
the use of primers only. The mastermix manufacturer noted no change in their reagents and the 
primer/probe manufacturer confirmed all quality control checks had passed. However, a new batch 
was distributed for testing. With no resolution of this issue an alternative Taq polymerase supermix, 
HotStarTaq Plus Mastermix (Qiagen), was trialled. This was used routinely at BHT within the 
molecular departments. Successful detection of all targets was achieved with the HotStarTaq Plus 
Mastermix and this mastermix was then used for the remainder of the project.  
 
Taking into consideration all results reported here, the optimised RT-PCR, in conjunction with the 




Rapid and accurate detection of CPOs is important for screening and management of patients. A 
robust, published assay which detected “the big 5” carbapenemases was optimised and evaluated 
in-house, for use in all future CPO testing, as part of this doctorate. Despite some initial issues with 




















detected all carbapenemases encoded by the positive control isolates. A variety of resistance 
mechanisms, other than carbapenemases, were also tested to ensure there was no cross reactivity 
which would lead to false positive results (Appendix 1).  No cross-reactions were observed with the 
negative control isolates, resulting in a desirable sensitivity and specificity of 100%.  
 
However, it is important to note that this assay detects the big five carbapenemases only. Isolates 
which phenotypically appear as a CPO but which would test negative by the in-house PCR, may 
possess a different carbapenemase enzyme (e.g. OXA-23, SPM, GES, SME, IMI/NMC-A). 
Therefore, if used in routine diagnostics, presumptive CPOs which were PCR-negative would need 
further testing to rule out the presence of an alternative carbapenemase enzyme or allele. This 
would mean the true prevalence of all carbapenemases could potentially be under-reported. The 
in-house PCR is also limited by the alleles it can detect, as it cannot detect new variants that have 
been discovered since this assay was published or those that emerge in the future (van der Zee et 
al., 2014). Van der Zee et al (2014) reported that KPC-3, KPC-2, NDM-1, OXA-48, IMP-18, IMP-28 
and VIM-1 were all detected successfully. However, the authors suggested that the IMP target 
would require additional testing to ensure all alleles can be detected (van der Zee et al., 2014). To 
overcome this issue, it is important that the primers are reviewed on a regular basis and updated, 
when relevant. 
 
A number of the positive control strains used in the PCR evaluation were reported to express VIM 
(n = 4). However, discrepant testing revealed negative results for the VIM target. Accuracy of 
testing VIMs in published literature is well documented (Bordin et al., 2019; Favaro et al., 2014; La 
et al., 2014; Mentasti et al., 2019). It is possible that the incorrect isolate was referred to the 
reference laboratory, which could explain the negative result by the in-house PCR, gel 
electrophoresis, lateral flow and external laboratory. However, it is also possible that the isolates 
possessed a VIM allele that could not be detected, as the in-house PCR is only reported to detect 
VIM-1.The assay employed by the reference laboratory also uses a multiplex PCR, which detects 
NDM, KPC, OXA-48 and VIM only, but specifically VIM-1, VIM-2 and VIM-7 (Ellington et al., 2016).  
PHE’s published evaluation reported this assay to have both a sensitivity and specificity of 100% 
for all targets (Ellington et al., 2016). However, the primers used in the reference method differ to 
those in the in-house PCR. Therefore, it is possible that these VIM alleles were ‘missed’ by the in-
house PCR, although, the discrepant testing provided by the Blizard Institute, School of Medicine & 
Dentistry, Queen Mary University of London casts doubt on this theory. 
 
The presence of an additional carbapenemase (NDM), in an OXA-48 producing isolate, was 
identified and further confirmed by gel electrophoresis during this evaluation, but it was not 
detected by the reference laboratory. This suggests that the in-house PCR assay was more 
sensitive than the one used by the reference laboratory and further confirms the need to regularly 
update the primers and probes used for carbapenemase detection.  
 
An isolate reported to have both OXA-48 and KPC genes was found to only be in possession of 
OXA-48 according to the in-house PCR assay. This was confirmed by gel electrophoresis and 
lateral flow device. It is possible that this discrepancy was caused by both methods covering 
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different alleles or a result of an error in initial testing or reporting by the reference laboratory, or 
that the referring hospital sent an incorrect isolate to the one which was originally tested. Another 
common occurrence in the Microbiology laboratory is the presence of mixed cultures, which could 
explain the initial detection of two separate carbapenemases, perhaps in two different CPOs, but 
only one CPO was subsequently saved. At BHT it is not uncommon to encounter two organisms 
with the same enzyme, which is likely due to a shared plasmid (Findlay et al., 2017a; Queenan and 
Bush, 2007).  
 
Comparison of DNA extraction methods, using both the automated QIAsymphony and a simple boil 
extraction, was performed to determine which was best for DNA recovery and laboratory workflow.  
The boil extraction would potentially facilitate routine use in the diagnostic laboratory by reducing 
cost and the test turnaround time. The boil method reduced the time for DNA extraction from 1.25 
hours to 30 minutes and the cost from £3.70 to approximately £0.03 per isolate.  Despite both 
methods successfully isolating DNA, which was amplified by PCR for all samples, the boil method 
resulted in lower Cq values, indicating a higher concentration of DNA present. A potential factor for 
this could be that the many steps involved with automated extraction result in the loss of some 
DNA. Although this suggests that the boil method is superior to the automated method in recovery 
of DNA, it is likely that the quality of DNA recovered is less than that of the QIAsymphony, as the 
automated method purifies DNA using buffers and alcohols, whereas the boil method simply 
breaks open bacterial cells to release any DNA present. Because of this simplistic method, there is 
also a higher risk of other cell debris being present after the boil extraction, which could interfere 
with subsequent PCR assays. This finding has also been reported in another study, where the boil 
extraction method was preferred to the automated DNA extraction in an effort to reduce both time 
and cost (Oueslati et al., 2018). 
 
Comparing the in-house PCR method with the routine CPO screening at BHT, it can be deduced 
that turnaround times have the potential to be greatly reduced. The current method takes 48 hours 
until a presumptive CPO isolate is referred to the reference laboratory, then up to a further 2 weeks 
for the reference laboratory to perform their testing and return a result. During this time the patient, 
according to the PHE toolkit and BHT infection control policy, is isolated for the duration of their 
stay with strict IPC measures in place. This results in an extremely large cost incurred for the Trust 
and is not practical, given the large number of presumptive isolates identified routinely at BHT and 
the cost of using side rooms or cohorting patients. The in-house PCR, employing the boil extraction 
method, has the potential to reduce this time from >2 weeks to 48 hours for a confirmed result. 




In the current climate of cost-savings, this PCR is cost effective with the potential for routine use or 
in an outbreak setting. Not only is this PCR highly sensitive, it also detected carbapenemase genes 
that the reference laboratory’s test did not. Regular review of both primers and probes would be 
required to ensure validity that all alleles are covered. However, the allele type of the control 
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isolates was not known; this could be considered for future work. By introducing the boil extraction 
method with this real-time PCR assay, the cost and turnaround time of carbapenemase 
identification is reduced further, enabling this test to be performed routinely, if and when required.  
In comparison to the current CPO screening protocol, this PCR would enable detection of CPOs 
carrying NDM, KPC, VIM, IMP or OXA-48 within 48 hours of sample receipt. This TAT could be 
reduced further, were this assay to be adapted for direct testing of patient samples. Though this 
would remove the immediate need for culture and sensitivity testing and provide a same day result, 
confirmation of a positive PCR result would require subsequent identification of the causative 
organism and susceptibility testing. Future work should include determining the limit of detection, to 
demonstrate how many colonies are required for this assay. 
 
Implementation of this assay could help facilitate optimal infection control of infected or colonised 
patients to prevent transmission of CPOs within the hospital and community. This RT-PCR was 






































4.1.1 Prevalence  
Several PPSs conducted both nationally and internationally in conjunction with the routine reporting 
from both diagnostic samples and carbapenemase screening samples, have provided more insight 
into the prevalence of CPOs worldwide (Carter et al., 2015; Poole et al., 2016; Ruiz-Garbajosa et 
al., 2016). Despite this, the true prevalence of CPOs is still very much unknown and is thought to 
be significantly underestimated, due to predominantly reactive, rather than active, screening 
(Henderson et al., 2019). Prior to this project, no community-based studies investigating the 
prevalence of CPOs within the UK had been published (Henderson et al., 2019).  
 
4.1.2 Barts Health Trust infection control policy 
BHT serves a population of 2.5 million, with 1,706 acute and general beds, 177 critical care beds 
and 220 maternity beds.  Of this population, approximately 36% were of Pakistani, Bangladesh or 
Indian origin in the 2017 census (London Datastore), who, if having previously travelled to these 
countries, would be deemed as “high risk”. This, according to the PHE toolkit, requires these 
patients to be isolated and screened in triplicate, prior to de-escalation, if warranted. 
 
The Trust policy states that patients are screened according to the criteria of the PHE toolkit and 
managed accordingly. Unlike other London Trusts, no specific patient groups were screened for 
CPOs at BHT prior to this study. Screening was only performed reactively on suspected or 
confirmed CPO-positive patients and their contacts. Therefore, it was important to establish which 
patients needed to be investigated for CPOs, based on BHT’s patient population, local CPO 
prevalence and at-risk patient groups. 
 
4.1.3 Point Prevalence Studies 
Point prevalence is the term given to the total number of cases at a specified time point (Centers 
for Disease Control and Prevention). This PPS was performed over a 13-month period. Due to staff 
shortages and lack of co-operation from nursing staff, however, each ward and site was tested at a 
specific time point within the study period. Many PPS have been published worldwide, including in 
the UK (Brett et al., 2019; Carter et al., 2015; Ehrhard et al., 2014; Henderson et al., 2020; Huang 









The aim of this study was to determine the prevalence and epidemiology of CPOs in the population 
served by BHT. To date, there have been no reported studies which investigate community CPO 
prevalence within England, making this study novel in our understanding of CPOs.  
 
4.3 Methods  
 
4.3.1 Sources of samples 
Inpatient screening 
Rectal swabs were collected from all consenting inpatients (Royal London Hospital, Whipps Cross 
University Hospital, Newham University Hospital and St Bartholomew’s Hospital), alongside the 
ward’s medical speciality, patient’s country of birth, history of foreign travel, length of hospitalisation 
and history of prior hospitalisation within the past 12 months (Table 10). The ward and bed number 
were used to identify the samples. No patient identifiable information was collected.  
 
For patient groups lacking the capacity to consent (intensive care unit, high dependency unit and 
critical care), no study samples were collected. However, upon completion of routine diagnostic 
testing, stool samples from these wards were referred to this study. Patient identifiable information 
including name, NHS number and hospital number were removed prior to the sample being 
referred.  
 
Community screening  
A total of 200 non-duplicate community stool samples, received sequentially by the Microbiology 
Laboratory at BHT, were included. Patient age, sex and foreign travel history were extracted from 
the laboratory information management system (LIMS), enabling the identification of potential risk 
factors for CPO carriage. 
 
4.3.2 Processing of samples 
Approximately 200 µl of swab diluent, or a pea-sized portion of stool, was transferred into 3 ml of 
nutrient broth and incubated aerobically overnight at 37°C. Following this non-selective enrichment, 
the broth was sub-cultured, using a 10 µl loop, onto selective media (mSuperCARBA, EO labs) and 
incubated for a further 18 - 24 hours, aerobically, at 37°C. Any bacterial growth was identified by 
MALDI-TOF (Bruker Daltonics, Bremen, Germany) with all Enterobacterales, Acinetobacter species 
and Pseudomonas species undergoing AST by disk diffusion, according to EUCAST guidelines 
(EUCAST, 2018). Antibiotics tested were supplied by Oxoid and included meropenem 10 µg 
(MER), ertapenem 10 µg (ERT), fosfomycin 200 µg (FOS), mecillinam 10 µg (MEC), amikacin 30 
µg (AMI), temocillin 30 µg (TEM) and piperacillin/tazobactam 36 µg (TZP). All isolates, regardless 





4.3.3 Statistical analysis  
Statistical analysis was performed to determine the relative risk and 95% confidence interval for the 
potential risk factors.  
The relative risk, calculated the probability of the suspected risk factor occurring within the patient 
groups harbouring a CPO e.g. those documenting foreign travel compared to those not noting 
travel abroad.  
 
Relative risk= A / (A + B) 
          C / (C + D)  
A, number of patients with a CPO and risk factor; B, number of patients without a CPO and risk 
factor; C, number of patients with a CPO and no risk factors; D, number of patients without a CPO 
and no risk factor. 
 
The 95% confidence interval provides a range of values which are 95% certain to match the mean 
of the population being sampled.  
 
 95% confidence interval 
                    S 
X + 1.96 
                  √(N)   
  
X, mean; S, standard deviation; N, number of study participants 
 
4.3.4 Ethics 
Prior to an application with the Health Research Authority (HRA), the Joint Research Management 
Office (JRMO) at BHT had to first approve the project. Full approval from the Trust was received in 
January 2017. The Integrated Research Application System (IRAS) application was submitted as a 
proportionate review and full HRA approval being achieved (IRAS 219422). 
A substantial amendment was made in April 2017 to increase the inpatient study numbers from 200 
to include all inpatients.  
A further substantial amendment was made in November 2017 to include patients unable to 




4.4.1 Inpatient prevalence detected from the point prevalence study  
A total of 977 inpatients were tested as part of the PPS, with a CPO detected in 30/977, generating 
an overall prevalence of 3.1%. Prevalence was lowest at Newham University Hospital (NUH) and in 
ITU, while the highest prevalence was 4.5% at Whipps Cross Hospital (WX). Five patients 





Table 9: Distribution of CPOs across all sites of BHT 
   Site                Number of samples       Number of CPOs       Prevalence (%) 
RLH 290 5 NDM* 
4 OXA-48* 
2.76 
Barts 179 4 NDM 2.2 
NUH 96 1 NDM 1.04 
WX 353 10 NDM^ 
10 OXA-48^ 
4.5 
ITU (All sites) 59 1 NDM 1.69 
Total 977 35 3.1 
(Henderson et al., 2020) 
*9 isolates from 8 patients; ^20 isolates from 16 patients; RLH, Royal London; Barts, St 
Bartholomew’s Hospital; ITU, Intensive care unit; NUH, Newham University Hospital; WX, Whipps 
Cross University Hospital 
 
The majority of the carbapenemases at BHT were NDMs (60%), followed by OXA-48s (40%). No 










Foreign travel in 
the last 12 
months?  
Previous hospitalisation 







PPS1 Cardiac - - - - K. pneumoniae NDM 
PPS2 Cardiac UK Budapest - - K. pneumoniae NDM 
PPS3 Thoracic surgery UK No - - K. pneumoniae NDM 
PPS4 - - - - - E. cloacae NDM 
PPS5 Elderly care Ireland No Yes, NK 7 days E. cloacae NDM 
PPS6 Diabetes UK - - 2 weeks E. cloacae NDM 
PPS7 - - - - 8 days E. coli NDM 
PPS8 - - - - 3 days E. coli NDM 
PPS9 Urology - - Yes, NK 6 days E. coli NDM 
PPS10 Urology England - - 6 weeks E. coli NDM 
PPS11 - South Africa No No 4 weeks K. pneumoniae NDM 
PPS12 Orthopaedics India Yes- Pakistan Yes, London 5 days E. coli NDM 
PPS13 - - - - - E. coli NDM 
PPS14 OPS - No Yes, London 6 days P. oryzihabitans NDM 
PPS15 - - - - - K. pneumoniae OXA-48 
PPS16 Respiratory - - - - K. pneumoniae OXA-48 
PPS17 Renal USA No Yes, London - E. cloacae NDM 
PPS18 Renal - No Yes, London - E. cloacae OXA-48 
PPS19A Renal UK Portugal & Dubai Yes, NK - K. pneumoniae OXA-48 
PPS19B Renal UK Portugal & Dubai Yes, NK - K. pneumoniae OXA-48 
PPS20 - - - - - P. mirabilis NDM 
PPS21 OPS Bangladesh Yes No - E. coli NDM 
PPS22 I&I - Congo Yes, London 6 weeks K. pneumoniae NDM 
PPS23 I&I Mozambique Portugal Yes, Abroad - E. cloacae NDM 
PPS24 OPS UK No - 6 days K. pneumoniae NDM 
PPS25 Respiratory UK - - - E. coli NDM 
PPS26 Elderly care - - - - K. pneumoniae OXA-48 
PPS27A Elderly care UK No No 4 weeks P. mirabilis OXA-48 
PPS27B Elderly care UK No No 4 weeks K. pneumoniae OXA-48 
PPS28A Elderly care UK No Yes, NK 1 week K. pneumoniae OXA-48 
PPS28B Elderly care UK No Yes, NK 1 week E. coli OXA-48 
PPS29A Urology UK No No 6 weeks E. coli OXA-48 
PPS29B Urology UK No No 6 weeks C. freundii OXA-48 
PPS30A ENT UK No No 1 week E. coli OXA-48 
PPS30B ENT UK No No 1 week K. pneumoniae OXA-48 
OPS, Old people service; I&I, Infection & immunity; NK, Not known; ENT, Ear, nose & throat; -, data not provided 
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Much of the risk-factor data was unknown, however, it was collected for 56.7% of cases with 
country of birth and foreign travel, 76.7% for speciality, 50% for previous hospitalisation and 56.7% 
for total length of hospitalisation.  
 
The countries of birth reported included the UK 36.6% (11), Ireland 3.3 % (1), South Africa 3.3 % 
(1), India 3.3 % (1), Bangladesh 3.3 % (1), USA 3.3 % (1), Dominican Republic of Congo 3.3% (1) 
and Mozambique 3.3% % (1). Foreign travel was reported to Budapest 3.3% (1), Pakistan 3.3% 
(1), Portugal 6.7% (2), Dubai 3.3% (1), Congo 3.3% (1), unknown origin 3.3% (1) and no travel 
selected 36.7% (11). Speciality was reported as cardiac 6.7% (2) thoracic surgery 3.3% (1), 
diabetes 3.3% (1), urology/ renal 20% (6), orthopaedics 3.3% (1), OPS 10% (3), respiratory 6.7% 
(2), ENT 3.3% (1) care of the elderly 13% (4) and I&I 6.7% (2). Previous hospitalisation was 
recorded as previous hospitalisation but location unknown 10% (3), WX 10% (3), Barts 3.3% (1), 
Queens Hospital 3.3% (1) and a Portuguese hospital 3.3% (1). The total length of hospitalisation 
ranged from 5 days to 6 weeks. These risk factors and calculated relative risk are listed in table 11. 
 
Table 11: Risk factors and associated relative risk 





Relative risk 95% confidence 
intervals 
Hospital admission >2 weeks 146 5 1.34 0.47 - 3.87 
Any previous hospitalisation 
within 12 months 
127 12 5.08 2.1 - 12.2 
UK hospitalisation within 12 
months 
123 5 2.2 0.7 - 6.6 
Hospitalisation abroad within 
12 months 
4 1 17.28 2.8 - 107.9 
Foreign travel in past 12 
months 
52 7 5.43 1.9 - 10.6 
Travel to India, Pakistan or 
Bangladesh 
11 1 4.97 0.7 - 35.49 
Born outside of the UK and 
Ireland 
128 5 0.99 0.4 - 2.6 
Born in India, Pakistan or 
Bangladesh 
53 2 1.27 0.3 - 5.4 
Renal care 45 3 1.27 0.4 - 4 
Elderly Care 100 7 1.39 0.61 - 3.15 
 
Hospitalisation within the past 12 months was associated with a high risk of CPO carriage (5.08). 
Including, where specified, both hospitalisations abroad and within the UK, 17.28 and 2.2, 
respectively. Specialities associated with increased burden of CPO carriage included renal patients 





4.4.2 Community prevalence of CPOs detected  
The community study population was comprised of a relatively even split of male to female patients 
(48.5 and 51.5%), aged between 1 - 93 years. A large proportion (77%) of ethnicity codes were not 
completed on the LIMS when the original diagnostic sample was sent, therefore, this data was 
limited. Where this information was available, 9% were British, 6.5% Asian, 1% Caribbean and 1% 
African and 5.5% were listed as other.  Foreign travel was listed for 23.5% (Table 12). 
 
Table 12: Number of participants and countries associated with foreign travel 






Foreign travel  Number of 
participants 
Bali  1 Greece  1 Philippines  1 
Bangladesh  8 Hungary  1 Portugal  1 
Brazil 1 India  5 Romania  1 
Caribbean 2 Lithuania  1 Spain  2 
Egypt  1 Mexico  1 Sri Lanka  2 
Estonia  1 Morocco  4 Thailand   1 
France  1 Nepal  2 Turkey  3 
Germany  1 Nigeria  1 Vietnam  1 
Gran Canaria  1 No travel 121   
Granada  1 Not listed 30   
 
A total of 20/200 (10%) isolates grew on selective media and went onto be identified, have AST 
and in-house PCR (Table 13). From these 20 isolates, only one tested positive for possession of an 
enzyme by PCR: an NDM. Demographical information from this patient revealed they were male, 
born in 1985, had recently travelled to the Caribbean and were suffering from diarrhoea. The 
antibiogram of this NDM-producing P. aeruginosa revealed resistance to ertapenem, 


















Table 13: RT-PCR, risk factor and antibiogram results for the community isolates 
 
 
G - Other mixed race, K – Bangladeshi, NS- Not stated, A - British 
(Henderson et al., 2019) 
 
  








R R S R R R R F G  NS 
Enterobacter 
cloacae 
S R S R S S S M K  None 
Escherichia 
coli 
R R S S S S S F NS Egypt 
Acinetobacter 
baumannii 
I I S R R S R F NS Caribbean  
Pseudomonas 
citronellolis 
I S S R R S R M A  NS 
Pseudomonas 
graminis 




R R S R S S R M NS Caribbean   
Pseudomonas 
citronellolis 
S S S R R S R M NS None 
Enterobacter 
asburiae 
R R I S R S R M A  None 
Pseudomonas 
aeruginosa  
S I R R S S R F NS None 
Enterobacter 
kobei 
S R S R S S S F NS None 
Pseudomonas 
graminis 
R S S R R I R M A  None 
Aeromonas 
hydrophila 
S S S S S S S M NS None 
Comamonas 
terrigena 
R R S R R I R M NS None 
Klebsiella 
pneumoniae 
S S S S R S S M NS None 
Escherichia 
coli 
S R S R S S S F NS None 
Proteus 
mirabilis  
S S I S S S S M NS None 
Pseudomonas 
otitidis 
R S S R R R R F NS None 
Pseudomonas 
aeruginosa  
I S S R R S R M NS None 
Escherichia 
coli 






PHE guidelines state that patients from high-risk geographical locations such as Bangladesh, India, 
South East Asia, Italy, Turkey, Greece and Israel are considered high risk for CPO carriage and 
infection. At BHT, a significant proportion of the patient population originates from these high-risk 
locations, however, no active screening based on these criteria is performed.  
 
On a global scale, the exact prevalence of CPOs has not been determined, with areas including 
Africa and the Caribbean largely unknown, compared with Europe, Asia and the USA, where there 
is an array of published data (Trepanier et al., 2017; van Duin and Doi, 2017). Even countries in 
close proximity to each other demonstrate a large difference in CPO prevalence. For example, 
France has an estimated CPO prevalence of <1%, compared with Italy, which is reported to have a 
much higher CPO burden of 26.8% (ECDC, Surveillance Atlas of Infectious Diseases). Within 
England there are several published reports on PPSs looking at carbapenemase carriage from 
Cambridge, Manchester and Greater London (Otter et al., 2016; Poole et al., 2016; Wilson et al., 
2018). The prevalence of CPOs varies greatly, dependant on the area in which it was performed. 
Hospitals in Manchester have published rates of up to 11%, compared with Cambridge, where no 
cases of CPOs were reported. Similarly, this has been observed with Vietnam also, where the CPO 
prevalence has been reported as an alarming 52% (Tran et al., 2019),  whereas, the neighbouring 
country of Thailand has reported a prevalence of just 1.4% (Chotiprasitsakul et al., 2019). This 
further emphasises the need for more local data and enhanced screening, to enable us to 
determine the true prevalence at a local, national and international level.  
 
4.5.2 Inpatient prevalence of CPOs 
The overall prevalence of CPOs determined in this study was 3.1% (Table 9). This is higher 
compared with two other large London acute NHS Trusts (Otter et al., 2016, Carter et al., 2015). Of 
note, the prevalence calculated here was also higher than the figure calculated by PHE (2.2%), 
which was based on data from diagnostic and routine samples. This is likely due to the PPS being 
active surveillance and, therefore, was expected to return more positive results, rather than the 
PHE data which was based on passive surveillance.  
 
Only two carbapenemases were detected in the PPS, NDM and OXA-48, of which NDM was 
identified in the majority of CPOs (60%). Other studies conducted in London reported similar 
findings, indicating that BHT suffers with CPEs similarly to other hospitals in the same city (Otter et 
al., 2016). NDMs were originally identified in India and still have a high prevalence in Asia (van 
Duin and Doi, 2017). Given that BHT serves a large proportion of residents from that part of the 
world, the high prevalence observed in this study is not unsurprising. A UK study performed over a 
6 month period, with the aim of investigating CPE prevalence, identified KPC as the most 
frequently isolated carbapenemase (56%), followed by OXA-48-like (28%), NDM (12%) and VIM 
(4%) (Trepanier et al., 2017). As Manchester is reported to have a large burden of KPC-producers, 
plus small numbers of OXA-48 enzymes, it is likely that this KPC predominance skewed the study 
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findings and suggests that KPCs may indeed be more localised to Manchester and the surrounding 
areas, given the lack of KPC reports outside of this region (Poole et al., 2016). However, in keeping 
with all other UK reports, the PPS (Table 10) identified K. pneumoniae as the most frequently 
identified CPO (40%), followed by E. coli (31.4%) and E. cloacae (17.1%) (Freeman et al., 2020; 
Trepanier et al., 2017). 
 
4.5.3 Community prevalence of CPOs 
Just one CPO was identified in the community study, an NDM-producing P. aeruginosa, generating 
a prevalence of 0.5%.  Unlike the inpatient study, a higher proportion of community patients (19%) 
either originated from, or noted recent foreign travel to, a high-risk country, as determined by PHE 
(PHE, 2013). However, the CPO-positive patient here had no history of foreign travel to a high-risk 
region, but instead, a recent trip to the Caribbean. This community isolate was susceptible to 
meropenem in vitro, demonstrating the previously discussed antimicrobial susceptibility patterns 
reported with some carbapenemase producers (chapter 1.7 and 1.8.2). 
 
Few studies have been conducted on the community prevalence of CPEs, outside the UK, 
compared with inpatient prevalence. However, a recent review documented a global community 
CPE prevalence ranging between 0% - 29.5%, while a Chinese community study calculated the 
CPE prevalence as 1.1%, comprised mostly of NDMs (Kelly et al., 2017; Cheng et al., 2018). 
In Latin America and the Caribbean, both the presence and endemicity of carbapenemases has 
been documented throughout this region. KPCs were predominantly identified in Enterobacterales, 
OXA-type enzymes within A. baumannii and MBLs within P. aeruginosa, which is consistent with 
the one community CPO positive patient in this study (Escandon-Vargas et al., 2017). Similar to the 
community study performed here, a Belgian study also described CPO-positive patients to have 
travelled to countries not associated with a high CPE burden (Multicenter study of the prevalence 
of carbapenem non-susceptible Enterobacteriaceae (CNSE) and of carbapenemase-producing 
Enterobacteriaceae (CPE) in Belgium in 2015, A Multicenter Study Group, 2016). Together, this 
data highlights the need for a review of countries which are currently deemed as high-risk and, 
perhaps those which are not, within the PHE toolkit. 
 
4.5.4 Risk factors associated with CPO carriage 
Reviewing the PPS results, the renal and care of the elderly wards were the specialities with the 
highest burden of CPOs (7% and 6.7%, respectively). Renal patients frequently receive treatment 
abroad and are very rarely treated in side rooms, plus the decontamination of dialysis equipment 
in-between patients has proved challenging, due to the high demand versus the availability of 
equipment, all of which increases the risk of CPO acquisition and transmission (Graham-Brown et 
al., 2015). Moreover, the elderly commonly have reduced mobility and levels of hygiene, which 
could facilitate the transmission of CPOs between patients and the environment (PHE, 2015; Draz 
et al., 2018). The higher number of cases observed in elderly patients may also correspond with 
the higher prevalence of CPOs detected at WX, as this site covers a very large elderly population 
compared with the other hospitals within BHT. In addition, both renal and elderly patients are more 
likely to have increased use of antibiotics, which has been reported as a risk factor for CPO 
acquisition, and transfer between multiple wards, due to the management of co-morbidities (ECDC 
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Technical report, 2011). Despite these specialities appearing to have a higher burden of CPOs, 
with many contributing factors, their RR was low (1.27 and 1.39, respectively), suggesting they are 
not significant risk factors here.  
 
The PHE toolkit notes that previous hospitalisation, both abroad and within the UK, increases the 
risk of CPE acquisition (PHE, 2013). In this PPS, the majority of patients (79.9%) had documented 
previous hospitalisation (Table 11), of which 3.3% was abroad. The RR for all previous 
hospitalisation was high at 5.08, but low for the UK (2.2) and extremely high for hospitalisation 
abroad (17.28). However, it is important to note that hospitalisation abroad had a wide confidence 
interval due to the low number of patients in this category. Despite this, this study agrees that 
previous hospitalisation is a common risk factor for CPOs. 
 
The PHE toolkit also describes birth in a high-risk country as an important risk factor for CPOs. 
However, the RR for patients born in India, Pakistan or Bangladesh was low (1.27), compared with 
patients who had recently travelled to these areas (4.97). This suggests that travel to these 
countries poses a higher risk of CPO carriage, rather than place of birth. Travel abroad has 
frequently been noted as a risk factor for CPO carriage, therefore, this finding was not unsurprising 
(Peirano et al., 2014; PHE, 2013; Trepanier et al., 2017). The RR for overseas travel, not 
destination-specific, was similar to that calculated for travel to India, Pakistan and Bangladesh 
(4.53), suggesting that perhaps all travel should be considered a risk factor and not just specific 
countries. In addition, the overall RR for patients born overseas was low (0.99), which was similar 
to the RR calculated for patients born in India, Pakistan and Bangladesh. This adds further weight 
to the notion that birth in these countries is not a risk factor for BHT, however, travel is.  
 
A study conducted by Mookerjee et al. (2018) revealed that the presence of MDR bacteria 
increased the longer the patient was hospitalised (Mookerjee et al., 2018). Therefore, the length of 
hospital admission versus CPO prevalence was analysed in this PPS. However, no association 
was found, with a hospital stay >2 weeks resulting in a low RR (1.34). This was possibly because 
the admission period was highly varied for our study patients. 
 
Risk factors from the community study could not be accurately determined, as patients included in 
this study presented with presumptive gastro-intestinal infection, which likely changed the flora of 
the gastrointestinal tract at the time of sampling from its normal state. During an infection like this, 
the causative organism would be in high numbers, therefore, making the detection of a low-level 
CPO, if present, less likely (Sattar and Singh, 2020). In addition, just one CPO was isolated from 
the community study. In the future, if this study was to be repeated or conducted over a longer 
period of time, risk factors could potentially be identified.  
The prevalence across all of BHT (Table 9) varied across the different sites, despite the hospitals 
being in relatively close proximity to each other. Therefore, it is likely that hospital-specific factors 
are important here, rather than the patient population which is served. For example, WX 
predominantly treats an elderly population, the RLH has large vascular and neurological 
departments, a large trauma unit and tertiary referral centre, while SBH is a specialist centre for 
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oncology and cardiac services. All these factors likely play a role in the CPO variation observed 
here. 
 
4.5.5 Limitations to this study 
The methods in this study included the non-selective nutrient broth enrichment. Although this is an 
enrichment step, it cannot be determined if bacteria were preferentially increased in yield or 
whether there was a universal effect. Enrichment has the potential to increase the numbers of 
susceptible gut bacteria and reduce the numbers of MDR bacteria down to undetectable levels. To 
overcome this, a carbapenem disk could have been used to prevent the overgrowth of all 
susceptible bacteria and target the enrichment of MDR bacteria (Ciesielczuk et al., 2018). 
However, this was not performed, as the initial evaluation of the AST revealed CPOs susceptible to 
the carbapenem. Therefore, non-selective enrichment was performed to ensure detection of all 
possible CPOs. In addition, the rectal swab was not inspected for presence of faecal matter prior to 
testing, which PHE have reported may increase the recovery of CPOs (PHE, 2013). Therefore, the 
prevalence reported here could be under-represented. 
 
This PPS was designed to assess the prevalence of CPOs at specific time points. It was not to 
determine at what stage the patient acquired the CPO. To enable this information to be gathered, 
future studies could screen the patient on admission and then weekly thereafter, regardless of CPO 
status. It would also allow the determination of transient versus established carriage and whether it 
was possible for a previously positive carrier to revert and maintain a negative CPO status.  
 
A major limitation of this study was receiving partially completed questionnaires. This will have 
impacted the risk factor information. To overcome this, the researcher could accompany the nurse 
whilst collecting the sample, to ensure the questionnaire is completed fully. Reasons for incomplete 
paperwork included staff shortages and failure for staff to fully commit to the study. These reasons 
were attributed to 58% of all inpatients across BHT included in this study. In addition to patients 
feeling too unwell, a rectal swab may also have been perceived as an embarrassing sample type, 
meaning a proportion of inpatients did not participate in the study.  
 
The methodology employed in the community prevalence study also lends a degree of bias. 
Samples were tested from patients presenting with gastroenteritis-like symptoms. To overcome 
this, samples could be taken from a random group in the community, without any additional factors, 
for example, stool samples collected from individuals throughout the country (McNulty et al., 2018). 
 
Despite many advantages of PCR, its main limitation is the ability to detect pre-defined targets 
only. Therefore, this assay cannot detect new variants of the included carbapenemase targets, 
which would lead to false negative results and also carbapenemases not covered by this PCR, 
leading to under-reporting of CPOs. One way to overcome this limitation would be to perform whole 





4.6 Conclusion  
 
The PPS was conducted over a 13-month period and noted a 3.1% CPO prevalence at BHT. Risk 
factors were largely in agreement with the PHE toolkit, including previous hospitalisation. Renal 
and care of the elderly wards were also noted as specialities associated with an increased CPO 
burden.    
 
The community prevalence was deemed to be low at 0.5%, despite the great number of “high risk” 
patients served by BHT. This study also indicated that the countries listed as high risk, in the PHE 
toolkit, may need updating, as the positive patient noted recent travel to a country not listed.  
 
Currently, at BHT, no specific patient groups are routinely screened for CPOs. Therefore, it was 
important to establish which patients need to be investigated for CPOs, if any, based on BHT’s 
specific patient population, local CPO prevalence and at-risk patient groups, to prevent carriage, 
subsequent infection and possible outbreaks. This study highlighted the importance of all large 
acute trusts performing a CPO PPS to establish their own prevalence and screening protocol. 
 
Based on these findings, it would be prudent for BHT to start screening, i) care of the elderly, ii) 
renal patients, iii) patients noting previous travel abroad, iv) patients with previous hospitalisation, 























Chapter 5: Sequential Screening of Patients During a Suspected 




Carriage of a CPO is the term given when an individual is colonised with a carbapenemase 
producer. Carriage of CPOs is predominantly in the intestinal tract and, therefore, excretion 
(elimination) of the CPO through production of a faecal sample (Pan et al., 2019). With transient or 
intermittent carriage, the patient does not test positive for presence of a CPO at each screening 
point. The number of CPOs could be present in low numbers and therefore be undetectable. 
Detection also relies on the sensitivity of the test performed. This can therefore also be described 
as transient detection.  
 
Sequential screening to determine carriage status is the taking of multiple samples from the same 
patient, whether it be one closely followed by another, with no specific schedule, or at designated 
time points. For CPOs, results from these serial screens can be used to determine; i) at what stage 
the patient acquired the CPO, ii) identify the possible sources of acquisition, iii) determine whether 
conversion back to negative status can occur, iv) determine whether patients remain negative and 
v) identify transmission between patients. 
 
National guidelines state that, on admission, a suspected carrier of a CPE should have a rectal 
swab taken (day 0) and the patient isolated with strict IPC measures. If the screen is negative, a 
further two screens should take place 48 hours apart (day 2 and day 4). If the patient remains 
negative they can then be de-isolated, and no further screening is required. If the patient returns a 
positive screen, the patient must remain in isolation with weekly screens to monitor carriage status 
(PHE, 2013).   
 
A study conducted by Mookerjee et al. (2018) evaluated two screening scenarios for the detection 
of MDR bacteria and CPE. In one scenario patients received three screens as follows: within 24 
hours of admission, between 25-72 hours post admission and then between 73-120 hours post 
admission. The second group still received three sequential screens, however, specified time 
points were not assigned. The findings from this study determined that screening at specified time 
points displayed no difference in Gram-negative MDR bacteria, including CPE, as opposed to 
screening at non-designated time points which presented a large increase in the numbers of MDR 
bacteria as time went on. However, these were not CPE. The study concluded that serial screening 
is a useful tool in long term patients to detect carriage of MDR bacteria, but not specifically CPE 
(Mookerjee et al., 2018).  
 
The aim of this study was to review screening data to establish the carriage status and conversion 
between positive and negative CPE carriage. It was also to determine whether a previously 
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confirmed carrier for CPE can transition to and remain negative for CPE carriage, which would 
enable patients to be removed from isolation facilities.  
 
 5.2 Methods 
 
Screening data was extracted from the LIMS following a suspected outbreak of organisms 
harbouring OXA-48-like carbapenemases, over a 22-month period, from May 2016 to March 2018. 
This period was chosen to ensure the screening data included a number of positive samples for 
analysis. Data collected included patient demographics, dates of screening and CPE status. 
 
As the data extracted was performed by a registered Biomedical Scientist employed by BHT (not 
the main researcher), ethical approval was not required. Data was then anonymised before being 
available for analysis.   
 
Screening had been performed using a rectal swab and processed as described in chapter 3.4.1, 
with the addition of a temocillin disk to the enrichment broth to ensure recovery of OXA-48 
producers (Ciesielczuk et al., 2018). 
 
Screening was performed on admission to the outbreak ward, followed by weekly screening on all 
patients with a negative carrier status. When patients were confirmed as a CPE carrier, weekly 
screens were stopped based on a decision made by the outbreak control team, as they felt that 
taking additional samples may increase the risk of the CPE transmission in the local environment 
and between patients.   
 
5.3 The outbreak timeline and IPC measures 
 
During the outbreak a high standard of IPC practises were employed that exceeded the standard 
practices and SOP, with both daily hypochlorite cleaning, together with a one-off deep clean 
utilising UV light, which was performed following the first outbreak meeting in July 2016. In October 
of that year, environmental swabbing took place and identified an OXA-48-producing organism 
from a mattress of one of the ward beds. Cases increased dramatically from this time until 
December 2016, resulting in heightened training of staff, increased infection control staff 
attendance and regular audits conducted by a senior nurse.  In December 2016 the ward was 
closed, with only one patient remaining, and a further deep clean utilising UV light took place, prior 
to the ward being re-opened. Throughout 2017, cases continued to rise and fall at the same rate, 
with no known cause. Increased interventions during this time included allocating individual 
commodes, increased staff education, improved hand hygiene by staff and patients, active 
screening, cohorting of positive patients, reduced access to the ward, sampling and descaling of 
drains and introduction of a medical champion, who was responsible for the monitoring antibiotic 
prescribing. The final reduction in cases was achieved by disinfecting the entire ward, in December 
2017, with vaporised hydrogen peroxide, discarding of items which could not be decontaminated, 
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enhanced communication and compliance with strict personal protective equipment (PPE) and IPC 




A total of 815 patients were screened for carriage of organisms producing an OXA-48-like 
carbapenemase during the suspected outbreak on a surgical ward at BHT. Of these, 137 (16.8%) 
patients had at least one positive CPE detected, of which the majority were considered to be 
colonisation/carriage, while 4 CPE were recovered from clinical samples and, therefore, considered 
to be an infection. For these CPE-positive patients, 60% received just one screen, 24.1% had 2 
screens, 8% had 3 screens, 3% had 4 screens, 2% had 5 screens, 1.5% had 6 screens and 0.71% 
had 9 screens. 
 
Of the remaining 678 patients who were negative for a CPE during their admission, all had 
between 1 to 14 rectal screening swabs collected as part of their admission. As routine screening 
on this ward was recommended to take place weekly, a large proportion of the patients on this 
ward remained negative for the carriage of a CPO for the duration of their stay.  
 
Figures 7 to 10 below detail the screening schedule for each patient, according to the number of 
CPE screens they received. Due to the long-time line and interval between screening, some 



























Figure 7: Screening schedule for patients receiving two CPE screens (2016) 
Green box, negative screen; Red box, positive screen for OXA-48 CPE. The second screens for 
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Figure 8: Screening schedule for patients receiving two CPE screens (2017 – 2018) 
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Figure 9: Screening schedule for patients receiving three - four CPE screens (2016 – 2018) 
Green box, negative screen; Red box, positive screen for OXA-48
2016 2017 2018 

































Figure 10: Screening schedule for patients receiving five- nine CPE screens (2017 – 2018) 
Green box, negative screen; Red box, positive screen for OXA-48; orange box, for NDM
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Figures 7 to 10 reveal the screening schedule to be irregular for many patients, while most were 
performed on a weekly basis, as per the BHT policy. Despite the methods described for this 
chapter, many patients who were positive still received weekly screens thereafter. This outbreak 




There are few publications that have determined the relevance of sequential screening and the 
optimal number of CPE screens required for management of colonisation and infection. One study 
reported no significant findings when screens were performed at three designated time points, as 
per the PHE toolkit recommendations. Although there were no CPEs detected in this study, 
increased hospitalisation was associated with an increase in MDR bacteria and could therefore be 
perceived as a risk factor for CPE acquisition also (Mookerjee et al., 2018; PHE, 2013). A second 
study evaluated a new screening policy, whereby all re-admissions, who were previously known to 
be KPC positive, were screened for CPEs. The majority (83%) were found to be CPE negative on 
re-admission and all subsequent screens. However, 7.3% of these patients, who were CPE 
negative on re-admission, reverted back to positive, 89% of which occurred within the first three 
serial screens, demonstrating the value of these recommended sequential screens (Tucker et al., 
2019).  
 
Of the 815 patients admitted to the surgical ward during the OXA-48 outbreak, 83.2% were CPE 
negative throughout the duration of their stay, which was similar to the proportion of total negatives 
reported by Tucker et al. (2019).  
 
5.5.1 The PHE Toolkit 
Though the PHE guidance states all the requirements that need to be put in place in the event of 
an outbreak, it does not stipulate the frequency of screening required.  Instead it states that this 
information should be put into a plan for the early management of the outbreak. Based on the 
studies described above and the lack of PHE recommendations regarding serial CPE screens in an 
outbreak setting, BHT aimed to provide further insight into the number of sequential screens 
required and how this relates to the PHE toolkit, as discussed in detail below. 
 
5.5.2 Three or more screens 
From the 678 patients who screened negative for the duration of their stay on the surgical care 
ward, all received between 1 and 14 screens. This demonstrates that, although patients were 
exposed to a CPO, not all acquired or tested positive during their stay. It could be that these 
patients do not have a pre-disposing factor making them susceptible to CPO acquisition, such as 
decreased mobility, prior antibiotic use or presence of indwelling devices, to name but a few. It is 
also possible that these patients performed increased hand hygiene, had different nursing staff or 




From the 54/137 CPE-positive patients who received sequential screens (>1), a number of 
observations could be made. Despite a clear outbreak policy, nursing staff were not following the 
guideline of stopping sequential screens once a patient was confirmed as CPE positive. It was also 
evident that CPE carriage was highly varied, with no obvious pattern, as 41% of patients tested 
positive just once, while 59% tested positive on multiple occasions. For those receiving more than 
3 CPE screens, positivity was confirmed for 14/21 patients in weeks 3 to 5, with all negative 
screens prior to this. Therefore, determining the optimal number of CPE screens for patient 
management is difficult. Of these patients, 13/21 (62%) were positive within the 3-screen 
recommendation. The remaining 38% of patients on this ward would, therefore, have been reported 
as false negative carrier status. This has the potential to lead to further transmission between 
patients and the environment, as these patients would not have the correct IPC measures in place. 
Another patient reverted to negative after one year, which may indicate transient carriage or loss of 
CPE carriage. In this study, transient carriage was determined by patients converting from a 
positive to negative status, while established carriage was applied to those only returning positive 
CPE screens. This suggests that screening known positive carriers at set stages, to determine true 
carriage status, could prove valuable, especially if the patient has an on-going condition which 
requires frequent hospital admissions. Transient carriage has also been reported in literature, 
where a patient with a history of an NDM tested negative on subsequent screens. However, the 
index case in this study returned consistent positive screens, suggesting established carriage 
(D'Andrea et al., 2011). Another study suggested that NDM carriage was more likely to be transient 
compared with KPC carriage. A total of 11.3% of NDM carriers returned three subsequent negative 
screens and were deemed transient carriage, compared to 0% reported for KPC carriage. KPC 
carriage was also noted to persist for a long period of time following discharge (Lim et al., 2018). 
As this study did not detect any KPC-producers and only one NDM-producer reported as transient 
carriage, this finding cannot be confirmed or disputed.  
 
Seven patients, who received 2 to 9 CPE screens, returned negative screens following their one 
and only positive screen. This suggests that carriers, who initially screen positive, can revert to a 
negative status and stay negative for possession of a CPO. Guidance stipulates that once a patient 
has tested positive, they should remain in isolation for the duration of their stay in hospital and 
should be considered positive for their lifetime (PHE, 2013). Isolation whilst in hospital can affect a 
patient’s mental health and also has a large cost to the hospital (Tran et al., 2017). The majority of 
results presented here disagree with this notion that patients remain positive for life and should be 
considered as such. By removing this concept that CPE carriage is indefinite would allow more 
flexibility with patient management, if re-admitted, and free up side rooms for other patients where 
the infection control risk is higher, such as a patient with pulmonary Mycobacterium tuberculosis 
that is multi-drug resistant. However, further studies would be required to confirm whether this 
negative status becomes established or whether it is transient also. It is also possible that patients 
may continually alternate between positive and negative carriage due to the diversity and fluidity of 
the intestinal flora, which is influenced by a course of antibiotics or whether they have a 
gastrointestinal infection at the time of sampling, which can disrupt the normal flora, or even by diet 
and dietary supplements (Dudek-Wicher et al., 2018). 
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5.5.3 NDM positive isolates 
A total of five patients were positive for NDM-producing Enterobacterales during their stay on the 
outbreak ward. Upon detection of the NDMs, the entire outbreak ward was re-tested, as per Trust 
policy for contact cases, and no other NDM cases were detected. The admission stay of the NDM 
positive patients did not cross over with one another. Therefore, it is possible that these patients 
had a positive carrier status prior to admission to this ward, especially as all 5 NDMs were detected 
within the first 3 CPE screens, indicative of a community acquisition. One patient yielded an OXA-
48-producer, followed by an NDM-producer, just one week apart. As there were no other NDMs 
associated with the ward at the time, this was presumed to have been acquired from the 
community. This finding suggests that the patient possessed the NDM-producer on admission and 
then acquired the OXA-48-like carbapenemase-producer while residing on the outbreak ward.  
Though prevalence was low, data from the community study (chapter 4) supports the notion of 
NDMs circulating in the community served by BHT. Another reason for these sporadic cases could 
be possible transmission from the environment via nursing staff (Kabala et al., 2019; Irfan et al., 
2019). 
 
As well as being admitted to the surgical ward associated with the OXA-48 outbreak, these five 
patients had all been admitted to intensive care prior to transfer to BHT and they had received a 
variety of antimicrobials during their admission, both of which have been linked with CPE carriage 
(Labaste et al., 2019; Segagni Lusignani et al., 2020). Another possibility is that these patients 
acquired the NDM during their stay in ITU, as the PPS (chapter 4) identified NDM-producers in 
1.69% of all ITU patients across BHT. One patient was in end stage renal disease and had been on 
haemodialysis and another had been admitted prior to endoscopic retrograde cholangio-
pancreatography. Both of these factors utilise equipment which is often difficult to decontaminate 
thoroughly and requires frequent readmissions to hospital for treatments (Casey et al., 2018; 
Marion-Ferey et al., 2003).  
 
5.5.4 Acquisition of OXA-48 carbapenemase 
A total of 23/54 (42.6%) patients tested CPE negative initially before converting to positive carrier 
status. Of the remaining, 31/54 (57.4%) patients, excluding those with only one screen, were CPE 
positive on their initial screen, but it is difficult to gauge whether patients acquired OXA-48 on the 
ward or prior to admission. However, 10 patients admitted to this ward received more than 3 CPE 
screens and 9/10 of these had at least 3 negative screens before testing positive, suggesting ward-
based acquisition did occur here. It is highly likely that patients admitted to the surgical ward were 
not OXA-48 carriers prior to admission, but rather obtained the CPE after contact with the ward. 
However, as some of these patients had unknown status prior to admission, this cannot be 
confirmed. These patients may also have been transferred from another ward which was identified 
as having a high burden of CPOs (chapter 4). Given our patients came from several boroughs 
across East London and underwent different types of surgery, it is possible that all positive cases 
from this ward obtained the CPE from the community. Patients may have carried a CPO on 
admission, but this was not revealed until after a course of antibiotics affected the gut flora 
(McDonald, 2017). Typing of these OXA-48 isolates by the reference lab and comparison with 
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other London-referred strains would reveal whether this was likely a hospital or community-source 
outbreak (Becker et al., 2018).  
 
5.5.5 Limitations 
This data revealed that, in several instances, the screening policy of taking three samples 48 hours 
apart was not followed. As turnaround times for these tests can vary between 48-72 hours, it is 
possible that the wards collected a repeat sample before the initial result was available. The 
outbreak control team recommended discontinuing repeat screening following a positive CPE 
result, but this guidance was also not followed in many instances. Despite this influencing the data 
for analysis, it did illustrate the heterogeneity of CPE carriage within these patients and in an 
outbreak setting.  
 
Though the PHE toolkit specifies 3 CPE screens for routine testing, when it comes to an outbreak 
setting the recommendations are not so clear (PHE, 2013). A small proportion of patients analysed 
here received more than 3 CPE screens, hence some conclusions could be made. However, this 
study would benefit from a much larger proportion of patients within this group so the true value of 




It was clear from this study that CPE detection was highly diverse within the same patient, but also 
between patients, demonstrating the importance of sequential CPE screening in identifying CPE 
carriage, whether established or transient. This variation in carriage also demonstrates the value of 
completing weekly screens, as recommended in the Trust IPC policy and the PHE toolkit, to 
monitor carriage status. The PHE toolkit also recommends that, once positive, a patient should be 
considered CPE positive for life. However, data from sequential screens indicate that perhaps 
‘positive for the hospital admission’ would be more appropriate and practical, with CPE status being 
reset at each admission until the CPE screen is performed, as CPE positivity is not a permanent 
state in the patients monitored here. 
 
Though the number of CPE screens collected from patients was highly varied in frequency and 
results, the majority (62%) of CPE positive cases were detected within 3 screens, as per the 
recommendation of the PHE toolkit. This allowed IPC teams to determine which of their patients 
had a CPE for optimal management and it also identified possible CPEs circulating in the 
community, such as the NDM cases observed here. However, the remaining 38% of patients did 
not test positive until further screening and would therefore have gone undetected. This suggests 
that weekly monitoring in outbreak situations is necessary to enable the identification of all carriers. 
 
Based on the data presented here, a new CPE screening proposal was formed, as follows: 1) 
screen outbreak wards weekly, as this will identify patients admitted with a CPE but also those that 
acquire one during their admission, 2) if a patient tests positive, screen weekly to determine 
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transient versus established carriage 3) if patient tests negative, cohort with other negative patients 
or transfer to an alternative ward and continue weekly screens, 4) upon re-admission previous 
positive carriers should be re-screened and managed according to their test result, rather than 
previous status.  
 
This research demonstrates the importance of serial screening of CPE carriers, to determine 
transient versus established carriage. Therefore, this study disagrees with the PHE toolkit, which 
states that all CPE carriers should be labelled as a positive carrier status for their lifetime and, 
instead, it can be recommended that patients are de-isolated if they subsequently become 








































The genome is comprised of all the genetic information present in a living cell. Whole genome 
sequencing (WGS) is a method which enables the analysis of this genetic information. WGS can 
be used to detect single-nucleotide variants, insertions, deletions, copy number changes and large-
scale structural variants (Klintman et al., 2018).  
 
Sequencing is comprised of three main steps, 1) library preparation, 2) amplification and 3) 
sequencing. The first step, library preparation, involves the DNA being broken down to result in 
shorter strands. These strands are then joined together to form a complementary counterpart, 
known as library fragments. Secondly, amplification takes place, this can be performed by either 
emulsion PCR or bridge PCR. This step results in the production of large volumes of DNA. The 
finally stage is sequencing, which can be performed in a variety of ways depending on the platform 
and method being used. Pyrosequencing works by formation of a complementary strand and the 
detection of pyrophosphate, following the addition a deoxyribonucleotide triphosphates (dNTP) to 
the strand (Petrosino et al., 2009). Ion torrent semiconductor sequencing is another method of 
sequencing which forms a complementary strand, utilising a semiconductor chip to detect hydrogen 
ions released during the process. Sequencing by ligation, uses DNA ligase to join DNA strands. 
This method involves the target sequence being conjugated to a bead, which is then exposed to 
fluorescently labelled probes. Upon binding to the target sequence, the fluorescence emitted when 
the probe is cleaved can be measured (Brown et al., 2017). Reversible terminator sequencing, also 
referred to as Illumina sequencing, utilises the addition of fluorescently labelled dNTPs, which emit 
a signal and are then cleaved to allow repetition of this step (Illumina, Whole-Genome Sequencing, 
2020). 
 
Analysis of the data produced is dependent on the platform used for sequencing. Each instrument 
utilises different data analysis tools, however, they all involve several core methods, as follows. 
The first stage outputs the files into sequencing reads, known as FASTQ files, together with the 
quality scores, referred to as the Phred quality score. Secondly, reads are then trimmed, with 
removal of low quality reads and then assessed to determine the quality of data. The next step is 
the assembly of reads, which can be classified as either de novo assembly or mapping to a 
reference genome. Where there is no reference sequence (de novo) the reads are then mapped 
back to the assembly to identify areas of low coverage. The quality of de novo data relies on the 
continuity of gene segments, known as contigs with overlapping DNA sequences size (Lander et 
al., 2001). The final step involves the interrogation of the results and extraction of the specific data 
the user is investigating, such as SNP difference, antibiotic resistance genes or genotype (Quainoo 




WGS in bacteriology has a variety of applications, some of which include identification of i) 
bacterial species, ii) resistance genes and mutations, iii) acquired virulence genes, iv) restriction-
modification sites, v) pathogenicity islands, vi) genes involved in toxin production, vii) multi-locus 
sequence typing, viii) plasmids, ix) plasmid typing, x) serotype, xi) spa type and xii) fim type in 
E.coli. These applications make WGS an important tool in microbiology 
(http://www.genomicepidemiology.org/).  
 
Outbreaks of MDR bacteria occur when transmission of bacteria or the transfer of mobile genetic 
elements, within a population, takes place. Vertical transmission is the term used when the 
movement of genes passes from a bacterium to its progeny. Horizontal gene transmission is the 
transmission of resistance inferring mobile elements, such as plasmids and transposons to other 
bacteria (Partridge et al., 2018). Plasmids are small circular DNA fragments, located outside of the 
chromosome, which frequently possess resistance genes and virulence factors. For example, 
IncH12 which has been described to have a role in the transmission of blaIMP-4 (Roberts et al., 
2019). The ability to transfer resistance genes between different genera of bacteria in this way 
enables bacteria to evolve rapidly under environmental stress (Orlek et al., 2017). Transposons are 
DNA fragments which can change location within a genome, making them highly transferable 
between both plasmids and the chromosome (Schaack et al., 2010). They are comprised of short 
tandem repeats at each end and encompass various genes. For example, Tn4401, which has been 
described in K. pneumoniae, is comprised of two insertion sequences, a resolvase gene (tnpR), a 
transposase gene (tnpA) and two 32bp inverted sequences (Cheruvanky et al., 2017). 
 
 
Multi locus sequence typing (MLST) is a tool which can determine the profile of a bacterial species 
and has been used to assess the relatedness of bacterial populations. This technique identifies the 
allele sequences, with assigned numbers, present at specific loci. Isolates are deemed to have the 
same sequence type, if the identical alleles are present at each loci. Relationships between 
different strains can then be determined based on these sequences (Figueroa et al., 2015). For 
example, two bacteria of the same species, with the same sequence type, can then be classed as 
the same clonal complex or strain.  
 
 
Chapter 5 referred to a CPE outbreak on a surgical care ward which lasted over 18 months. This 
suspected outbreak consisted primarily of OXA-48 producers and included several different 
bacterial genera. Due to the varied genera and species reported, it was important to establish 
whether these organisms possessed the same resistance mechanisms and, therefore, determine 
whether transfer of bacteria had occurred between patients within this ward, indicating an outbreak, 









The aim of this part of the study was to answer two principal questions. Firstly, whether isolates 
collected from the prevalence studies (chapter 4) were in any way related to each other or the 
outbreak of OXA-48 producers. Secondly, to establish whether the suspected OXA-48 outbreak, 
was indeed caused by the same strain(s), transmission of a specific mobile genetic element 
between isolates or whether multiple organisms and elements were at play. 
 
6.3 Methods  
 
6.3.1 Isolates for whole genome sequencing (WGS) 
All viable isolates from the PPS (n = 37) and the community (n = 1) prevalence study (chapter 4), 
together with a selection of isolates (n = 16) from the suspected OXA-48 outbreak (chapter 5), 
were sent to MicrobesNG (University of Birmingham, UK) to undergo WGS (Table 14). Isolates 
were cultured on Columbia blood agar (Oxoid, Basingstoke, UK) at 37°C in CO2 for 18-24 hours 
and inoculated into single vials of beads (Microbank, Pro-Lab, Wirral) for transportation to Microbes 
NG. 
 
6.3.2 WGS method 
Samples were washed in extraction buffer and then cells were lysed to release DNA. The DNA was 
purified using SPRI beads (Beckman Coulter, Indianapolis, USA) and eluted prior to quantification, 
by Qubit. Libraries were then sequenced using the Illumina HiSeq (Illumina, California, USA) 
platform using the 250bp paired end read protocol. Trimming and read quality analysis were 
performed by Trimmomatic and quality determined by SAMtools, BWA-MEM and BedTools. A 
genomics software package was then used to map reads to a reference genome (Ormsby et al., 
2016; Percy et al., 2016). Reads as FASTA and FASTQ sequences, respectively, for each isolate 
were made available for subsequent analysis and interrogation. 
 
The FASTA files of reads were analysed using online tools provided by the Center for Genomic 
Epidemiology (http://www.genomicepidemiology.org/). Each genome was analysed for MLST 
profile, plasmid content and acquired antibiotic resistance genes. Relatedness of isolates was 
further determined using CSI phylogeny tools (Kleinheinz et al., 2014; Thomsen et al., 2016). To 
produce the phylogenetic trees for each strain, the FASTA file was uploaded and the assembled 
genome aligned to a reference genome. Filtering removed SNPs within ten base pairs of one 
another and validated SNP positions prior to linking and alignment. The phylogenetic tree was then 
constructed using this alignment (Leekitcharoenphon et al., 2021). The sequence type of each 
strain was determined by the combination of alleles detected from the FASTA file containing the 
assembled genome. The database obtains the allele sequences from PubMLST.org (Larsen et al., 
2021).  The identifcation of acquired antibiotic resistance genes was performed using the 





Plasmids were identified using PlasmidFinder, which uses the NCBI nucleotide to determine the 
plasmid type (Carattoli et al., 2014). A 95% threshold for minimum percentage identify and 60% 




6.4.1 MLST Analysis 
A vast array of genomic characteristics, including resistance markers, plasmids and sequence type, 
were identified within the study isolates and are detailed in Table 14. Thirty-one different sequence 
types were identified, with 1 – 13 MLST groups per species. K. pneumoniae demonstrated the 
greatest variation with 13 different MLST groups, E. coli with 9 and E. cloacae with 9. P. 
aeruginosa and C. freundii only had one isolate and, therefore, just one sequence type (ST) each. 
Both P. mirabilis isolates had an unknown ST. The most common MLST group identified was 
ST245 (n=2) and ST145 (n=2) within E. cloacae and ST17 (n = 10) for K. pneumoniae.  
 
All isolates from the Surgical Care ward (OUT1 to OUT9, Table 14) associated with the OXA-48 
outbreak were compared to identify any links. All belonged to different genera and MLST group, 
except two, which were K. pneumoniae belonging to ST597. The remaining 7 isolates, which were 
from subsequent suspected outbreaks at WX hospital (OUT10 to OUT 16, Table 14), were all K. 
pneumoniae. The majority (n=6) belonged to ST17 and contained identical plasmids and acquired 
resistance genes. 
 
Interestingly, K. pneumoniae ST17 was observed in both the prevalence study (n=4) and surgical 
ward outbreak (n=6), however, the outbreak samples contained an additional plasmid (IncU). The 
resistance genes detected in these isolates were identical. These patients were all inpatients at the 
same hospital, across four different wards.   
 
6.4.2 Plasmids 
The number of plasmids identified within each isolate ranged from one to seven, with IncL/M(OXA-
48), IncN2, IncFIB(K) and IncFII(K) prevalent across all studies. The IncU plasmid was only 
identified in outbreak isolates belonging to K. pneumoniae ST17 (Table 14). There do not appear to 
be any species-specific plasmids. However, the majority of isolates of the same ST carried the 
same plasmids (e.g. IncL/M(pOXA-48), IncFIB(K) and IncU). Each outbreak isolate encoded 
between 2 and 6 different plasmids, the majority of isolates (n=15) encoded an IncL/M(pOXA-48) 
plasmid and 13/16 isolates encoded an IncFIB(K) plasmid. IncHI2A was widely detected in isolates 
which tested positive for an NDM. 
 
6.4.3 Acquired resistance genes 
In total, 95 different antibiotic resistance genes were identified by WGS within the prevalence study 
collection. The number of genes detected per isolate ranged from 1 to 22. There does not appear 
to be any correlation between plasmid number and number of genes conferring resistance. The 
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outbreak isolates (OUT1 - OUT16) appear more conserved, with isolates OUT 10 - OUT15 
possessing identical genes. Isolate OUT16, despite possessing identical plasmids to the other 
outbreak isolates, had additional resistance genes (blaACT-15, sul1, and aadA2b). The number of 
genes detected per outbreak isolate ranged from 1 to 31.  
The antibiotic groups against which resistance would be conferred on expression of the resistance 
genes present in this study (with examples) include; beta-lactam class of antibiotic (blaCTX-M-15), 
carbapenems (blaNDM-1), quinolones (qnrB23), colistin (mcr-9), macrolides (ere(A)), fosfomycin 
(fosA), sulphonamide (sul2), trimethoprim (dfrA14), phenicol (catA2) and aminoglycosides (aph(3'')-
Ib). 
 
The beta-lactamase genes were the most frequently detected, with a higher number of quinolone 
resistance genes noted in K. pneumoniae isolates and more macrolide resistance genes in E. coli 
than the other species. No genes appeared species-specific, however, fosfomycin genes were not 




Table 14: MLST groups, plasmids and resistance genes identified in isolates from outbreak (OUT), community (COM) and point prevalence 
studies (PPS)  
Isolate Source  
 
Hospital/ 
ward ST  
Plasmids [% Identity; template 
length; contig; position in contig] 




















IncL/M(pOXA-48) [100; 661/661; 
NODE_17_length_58177_cov_38.1
57898; 49268..49928] 
blaCMY-129 [99.65; 1146/1146; NODE_2_length_532108_cov_10.665332; 
19202..20347], blaOXA-48 [100; 798/798; 
NODE_24_length_2231_cov_41.418151; 26..823], qnrB23 [99.23; 
645/645; NODE_16_length_71060_cov_10.541215; 31461..32105], sul1 
[100; 840/840; NODE_14_length_99687_cov_20.988560; 27512..28351], 
dfrA12 [100; 498/498; NODE_14_length_99687_cov_20.988560; 
25311..25808], tet(D) [100; 1185/1185; 
NODE_14_length_99687_cov_20.988560; 32025..33209], aadA2 [100; 








































































IncHI2 [100; 327/327; 
NODE_10_length_159803_cov_27.
153780; 58870..59196], IncHI2A 
[100; 630/630; 
NODE_10_length_159803_cov_27.




blaACT-7 [99.48; 1146/1146; NODE_3_length_460426_cov_26.042162; 
439540..440685], blaCTX-M-15 [100; 876/876; 
NODE_34_length_11368_cov_25.744240; 7668..8543], blaNDM-1 [100; 
813/813; NODE_27_length_384493_cov_65.179821; 229..23728], blaOXA-1 
[100; 831/831; NODE_43_length_2439_cov_29.035035; 706..1536], blaTEM-
1B [100; 861/861; NODE_34_length_11368_cov_25.744240; 3986..4846], 
fosA [96.01; 426/426; NODE_3_length_460426_cov_26.042162; 
277014..277439], qnrB1 [100; 645/645; 
NODE_38_length_6049_cov_26.996960; 4532..5176], sul2 [100; 816/816; 
NODE_34_length_11368_cov_25.744240, dfrA14 [100; 474/474; 
NODE_37_length_6379_cov_27.928983; 378..851], tet(A) [94.92; 
1200/1200; NODE_40_length_4010_cov_33.270152; 1180..2379], aac(6')-
Ib-cr [100; 600/600; NODE_43_length_2439_cov_29.035035; 1667..2266], 
aadA1 [99.75; 792/792; NODE_51_length_1176_cov_25.326978; 
253..1044], aph(3'')-Ib [100; 804/804; 
NODE_34_length_11368_cov_25.744240], aph(6)-Id [100; 837/837; 
NODE_34_length_11368_cov_25.744240; 2429..3265], catB3 [100; 

























































IncFIB(pECLA) [100; 560/560; 
NODE_17_length_47821_cov_29.3
74282; 4643..5202], IncFII(pECLA) 
[100; 747/747; 
NODE_17_length_47821_cov_29.3




Col(pHAD28) [96.12; 129/131; 
NODE_39_length_2077_cov_5348.
874359; 1832..1960] 
blaACT-16 [99.48; 1139/1140; NODE_11_length_160885_cov_20.239938; 
140138..141276], blaCTX-M-15 [100; 876/876; 
NODE_27_length_14218_cov_25.552125; 2762..3637], blaNDM-1 [100; 
813/813; NODE_28_length_8856_cov_55.940428; 978..1790], blaOXA-1 
[100; 831/831; NODE_38_length_2440_cov_29.517510; 707..1537], blaTEM-
1B [100; 861/861; NODE_27_length_14218_cov_25.552125], catA2 (96.23; 
566/642; NODE_41_length_1484_cov_24.591010; 128..693], catB3 [100; 
442/633; NODE_38_length_2440_cov_29.517510; 128..569], fosA [95.54; 
426/426; NODE_5_length_323008_cov_20.129794; 317864..318289], 
qnrB1 [100; 645/645; NODE_31_length_6121_cov_28.521855; 946..1509], 
sul2 [100; 816/816; NODE_27_length_14218_cov_25.552125; 
9740..10555], dfrA14 [100; 474/474; 
NODE_30_length_7931_cov_28.005510; 5680..6153], aac(6')-Ib-cr [100; 
600/600; NODE_38_length_2440_cov_29.517510; 1668..2267], aph(3'')-Ib 
[100; 804/804; NODE_27_length_14218_cov_25.552125; 8876..9679], 











RLH/ 9E 245 
IncFIB(K) [98.93; 560/560; 
NODE_20_length_18213_cov_86.7
69988; 5074..5633], IncL/M(pOXA-
48) [100; 661/661; 
NODE_13_length_40780_cov_146.
801023; 8250..8910] 
blaACT-16 [99.56; 1139/1140; NODE_8_length_164443_cov_75.402858; 
143861..144999], blaOXA-48 [100; 798/798; 
NODE_31_length_2231_cov_119.899067; 1409..2206], fosA [96.01; 
426/426; NODE_3_length_377331_cov_72.301420; 43959..44384], qnrA1 
[99.85; 657/657; NODE_16_length_31093_cov_113.772815; 10059..10715, 
sul1 [100; 840/840; NODE_16_length_31093_cov_113.772815; 
7010..7849], aadA2b [99.87; 780/780; 
NODE_16_length_31093_cov_113.772815; 5726..6505], ant(2'')-Ia [100; 









RLH/ 9F 245 
IncFIB(K) [98.93; 560/560; 
NODE_23_length_18213_cov_23.5
49099; 5074..5633], IncL/M(pOXA-
48) [100; 661/661; 
NODE_16_length_40780_cov_48.8
93390; 8250..8910] 
blaACT-16 [99.56; 1139/1140; NODE_10_length_164444_cov_14.872430; 
19446..20584], blaOXA-48 [100; 798/798; 
NODE_32_length_2231_cov_49.592451; 26..823], fosA [96.01; 426/426; 
NODE_4_length_376448_cov_15.060486; 43959..44384], qnrA1 [99.85; 
657/657; NODE_20_length_31087_cov_22.224193; 20373..21029], 
aadA2b [99.87; 780/780; NODE_20_length_31087_cov_22.224193; 











































IncFIB(pECLA) [100; 560/560; 
NODE_25_length_67045_cov_15.2
37485; 23369..23928], 
IncFII(pECLA) [100; 747/747; 
NODE_25_length_67045_cov_15.2
37485; 59677..60423], IncHI2 [100; 
327/327; NODE_28_length_58712-
cov_21.102927; 37305..37631], 
IncHI2A [100; 630/630; 
NODE_28_length_58712-
cov_21.102927; 21810..22439] 
blaACT-14 [98.78; 1146/1146; NODE_27_length_64960_cov_12.241528; 
23358..24503], blaNDM-1 [100; 813/813; 
NODE_47_length_14233_cov_75.130086], blaOXA-1 [100; 831/831; 
NODE_58_length_2440_cov_88.599654; 904..1734], blaTEM-1B [100; 
861/861; NODE_44_length_23830_cov_18.565414; 7998..8858], mcr-9 
[100; 1620/1620; NODE_22_length_72535_cov_23.479381; 783..2402], 
catA2 [96.11; 642/642; NODE_61_length_1649_cov_15.905388; 217..858], 
catB3 [100; 442/633; NODE_58_length_2440_cov_88.599654; 
1872..2313], fosA [96.01; 426/426; 
NODE_41_length_31656_cov_12.109106; 2802..3227] , aac(6')-Ib-cr [100; 













Barts/ 5C 145 
IncHI2 [100; 327/327; 
NODE_30_length_58713_cov_10.9




blaACT-14 [98.78; 1146/1146; NODE_9_length_187936_cov_7.031836; 
37680..38825], blaACT-5 [98.78; 1146/1146; 
NODE_9_length_187936_cov_7.031836], blaDHA-1 [100; 1140/1140; 
NODE_36_length_40976_cov_8.925580; 8828..9967], blaNDM-1 [100; 
813/813; NODE_16_length_106906_cov_10.220427; 92889..93701], mcr-9 
[100; 1620/1620; NODE_61_length_2659_cov_7.657188; 258..1877], 
ere(A) [100; 1043/1227; NODE_36_length_40976_cov_8.925580; 
32997..34039], mph(A) [100; 906/906; 
NODE_36_length_40976_cov_8.925580; 196.1101], fosA [94.84; 426/426; 
NODE_39_length_29967_cov_6.402480], qnrB4 [100; 645/645; 
NODE_36_length_40976_cov_8.925580; 14092..14736], aac(6')-Iic [100; 













RLH/ 9F 118 
IncFIB(pECLA) [100; 560/560; 
NODE_17_length_88967_cov_30.8
76328; 67965..68524], 
IncFII(pECLA) [99.6; 747/747; 
NODE_17_length_88967_cov_30.8
76328; 24278..25024 ], IncHI2 
[100; 327/327; 
NODE_26_length_63231_cov_31.5




blaACT-14 [99.1; 1146/1146; NODE_12_length_145361_cov_28.810100; 
126431..127576], blaNDM-1 [100; 813/813; 
NODE_37_length_14233_cov_32.934142; 6545..7357], blaOXA-1 [100; 
831/831; NODE_48_length_2440_cov_29.958495; 707..1537], blaTEM-1B 
[100; 861/861; NODE_33_length_23830_cov_30.288909; 7998..8858], 
mcr-9 [100; 1620/1620; NODE_32_length_24452_cov_31.043535; 
783..2402], catA2 [96.11; 642/642; 
NODE_51_length_1649_cov_22.584757; 217..858], catB3 [100; 442/633; 
NODE_48_length_2440_cov_29.958495; 128..569], aac(6')-Ib-cr [100; 


















WX/ B3 145 
IncHI2 [100; 327/327; 
NODE_30_length_58713_cov_10.9




blaACT-14 [98.78; 1146/1146; NODE_9_length_187936_cov_7.031836; 
37680..38825], blaACT-5 [98.78; 1146/1146; 
NODE_9_length_187936_cov_7.031836], blaDHA-1 [100; 1140/1140; 
NODE_36_length_40976_cov_8.925580; 8828..9967], blaNDM-1 [100; 
813/813; NODE_16_length_106906_cov_10.220427; 92889..93701], mcr-9 
[100; 1620/1620; NODE_61_length_2659_cov_7.657188; 258..1877], 
ere(A) [100; 1043/1227; NODE_36_length_40976_cov_8.925580; 
32997..34039], mph(A) [100; 906/906; 
NODE_36_length_40976_cov_8.925580; 196.1101], fosA [94.84; 426/426; 
NODE_39_length_29967_cov_6.402480], qnrB4 [100; 645/645; 
NODE_36_length_40976_cov_8.925580; 14092..14736], aac(6')-Iic [100; 






































Col440I [95.61; 114/114; 
NODE_58_length_2634_cov_34.76
9047; 1718..1831], IncFII(K) [97.3; 
148/148; 
NODE_95_length_2096_cov_2.157
440; 1491..1638], IncHI2 [100; 
327/327; 
NODE_215_length_1526_cov_1.46




blaDHA-1 [100; 842/1140; NODE_183_length_1611_cov_1.349730; 
770..1611], blaDHA-24 [100; 842/1140; 
NODE_183_length_1611_cov_1.349730; 770..1611], blaDHA-7 [100; 
842/1140; NODE_183_length_1611_cov_1.349730; 770..1611], blaNDM-1 
[99.83; 594/813; NODE_1868_length_601_cov_0.835443; 8..601], blaNDM-18 
[99.83; 594/828; NODE_1868_length_601_cov_0.835443; 8..601], blaNDM-2 
[99.83; 594/813; NODE_1868_length_601_cov_0.835443; 8..601], blaOXA-1 
[100; 579/831; NODE_522_length_1084_cov_1.306165; 18..596], blaOXA-396 
[99.62; 789/789; NODE_21_length_121104_cov_23.421006; 
56770..57558], blaPAO [99.58; 1194/1194; 
NODE_12_length_211711_cov_20.878233; 90869..92062], catB3 [99.55; 
439/633; NODE_3101_length_439_cov_0.733974; 1..439], catB7 [99.38; 
639/639; NODE_20_length_130552_cov_21.505041; 52305..52943], fosA 
[99.76; 408/408; NODE_2_length_417368_cov_20.480183; 
159419..159826], sul1 [99.63; 545/867; 
NODE_674_length_983_cov_2.531542; 438..982], aac(6')-Iic [100; 
582/582; NODE_126_length_1852_cov_1.853913; 280..861], aadA5 [100; 



















IncHI2 [100; 327/327; 
NODE_30_length_58713_cov_10.9




blaNDM-1 [99.83; 594/813; NODE_1868_length_601_cov_0.835443; 8..601], 
blaNDM-2 [99.83; 594/813; NODE_1868_length_601_cov_0.835443; 8..601], 
cat [98.32; 655/654; NODE_1_length_1031953_cov_17.889809], sul2 
[100; 816/816; NODE_23_length_7960_cov_28.743776; 457..1272], tet(J) 


















IncX3 [100; 374/374; 
NODE_19_length_37591_cov_7.86
4403] 
blaOXA-181 [100; 798/798; NODE_22_length_12486_cov_7.982685; 
7500..8296], cat [98.63; 655/654; 
NODE_1_length_613874_cov_19.116986; 332001..332654], qnrS1 [100; 
657/657; NODE_22_length_12486_cov_7.982685; 1155..1811], tet(J) [99; 














IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.1885




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 
















































































































ColKP3 [100; 229/280; 
NODE_43_length_3012_cov_64.27
9723; 129..357], IncFIB(K) [98.93; 
560/560; 
NODE_31_length_16754_cov_30.7
76508; 12597..13156], IncFII(K) 
[95.95; 148/148; 
NODE_20_length_61807_cov_27.7




IncL/M(pOXA-48) [100 ; 661/661; 
NODE_16_length_40780_cov_55.8
91988; 31871..32531] 
blaOXA-1 [100; 831/831; NODE_46_length_2437_cov_29.770563; 
902..1732], blaCTX-M-15 [100; 876/876; 
NODE_33_length_10980_cov_31.012900; 7468..8343], blaOXA-181 [100; 
798/798; NODE_43_length_3012_cov_64.279723; 1960..2757], blaSHV-99 
[99.88; 861/861; NODE_7_length_306089_cov_16.711896; 
100568..101428], blaTEM-1B [100; 861/861; 
NODE_33_length_10980_cov_31.012900; 3786..4646], catB3 [100; 
442/633; NODE_46_length_2437_cov_29.770563; 1870..2311], fosA 
[98.57; 420/420; NODE_10_length_197052_cov_24.408450; 
14017..14436], fosA7 [90.78; 423/423; 
NODE_22_length_52885_cov_26.607605; 28129..28551], oqxA [99.49; 
1176/1176; NODE_1_length_776734_cov_23.561549; 735140..736315], 
oqxB [98.76; 3153/3153; NODE_1_length_776734_cov_23.561549; 
731964..735116], qnrB1 [100; 645/645; 
NODE_47_length_2210_cov_25.187710; 947..1591], sul2 [100; 816/816; 
NODE_33_length_10980_cov_31.012900; 550..1365], qnrS1 [100; 
657/657; NODE_42_length_3212_cov_62.058347; 1402..2058], dfrA14 
[100; 474/474; NODE_35_length_6980_cov_29.240333; 4730..5203], 
tet(A) [100; 1200/1200; NODE_34_length_9895_cov_28.826372; 
2716..3915], aac(3)-Ila [99.77; 861/861; 
NODE_44_length_2853_cov_28.432502; 171..1031], aac(6')-Ib-cr [100; 
600/600; NODE_46_length_2437_cov_29.770563; 172..771], aph(3'')-Ib 
[100; 804/804; NODE_33_length_10980_cov_31.012900; 1426..2229], 




















IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.1885




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 















IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.1885




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 






























IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.1885





blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 




























































RLH/ 13F 11 
Col440I [97.37; 114/114; 
NODE_56_length_4637_cov_162.0
33703; 1117..1230], Col440II 
[97.51; 281/282; 
NODE_53_length_5449_cov_195.1
09169; 4498..4778], IncFIA(HI1) 
[97.16; 388/388; 
NODE_24_length_cov_53.514657; 
9691..10078],  IncFIB [100; 
439/439; 
NODE_26_length_77093_cov_44.4
05660; 12572..13010], IncFII(K) 
[97.27; 148/148; 
NODE_24_length_78964_cov_53.5




blaOXA-1 [100; 831/831; NODE_63_length_2437_cov_45.795671; 
707..1537], blaTEM-1C [100; 861/861; 
NODE_58_length_3815_cov_47.659707; 1714..2574], blaCTX-M-15 [100; 
876/876; NODE_59_length_3694_cov_91.518363; 2644..3519], blaNDM-5 
[100; 813/813; NODE_32_length_45679_cov_91.239946; 2400..3212], 
mph(A) [100; 906/906; NODE_51_length_6196_cov_46.036909; 
196..1101], catA2 [96.12; 642/642; 
NODE_70_length_1649_cov_45.324573; 217..858], catB3 [100; 442/633; 
NODE_63_length_2437_cov_45.795671], fosA [99.27; 412/420; 
NODE_6_length_270450_cov_25.716410; 255963..256374], oqxA [100; 
1176/1176; NODE_25_length_78307_cov_23.745638; 46368..47543], 
oqxB [100; 3153/3153; NODE_25_length_78307_cov_23.745638; 
43192..46344], qnrS1 [100; 657/657; 
NODE_47_length_11205_cov_50.558224; 1916..2572], sul1 [100; 840/840; 
1..840; NODE_71_length_1597_cov_66.149660; 453..1292], sul2 [100; 
816/816; NODE_47_length_11205_cov_50.558224; 8820..9635], dfrA1 
[99.79; 474/474; NODE_67_length_1681_cov_40.460746; 145..618], 
dfrA12 [100; 498/498; NODE_67_length_2008_cov_37.849016; 133..630], 
tet(A) [100; 1200/1200; NODE_55_length_4699_cov_54.858705], aac(6')-
Ib-cr [100; 600/600; NODE_63_length_2437_cov_45.795671; 1668..2267], 
aadA1 [100; 792/792; NODE_69_length_1681_cov_40.460746; 711..1502], 
aadA2 [100; 792/792; NODE_67_length_2008_cov_37.849016; 














































































Col(IRGK) [97.3; 185/184; 
NODE_57_length_2476_cov_1074.
991486; 579..763], IncFIB(K) 
[98.93; 560/560; 
NODE_29_length_18956_cov_24.9
06846; 11816..12375], IncHI2 [100; 
327/327; 
NODE_15_83853_cov_26.050331; 




blaDHA-1 [100; 1140/1140; NODE_31_length_16162_cov_22.598129; 
13590..14729], blaNDM-1 [100; 813/813; 
NODE_43_length_5606_cov_14.073736; 4315..5127], blaOXA-1 [100; 
831/831; NODE_54_length_2957_cov_26.659364; 1227..2057], blaSHV-11 
[99.88; 861/861; NODE_2_length_648819_cov_12.581136; 
223577..224437], blaSHV-13 [99.88; 861/861; 
NODE_2_length_648819_cov_12.581136; 223577..224437], blaSHV-70 
[99.88; 861/861; NODE_2_length_648819_cov_12.581136; 
223577..224437], mcr-9 [100; 1620/1620; 
NODE_55_length_2659_cov_22.354265; 783..2402], ere(A) [100; 
1043/1227; NODE_30_length_16540_cov_27.475050; 6938..7980], 
mph(A) [100; 906/906; NODE_47_length_4372_cov_24.624028], catB3 
[100; 633/633; NODE_54_length_2957_cov_26.659364; 457..1089], fosA5 
[100; 420/420;NODE_4_length_362391_cov_14.617870; 347928..348347], 
oqxA [99.67; 1176/1176; NODE_5_length_349618_cov_13.912696; 
309236..310411], oqxB [99.65; 3153/3153; 
NODE_5_length_349618_cov_13.912696; 306060..309212], qnrB4 [100; 
645/645; NODE_31_length_16162_cov_22.598129; 8821..9465], sul1 [100; 
727/840; NODE_68_length_997_cov_52.739080; 1..727], dfrA17 [100; 
474/474; NODE_62_length_1823_cov_23.609080; 1206..1670], aac(6')-Iic 
[100; 582/582; NODE_30_length_16540_cov_27.475050; 2043..2624], 
aac(6')-Ib-cr [100; 600/600; NODE_54_length_2957_cov_26.659364; 



























IncFIA(HI1) [98.45; 388/388; 
NODE_11_length_129554_cov_51.




IncL/M(pOXA-48) [100; 661/661; 
NODE_22_length_40690_cov_120.




blaOXA-48 [100;798/798; NODE_41_length_2231_cov_119.058100; 
1409..2206],  fosA [96.43; 420/420; 
NODE_9_length_265037_cov_29.316353; 14064, fosA7 [92.83; 279/423; 
NODE_7_length_369586_cov_31.319551; 26885..27162] oqxA [99.41; 
1176/1176; NODE_10_length_168567_cov_28.030877; 12499..13674], 











































































Col440I [100; 114/114; 
NODE_37_length_4778_cov_158.0
40636; 4050..4163], Col440II 
[97.52; 282/282; 
NODE_39_length_4566_cov_137.0
98896; 602..883], IncFIB(K) [98.93; 
560/560; 
NODE_19_length_59581_cov_17.0




IncL/M(pOXA-48) [100; 661/661; 
NODE_23_length_40734_cov_39.4
35245; 8250..8910] 
blaCTX-M-15 [100; 876/876; NODE_31_length_10980_cov_16.195891; 
2638..3515], blaOXA-1 [100; 831/831; 
NODE_43_length_2437_cov_17.163203; 902..1732], blaOXA-48 [100; 
798/798; NODE_44_length_2231_cov_44.248092; 1409..2206], blaSHV-27 
[100; 861/861; NODE_11_length_185800_cov_10.740431; 65940..66800], 
blaTEM-1B [100; 861/861; NODE_31_length_10980_cov_16.195891; 
6335..7195], catB3 [100; 442/633; 
NODE_43_length_2437_cov_17.163203; 1870..2311], fosA [99.76; 
420/420; NODE_12_length_176731_cov_13.939112; 5277..5696], oqxB 
[99.41; 1176/1176; NODE_3_length_466918_cov_13.016665; 
32156..35308], oqxA [99.41; 1176/1176; 
NODE_3_length_466918_cov_13.016665; 30957..32132], qnrB1 [100; 
645/645; NODE_29_length_13795_cov_17.164399; 948..1592], sul2 [100; 
816/816; NODE_31_length_10980_cov_16.195891; 9616..10431], dfrA14 
[100; 474/474; NODE_33_length_69880_cov_14.091055; 1779..2252], 
tet(A) [100; 1200/1200; NODE_29_length_13795_cov_17.164399; 
9820..11019], aac(3)-Iia [99.77; 861/861; 
NODE_42_length_2853_cov_15.380411; 171..1031], aac(6')-Ib-cr [100; 
600/600; NODE_43_length_2437_cov_17.163203; 172..771], aph(3'')-Ib 
[100; 804/804; NODE_31_length_10980_cov_16.195891; 8752..9555], 

















RLH/ 9F 277 
IncFIB(K) [100; 560/560; 
NODE_12_length_130533_cov_42.
628154; 65109..65668], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_19_length_40780_cov_126.
228864; 31871..32531] 
blaOXA-48 [100; 798/798; NODE_29_length_2231_cov_114.079729; 
26..823], blaSHV-27 [99.88; 861/861; 
NODE_1_length_777580_cov_31.918466; 406071..406931], fosA [98.57; 
420/420; NODE_7_length_376294_cov_41.992115; 14046..14465], oqxA 
[99.49; 1176/1176; NODE_6_length_463539_cov_40.366389; 
398071..399246], oqxB [99.08; 3154/3153; 
NODE_6_length_463539_cov_40.366389; 394895..398047], tet(D) [100; 
























































Col440I [97.37; 114/114; 
NODE_215_length_179_cov_1049.
942308; 49..162], INCFIB(K) [100; 
560/560; 
NODE_35_length_21734_cov_13.1
11214; 4153..4712], IncHI2 [100; 
327/327; 
NODE_24_length_58713_cov_21.1




blaNDM-1 [100; 813/813; NODE_19_length.94516_cov_21.200956], blaOXA-1 
[100; 831/831; NODE_60_length_2956_cov_21.641569; 901..1731], blaSHV-
145 [99.88; 861/861; NODE_1_length_591047_cov_10.63381; 
188201..119061], blaSHV-179 [99.88; 861/861; 
NODE_1_length_591047_cov_10.63381; 188201..119061], blaSHV-194 
[99.88; 861/861; NODE_1_length_591047_cov_10.63381; 
188201..119061], blaSHV-199 [99.88; 861/861; 
NODE_1_length_591047_cov_10.63381; 188201..119061], blaSHV-26 [99.88; 
861/861; NODE_1_length_591047_cov_10.63381; 188201..119061], blaSHV-
78 [99.88; 861/861; NODE_1_length_591047_cov_10.63381; 
188201..119061], blaSHV-98 [99.88; 861/861; 
NODE_1_length_591047_cov_10.63381; 188201..119061], mcr-9 [100; 
1620/1620; NODE_61_length_2659_cov_18.737757; 783..2402], mph(A) 
[100; 906/906; NODE_43_length_10156_cov_19.404627], catB3 [100; 
633/633; NODE_60_length_2956_cov_21.641569; 1869..2501], fosA [100; 
420/420; NODE_5_length_358683_cov_11.356781; 334490..334909], 
oqxA [99.24; 1176/1176; NODE_3_length_413980_cov-10.919638; 
347150..348325], oqxB [98.57; 3153/3153; 
NODE_3_length_413980_cov_10.919638; 343974..347126], sul1 [100; 
840/840; NODE_43_length_1-156_cov_19.404627; 6412..7251], dfrA17 
[100; 474/474; NODE_43_length_10156_cov_19.404627; 8717..9190], 
aac(6')-Ib-cr [100; 600/600; NODE_60_length_2956_cov_21.641569; 


















































Barts/ 4C 502 
Col440I [95.61; 114/114; 427/327; 
NODE_84_length_776_cov_4835.2
61538; 68..181], IncFII(K) [97.3; 
148/148; 
NODE_47_length_15926_cov_24.8
66257; 2834..2981], IncHI2 [100; 
327/327; 
NODE_30_length_63293_cov_33.7
16873; 37304..37630], IncHI2A 
[100; 630/630; 
NODE_30_63293_cov_33.716873; 
21809..22438], IncR [100; 251/251; 
NODE_40_length_27059_cov_29.4
69850; 10860..1110]] 
blaDHA-1 [100; 1140/1140; NODE_44_length_18595_cov_34.142084; 
14714..15853], blaNDM-1 [100; 813/813; 
NODE_26_length_81658_cov_38.556721; 76532..77344], blaOXA-1 [100; 
831/831; NODE_63_length_2958_cov_29.046980; 901..1731], blaSHV-11 
[100; 861/861; NODE_22_length_108290_cov_14.515805; 40649..41509], 
blaSHV-62 [100; 861/861; NODE_22_length_108290_cov_14.515805; 
40649..41509], mcr-9 [100; 1620/1620; 
NODE_42_length_24534_cov_35.939730; 22133..23752], ere(A) [100; 
1043/1227; NODE_45_length_16424_cov_34.150334; 6939..7981], 
mph(A) [100; 906/906; NODE_61_length_4370_cov_35.792600; 
3272..4177], catB3 [100; 633/633; 
NODE_63_length_2958_cov_29.046980; 1869..2501], fosA [98.57; 
420/420; NODE_27_length_79054_cov_16.416892; 14064..14483], qnrB4 
[100; 645/645; NODE_44_length_18595_cov_34.142084; 9945..10589], 
sul1 [100; 840/840; NODE_44_length_18595_cov_34.142084; 388..1227], 
dfrA17 [100; 474/474; NODE_68_length_1823_cov_31.550708], aac(6')-Iic 
[100; 582/582; NODE_45_length_16424_cov_31.550708; 749..1537], 
aac(6')-Ib-cr [100; 600/600; NODE_63_length_2958_cov_29.046980; 























































Col440I [95.61; 114/114; 427/327; 
NODE_84_length_776_cov_4835.2
61538; 68..181], IncFII(K) [97.3; 
148/148; 
NODE_47_length_15926_cov_24.8
66257; 2834..2981], IncHI2 [100; 
327/327; 
NODE_30_length_63293_cov_33.7
16873; 37304..37630], IncHI2A 
[100; 630/630; 
NODE_30_63293_cov_33.716873; 
21809..22438], IncR [100; 251/251; 
NODE_40_length_27059_cov_29.4
69850; 10860..1110]] 
blaDHA-1 [100; 1140/1140; NODE_44_length_18595_cov_34.142084; 
14714..15853], blaNDM-1 [100; 813/813; 
NODE_26_length_81658_cov_38.556721; 76532..77344], blaOXA-1 [100; 
831/831; NODE_63_length_2958_cov_29.046980; 901..1731], blaSHV-11 
[100; 861/861; NODE_22_length_108290_cov_14.515805; 40649..41509], 
blaSHV-62 [100; 861/861; NODE_22_length_108290_cov_14.515805; 
40649..41509], mcr-9 [100; 1620/1620; 
NODE_42_length_24534_cov_35.939730; 22133..23752], ere(A) [100; 
1043/1227; NODE_45_length_16424_cov_34.150334; 6939..7981], 
mph(A) [100; 906/906; NODE_61_length_4370_cov_35.792600; 
3272..4177], catB3 [100; 633/633; 
NODE_63_length_2958_cov_29.046980; 1869..2501], fosA [98.57; 
420/420; NODE_27_length_79054_cov_16.416892; 14064..14483], qnrB4 
[100; 645/645; NODE_44_length_18595_cov_34.142084; 9945..10589], 
sul1 [100; 840/840; NODE_44_length_18595_cov_34.142084; 388..1227], 
dfrA17 [100; 474/474; NODE_68_length_1823_cov_31.550708], aac(6')-Iic 
[100; 582/582; NODE_45_length_16424_cov_31.550708; 749..1537], 
aac(6')-Ib-cr [100; 600/600; NODE_63_length_2958_cov_29.046980; 















































IncFIA(HI1) [98.97; 387/388; 
NODE_27_length_36456_cov_22.4
48815; 849..1235], IncFIB(K) 
[98.93; 560/560; 
NODE_42_length_10527_cov_13.3




48) [100; 661/661; 
NODE_24_length_40780_cov_29.8




blaOXA-48 [100; 798/798; NODE_51_length_2231_cov_35.133164; 26..823], 
blaSHV-85 [99.88; 861/861; NODE_19_length_64646_cov_6.801175; 
58525..59385], blaTEM-1B [100; 861/861; NODE_28_length_cov_58.330508; 
32719..33579], fosA [99.76; 420/420; 
NODE_18_length_65163_cov_9.216434; 50527..50946], oqxA [99.41; 
1176/1176; NODE_3_length_385424_cov_8.618977; 343435..344610;], 
oqxB [98.57; 3154/3153; NODE_3_length_385424_cov_8.618977; 
340259..343411], aph(3”)-Ib [99.88; 804/804; 
NODE_38_length_15765_cov_20.976340; 3151..3954], aph(3”)-Ib [99.88; 
























IncFIB(AP001918) [98.24; 682/682; 
NODE_11_length_140912_cov_10
4.872593; 10356..11037], 
IncFIC(FII) [98.4; 499/499; 
NODE_11_length_140912_cov_10
4.872593; 95616..96114], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_18_length_40780_cov_134.
090891] 




































IncFIB(K) [98.82; 560/560; 
NODE_77_length_18834_cov_20.4
02951; 13890..14449], IncFII 
[99.62; 261/261; 
NODE_121_length_5114_cov_16.6
66332; 3514..3774], IncHI2 [100; 
327/327; 
NODE_31_length_58713_cov_16.0
16949; 37305..37631], IncHI2A 
[100; 630/630; 
NODE_31_length_58713_cov_16.0




blaDHA-1 [100; 1140/1140; NODE_79_length_18595_cov_16.880117; 
2743..3882], blaNDM-1 [100;813/813; 
NODE_84_length_16069_cov_23.405972; 3715..4527], blaOXA-1 [100; 
831/831; NODE_145_length_2962_cov_13.661376; 1229..2059], mcr-9 
[100; 1620/1620; NODE_151_length_2659_cov_14.107030; 258..1877], 
ere(A) [100; 1043/1227; NODE_87_length_14760_cov_15.880202; 
8444..9486], mph(A) [100; 906/906; 
NODE_128_length_4372_cov_15.942049; 196..1101], catB3 [100; 
633/633; NODE_145_length_2962_cov_13.661376; 459..1091], qnrB4 
[100; 645/645; NODE_79_length_18595_cov_16.880117; 8007..8651], sul1 
[99.76; 840/840; NODE_79_length_18595_cov_16.880117; 17369..18208], 
dfrA17 [100; 474/474; NODE-166_length_1823_cov_16.584316; 
1206..1679], aac(6')-Iic [100; 582/582; 
NODE_87_length_14760_cov_15.880202; 13800..14381], aac(6')-Ib-cr 
[100; 600/600; NODE_145_length_2962_cov_13.661376; 2190..2789], 




































07472; 21117..21798], IncFII [100; 
261/261;NODE_25_length_60871_
cov_37.166025; 6649..6909], IncI1 
[97.89;142/142;NODE_38_length_2
6474_cov_37.166025; 6649..6909], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_32_length_40733_cov_39.4
65769; 8250..8910] 
blaCTX-M-15 [100; 876/876; NODE_27_length_598892_cov_47.989224; 
519..1394], blaOXA-48 [100; 798/798; 
NODE_59_length_2231_cov_41.757422; 1409..2206], blaTEM-1C [99.88; 
861/861; NODE_60_length_2134_cov_33.341804; 1240..2100], qnrS1 
[100; 657/657; NODE_38_length_26474_cov_46.972027; 23748..24404], 




































IncFIB(K) [98.82; 560/560; 
NODE_77_length_18834_cov_20.4
02951; 13890..14449], IncFII 
[99.62; 261/261; 
NODE_121_length_5114_cov_16.6
66332; 3514..3774], IncHI2 [100; 
327/327; 
NODE_31_length_58713_cov_16.0
16949; 37305..37631], IncHI2A 
[100; 630/630; 
NODE_31_length_58713_cov_16.0




blaDHA-1 [100; 1140/1140; NODE_79_length_18595_cov_16.880117; 
2743..3882], blaNDM-1 [100;813/813; 
NODE_84_length_16069_cov_23.405972; 3715..4527], blaOXA-1 [100; 
831/831; NODE_145_length_2962_cov_13.661376; 1229..2059], mcr-9 
[100; 1620/1620; NODE_151_length_2659_cov_14.107030; 258..1877], 
ere(A) [100; 1043/1227; NODE_87_length_14760_cov_15.880202; 
8444..9486], mph(A) [100; 906/906; 
NODE_128_length_4372_cov_15.942049; 196..1101], catB3 [100; 
633/633; NODE_145_length_2962_cov_13.661376; 459..1091], qnrB4 
[100; 645/645; NODE_79_length_18595_cov_16.880117; 8007..8651], sul1 
[99.76; 840/840; NODE_79_length_18595_cov_16.880117; 17369..18208], 
dfrA17 [100; 474/474; NODE-166_length_1823_cov_16.584316; 
1206..1679], aac(6')-Iic [100; 582/582; 
NODE_87_length_14760_cov_15.880202; 13800..14381], aac(6')-Ib-cr 
[100; 600/600; NODE_145_length_2962_cov_13.661376; 2190..2789], 













































48) [100; 661/661; 
NODE_34_length_40777_cov_71.1
28044; 8250..8910] 
blaOXA-1 [100; 831/831; NODE_69_length_6627_cov_35.945231; 
2657..3487], blaOXA-48 [100; 798/798; 
NODE_96_length_2231_cov_61.857930; 26..823], blaTEM-78 [99.88; 
861/861; NODE_74_length_4675_cov_40.940413; 3040..3900], catA1 
[99.85; 660/660; NODE_101_length_1744_cov_26.186766; 738..1397], 
floR [98.27; 1214/1215; NODE_8_length_157436_cov_30.007876; 
155190..156403], sul1 [100; 840/840; 
NODE_69_length_6627_cov_35.945231; 4896..5735], aph(3')-Ia [100; 
816/816; NODE_74_length_4675_cov_40.940413; 1320..2135], aadA1 
[99.75; 792/792; NODE_69_length_6627_cov_35.945231; 3600..4391], 
dfrA36 [100; 588/588; NODE_8_length_157436_cov_30.007876; 


















































IncHI2 [100; 327/327; 
NODE_11_length_137288_cov_31.




mcr-9 [100; 1620/1620; NODE_14_length_86271_cov_31.894270; 
83870..85489], blaDHA-1 [100; 1140/1140; 
NODE_21_length_18595_cov_38.270360; 2743..3882], blaNDM-1 [100; 
813/813; NODE_20_length_cov_43.815595; 19210..20022], blaOXA-1 [100; 
831/831; NODE_24_length_2959_cov_29.110523; 1229..2059], ere(A) 
[100; 1043/1227; NODE_22_length_16424_cov_39.755538; 8444..9486], 
mph(A) [100; 906/906; NODE_23_length_4372_cov_47.573380; 
196..1101], catB3 [100; 633/633; NODE_24_length_2959_cov_29.110523; 
456..1091], qnrB4 [100; 645/645; 
NODE_21_length_18595_cov_38.270360; 8007..8651], sul1 [100; 840/840; 
NODE_21_length_18595_cov_38.270360; 17369..18208], dfrA17 [100; 
474/474; NODE_28_length_1823_cov_35.066627; 145..618], aac(6')-Iic 
[100; 582/582; NODE_22_length_16424_cov_39.755538; 13800..14381], 
aac(6')-Ib-cr [100; 600/600; NODE_24_length_2959_cov_29.110523; 








































































Col(BS512) [100; 233/233; 
NODE_93_length_2215_cov_528.9











9727; 524..784], IncI1 [100; 
142/142; 
NODE_38_length_37561_cov_31.9




blaCTX-M-15 [100; 876/876; NODE_87_length_3325_cov_25.394622; 
519..1394], blaNDM-5 [100; 813/813; 
NODE_70_length_9927_cov_23.731020; 8494..9306], blaOXA-1 [100; 
831/831; NODE_90_length_2438_cov_24.631328; 706..1536], blaTEM-1B 
[100; 861/861; NODE_98_length_1529_cov_47.943652; 522..1382], 
mph(A) [100; 906/906; NODE_82_length_4389_cov_24.167996; 
195..1100], catA1 [99.85; 600/600; 
NODE_74_length_7421_cov_24.724568; 351..1010], catB3 [100; 442/633; 
NODE_90_length_2438_cov_24.631328; 127..568], sul1 [100; 840/840; 
NODE_70_length_9927_cov_23.731020; 3342..4181], dfrA12 [100; 
498/498; NODE_70_length_9927_cov_23.731020; 1141..1638], tet(B)[100; 
1206/1206;NODE_86_length_3422_cov_36.888923; 1415..2620], aac(6')-
Ib-cr [100; 600/600; NODE_90_length_2438_cov_24.631328; 
1667..2266], aadA2 [100; 792/792; 
NODE_70_length_9927_cov_23.731020; 2046..2837], aph(3'')-Ib [100; 
804/804; NODE_80_length_4638_cov_23.886721; 970..1773] aph(3')-Ia 
[100; 816/816; NODE_101_length_1292_cov_23.174249; 265..1080], 
aph(6)-Id [100; 837/837; NODE_80_length_4638_cov_23.886721; 




























































IncFIA [99.74; 388/388; 
NODE_47_length_15023_cov_31.8
40695; 5663..6050], IncFIC(FII) 
[95.8;500/499; 
NODE_20_length_79345_cov_31.5
73468; 30341..30836], IncHI2 [100; 
327/327; 
NODE_28_length_49077_cov_20.0
09499; 21083..21409], IncHI2A 
[100; 630/630; 
NODE_28_length_49077_cov_20.0
09499; 36275..36904], IncI [100; 
137/141; 
NODE_26_length_58751_cov_23.4




blaDHA-1 [100; 1140/1140; NODE_42_length_18595_cov_21.303227; 
14714..15853], blaNDM-1 [100; 813/813; 
NODE_44_length_16983_cov_31.265721; 11857..12669], blaOXA-1 [100; 
831/831; NODE_66_length_2960_cov_59.400635; 1227..2057], blaTEM-1B 
[100; 861/861; NODE_40_length_19462_cov_20.598242; 17840..18700], 
mcr-9 [100; 1620/1620; NODE_71_length_2659_cov_15.667457; 
258..1877], ere(A) [100; 1043/1227; 
NODE_48_length_14530_cov_18.134069; 5045..6087], mph(A) [100; 
906/906; NODE_61_length_4373_cov_18.112106; 3272..4177], catB3 
[100; 633/633; NODE_66_length_2960_cov_59.400635; 457..1089], qnrB4 
[100; 645/645; NODE_42_length_18595_cov_21.303227; 9945..10589], 
qnrS1 [100; 657/657; NODE_40_length_19462_cov_20.598242; 
11822..12478], sul1 [100; 840/840; 
NODE_42_length_18595_cov_21.303227; 17430..18269], sul2 [100; 
816/816; NODE_58_length_5226_cov_18.868406; 2518..3333], dfrA17 
[100; 474/474; NODE_75_length_1823_cov_58.209316; 1206..1679], 
tet(A) [100; 895/1275; NODE_106_length_895_cov_24.854167; 1..895], 
aac(6')-Ib-cr [100; 600/600;NODE_66_length_2960_cov_59.400635; 
2188..2787], aadA5 [100;789/789;NODE_75_length_1823_cov_58.209316; 
287..1075] , aph(3'')-Ib [100; 804/804; 









































IncFIB(K) [99.82; 560/560; 
NODE_62_length_16088_cov_23.3
26233; 4386..4945], IncFII [99.62; 
261/261; 
NODE_87_length_5113_cov_24.17
2082; 3513..3773], IncN [99.22; 
514/514; 
NODE_34_length_55374_cov_63.9




blaOXA-181 [100; 798/798; NODE_67_length_12486_cov_83.032365; 


























































IncFIB(K) [98.82; 560/560; 
NODE_77_length_18834_cov_20
.402951; 13890..14449], IncFII 
[99.62; 261/261; 
NODE_121_length_5114_cov_16
.666332; 3514..3774], IncHI2 
[100; 327/327; 
NODE_31_length_58713_cov_16
.016949; 37305..37631], IncHI2A 
[100; 630/630; 
NODE_31_length_58713_cov_16




blaDHA-1 [100; 1140/1140; NODE_79_length_18595_cov_16.880117; 
2743..3882], blaNDM-1 [100;813/813; 
NODE_84_length_16069_cov_23.405972; 3715..4527], blaOXA-1 [100; 
831/831; NODE_145_length_2962_cov_13.661376; 1229..2059], mcr-9 
[100; 1620/1620; NODE_151_length_2659_cov_14.107030; 258..1877], 
ere(A) [100; 1043/1227; NODE_87_length_14760_cov_15.880202; 
8444..9486], mph(A) [100; 906/906; 
NODE_128_length_4372_cov_15.942049; 196..1101], catB3 [100; 
633/633; NODE_145_length_2962_cov_13.661376; 459..1091], qnrB4 
[100; 645/645; NODE_79_length_18595_cov_16.880117; 8007..8651], sul1 
[99.76; 840/840; NODE_79_length_18595_cov_16.880117; 17369..18208], 
dfrA17 [100; 474/474; NODE-166_length_1823_cov_16.584316; 
1206..1679], aac(6')-Iic [100; 582/582; 
NODE_87_length_14760_cov_15.880202; 13800..14381], aac(6')-Ib-cr 
[100; 600/600; NODE_145_length_2962_cov_13.661376; 2190..2789], 


















































IncFIB(K) [98.82; 560/560; 
NODE_86_length_11632_cov_15
.582877; 4387..4946], IncFII 
[99.62; 261/261; 
NODE_112_length_5115_cov_14
.441259; 3515..3775], IncHI2 
[100; 327/327; 
NODE_27_length_58706_cov_12




blaNDM-1 [100; 813/813; NODE_95_length_8841_cov_56.415079; 
3715..4527], blaDHA-1 [100; 1140/1140; 
NODE_76_length_16162_cov_10.119239; 13590..14729], blaOXA-1 [100; 
831/831; NODE_129_length_2958_cov_13.178382; 901..1731], mcr-9 
[100; 1620/1620; NODE_133_length_2656_cov_11.482009; 258..1877], 
ere(A) [100; 1043/1227; NODE_82_length_14530_cov_12.047212; 
5045..6087], mph(A) [100; 906/906; 
NODE_118_length_4373_cov_12.058172; 197..1102], catB3 [100; 
633/633; NODE_129_length_2958_cov_13.178382; 1869..2501], qnrB4 
[100; 645/645; NODE_76_length_16162_cov_10.119239; 8821..9465], sul1 
[100; 840/840; NODE_170_length_1050_cov_20.845070; 25..864], dfrA17 
[100; 474/474; NODE_151_length_1815_cov_10.837085; 1198..1671], 
aac(6')-Iic [100; 582/582; NODE_82_length_14530_cov_12.047212; 
150..731], aac(6')-Ib-cr [100; 600/600; 






















.254249; 2570..3251], IncFIC(FII) 
[95.79; 499/499; 
NODE_9_length_201798_cov_9.




blaTEM-1B [100; 861/861; NODE_44_length_13785_cov_91.995900; 
1946..2806], blaNDM-1 [100; 813/813; 
NODE_26_length_81658_cov_38.556721; 76532..77344], tet(A) [99.83; 























RLH/ 13C 307 
IncL/M(pOXA-48) [100; 661/661; 
NODE_28_length_44658_cov_70




IncFII(K) [95.95; 148/148; 
NODE_27_length_61773_cov_27
.195091; 59880.60027] 
aac(3)-IIa [99.77; 861/861; NODE_50_length_2853_cov_37.224505; 
1823..2683], aac(6')-Ib-cr [100; 600/600; 
NODE_51_length_2437_cov_26.073160; 172..771], aph(3'')-Ib [100; 
804/804; NODE_39_length_9046_cov_23.994282; 1426..2229], aph(6)-Id 
[100; 837/837; NODE_39_length_9046_cov_23.994282; 2229..3065], 
tet(A) [100; 1200/1200; NODE_36_length_13733_cov_33.557107; 
9819..11018], oqxA [98.9; 1176/1176; 
NODE_12_length_170719_cov_22.260856; 37128..38303], oqxB [98.57; 
3153/3153; NODE_12_length_170719_cov_22.260856; 38327..41479], 
qnrB1 [100; 645/645; NODE_36_length_13733_cov_33.557107; 
947..1591], dfrA14 [100; 474/474; 
NODE_40_length_8358_cov_49.900741; 6107..6580], catB3 [100; 
442/633; NODE_51_length_2437_cov_26.073160; 1870..2311], sul2 [100; 
816/816; NODE_39_length_9046_cov_23.994282; 550.1365], fosA [99.52; 
420/420; NODE_2_length_369203_cov_23.868247; 355589..356008], 
blaCTX-M-15 [100; 876/876; NODE_39_length_9046_cov_23.994282; 
7468..8343], blaOXA-1 [100; 831/831; 
NODE_51_length_2437_cov_26.073160; 902..1732], blaOXA-48 [100; 
798/798; NODE_53_length_2231_cov_66.073791; 26.823], blaSHV-106 
[99.88; 861/861; NODE_1_length_1038231_cov_22.047857; 





































RLH/ 13C 45 
IncL/M(pOXA-48) [100; 661/661; 
NODE_18_length_40779_cov_51
.508806; 31870..32530], 
IncFIB(K) [98.93; 560/560; 
NODE_13_length_137559_cov_2
2.907569; 58071..58630], 
IncFII(K) [95.95; 148/148; 
NODE_13_length_137559_cov_2
2.907569; 135695..135842] 
aac(3)-IIa [99.77; 861/861; NODE_29_length_2853_cov_25.333822; 
1823..2683], aac(6')-Ib-cr [100; 600/600; 
NODE_31_length_2438_cov_21.410645; 173..772], aph(3'')-Ib [100; 
804/804; NODE_23_length_11862_cov_21.121943; 4242..5045], aph(6)-Id 
[100; 837/837; NODE_23_length_11862_cov_21.121943; 5045..5881], 
fosA [100; 420/420; NODE_4_length_357810_cov_20.439096; 
334576..334995], catB3 [100; 442/663; 
NODE_22_length_13626_cov_24.812653; 1871..23121], dfrA14 [100; 
474/474; NODE_24_length_7676_cov_39.217512; 5425..5898], sul2 [100; 
816/816; NODE_23_length_11862_cov_21.121943; 3366..4181], blaCTX-M-15 
[100; 876/876; NODE_23_length_11862_cov_21.121943; 10284..11159], 
blaOXA-1 [100; 831/831; NODE_31_length_2438_cov_21.410645; 
903..1733], blaOXA-48 [100; 798/798; 
NODE_33_length_2231_cov_52.816370; 1409..2206], blaSHV-145 [99.88; 
861/861; NODE_1_length_1523427_cov_19.528232; 68786..69646], blaSHV-
179 [99.88; 861/861; NODE_1_length_1523427_cov_19.528232; 
68786..69646], blaSHV-194 [99.88; 861/861; 
NODE_1_length_1523427_cov_19.528232; 68786..69646], blaSHV-199 
[99.88; 861/861; NODE_1_length_1523427_cov_19.528232; 
68786..69646], blaSHV-78 [99.88; 861/861; 
NODE_1_length_1523427_cov_19.528232; 68786..69646], blaSHV-98 [99.88; 
861/861; NODE_1_length_1523427_cov_19.528232; 68786..69646], 
blaTEM-1B [100; 861/861; NODE_23_length_11862_cov_21.121943; 
6602..7462], tet(A) [100; 1200/1200; 
NODE_22_length_13626_cov_24.812653; 9712..10911], oqxA [99.24; 
1176/1176; NODE_2_length_437172_cov_20.015554; 30737..31912], 
oqxB [98.58; 3153/3153; NODE_2_length_437172_cov_20.015554; 








RLH/ 13C 86 
IncL/M(pOXA-48) [100; 661/661; 
NODE_24_length_40780_cov_73




blaOXA-48 [100; 798/798; NODE_36_length_2231_cov_62.315946; 26..823], 
oqxA [99.41; 1176/1176; NODE_1_length_419475_cov_51.134175; 
387041..388216], oqxB [98.73; 3153/3153; 
NODE_1_length_419475_cov_51.134175; 383865..387017], fosA [97.86; 


























RLH/ 13C 45 
IncL/M(pOXA-48) [100; 661/661; 
NODE_23_length_40509_cov_30
3.457877; 31600..32260], 
IncFIB(K) [98.93; 560/560; 
NODE_20_length_76080_cov_20
.412550; 44706..45265], IncFII(K) 
[99.32; 148/148; 
NODE_16_length_130604_cov_1




fosA [100; 306/420; NODE_27_length_13607_cov_10.814614; 
13175..13480], aph(3'')-Ib [100; 804/804; 
NODE_16_length_130604_cov_13.882807; 2866..3669], aph(6)-Id [100; 
837/837; NODE_16_length_130604_cov_13.882807; 3669..4505], sul2 
[100; 816/816; NODE_16_length_130604_cov_13.882807; 1990..2805], 
oqxA [99.24; 1176/1176; NODE_9_length_289938_cov_11.659123; 
258027..259202], oqxB [98.57; 3153/3153; 
NODE_9_length_289938_cov_11.659123; 254854..258003], blaOXA-48 [100; 
798/798; NODE_32_length_2231_cov_352.476251; 26..823], blaSHV-145 
[99.88; 861/861; NODE_17_length_118806_cov_11.254240; 
49668..50528], blaSHV-179 [99.88; 861/861; 
NODE_17_length_118806_cov_11.254240; 49668..50528],, blaSHV-194 
[99.88; 861/861; NODE_17_length_118806_cov_11.254240; 
49668..50528], blaSHV-199 [99.88; 861/861; 
NODE_17_length_118806_cov_11.254240; 49668..50528], blaSHV-26 [99.88; 
861/861; NODE_17_length_118806_cov_11.254240; 49668..50528], blaSHV-
78 [99.88; 861/861; NODE_17_length_118806_cov_11.254240; 











RLH/ 13C 248 
IncL/M(pOXA-48) [100; 661/661; 
NODE_7_length_58177_cov_71.
944220; 49268..49928], 
IncFIB(K) [99.46; 560/560; 
NODE_1_length_87729_cov_13.
625835; 14410..14969], IncFII(K) 
[99.32; 148/148; 
NODE_1_length_87729_cov_13.































RLH/ 13C 114 
IncL/M(pOXA-48) [100; 661/661; 
NODE_27_length_11363_cov_12
0.108135; 2454..3114], IncH12 
[100; 630/630; 
NODE_18_length_31351_cov_23




aac(3)-Iia [99.77; 861/861; NODE_38_length_2853_cov_47.093910; 
171..1031], aac(6')-Ib-cr [100; 600/600; 
NODE_40_length_2437_cov_54.324675; 172..771], aadA1 [99.87; 
779/792; NODE_57_length_906_cov_56.785623; 1..779], aph(3'')-Ib [100; 
804/804; NODE_29_length_6019_cov_31.028344; 3591..4394], aph(6)-Id 
[100; 837/837; NODE_29_length_6019_cov_31.028344; 2755..3591], 
catA1 [99.85; 655/660; NODE_53_length_1128_cov_25.049950; 125..779], 
catB3 [100; 442/633; NODE_40_length_2437_cov_54.324675; 
1870..2311], qnrB1 [100; 645/645; 
NODE_28_length_6120_cov_53.137494; 946..1590], tet(A) [94.92; 
1200/1200; NODE_36_length_4032_cov_89.807682; 1654..2853], dfrA1 
[100; 474/474; NODE_33_length_4657_cov_19.354746; 2288..2761], 
dfrA14 [100; 474/474; NODE_46_length_1423_cov_63.216821; 378..851], 
sul1 [100; 840/840; NODE_41_length_2421_cov_47.337838; 505..1344], 
sul2 [100; 816/816; NODE_29_length_6019_cov_31.028344; 4455..5270], 
blaACT-16 [99.56; 1140/1140; NODE_5_length_508062_cov_38.860874; 
487532..488671], blaCTX-M-15 [100; 876/876; 
NODE_31_length_5549_cov_27.215972; 1910..2785], blaOXA-1 [100; 
831/831; NODE_40_length_2437_cov_54.324675; 902..1732], blaOXA-48 
[100; 798/798; NODE_42_length_2231_cov_103.233249; 26..823], blaTEM-
1B [100; 861/861; NODE_29_length_6019_cov_31.028344; 1174..2034], 































RLH/ 13C 410 
Col(pHAD28) [95.56; 90/131; 
NODE_2305_length_174_cov_1.
851064; 3..91], IncFIA [99.74; 
388/388; 
NODE_55_length_23295_cov_13
.087966; 9383.9770], IncFIB 
[98.39; 682/682; 
NODE_1_length_234724_cov_5.
834964; 225277..225958], IncFII 
[100; 261/261; 
NODE_36_length_46617_cov_19
.267391; 6303.6566], IncQ1 [100; 
529/796; 
NODE_76_length_4639_cov_10.




qnrS1 [100; 657/657; NODE_62_length_12756_cov_29.088922; 
10946..11602], sul1 [100; 840/840; 
NODE_103_length_1316_cov_23.820017; 453..1292], sul2 [100; 816/816; 
NODE_76_length_4639_cov_10.420213; 1836..2651], dfrA12 [100; 
498/498; NODE_93_length_2003_cov_16.805970; 128..625], dfrA17 [100; 
474/474; NODE_86_length_3258_cov_15.843500; 1645..2118], tet(B) 
[100; 778/1206; NODE_99_length_1577_cov_13.444249; 1..778], blaCTX-M-
15 [100; 876/876; NODE_82_length_3813_cov_10.708356; 2763..3638], 
blaOXA-1 [100; 831/831; NODE_90_length_2437_cov_12.185281; 
903..1733], blaOXA-181 [100; 798/798; 
NODE_62_length_12756_cov_29.088922; 4190..4987], catB3 [100; 
442/633; NODE_90_length_2437_cov_12.185281; 1871.2312], aac(3)-Iid 
[99.88; 861/861; NODE_83_length_3779_cov_10.802848; 2757..3617], 
aac(6')-Ib-cr [100; 600/600; NODE_90_length_2437_cov_12.185281; 
173..772], aadA2 [100; 792/792; NODE_93_length_2003_cov_16.805970; 
1033..1824], aadA5 [100; 789/789; 
NODE_86_length_3258_cov_15.843500; 2249..3037], aph(3'')-Ib [100; 
804/804; NODE_76_length_4639_cov_10.420213; 972..1775], aph(6)-Id 














































RLH/ 13C 597 
IncL/M(pOXA-48) [100; 661/661; 
NODE_60_length_33518_cov_11
.587883; 7135..7795], IncFIB(K) 
[98.64; ; 514/560; 
NODE_830_length_1558_cov_2.




catB3 [100; 414/633; NODE_2797_length_479_cov_1.556818; 1..414], 
sul2 [100; 816/816; NODE_1260_length_921_cov_2.826196; 43..858], 
aac(6')-Ib-cr [100; 552/600; NODE_2021_length_601_cov_2.879747; 
50..601], aph(3'')-Ib [100; 769/804; 
NODE_802_length_1646_cov_3.262673; 878..1646], aph(6)-Id [100; 
837/837; NODE_802_length_1646_cov_3.262673; 42..878], blaCTX-M-15 
[100; 859/876; NODE_1259_length_921_cov_3.241814; 63..921], blaLEN16 
[99.88; 861/861; NODE_301_length_10977_cov_10.547926; 3058..3918], 
blaOXA-48 [100; 798/798; NODE_694_length_2231_cov_6.458439; 26..823], 
blaTEM-104 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572], 
blaTEM-122 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-141 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-163 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-164 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-198 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-1B [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-201 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-206 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-207 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-209 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-214 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-217 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-230 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-234 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-30 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
blaTEM-99 [100; 572/861; NODE_2158_length_572_cov_1.561798; 1..572],, 
fosA [98.33; 420/420; NODE_68_length_31196_cov_12.855478; 
24337..24856], fosA7 [91.72; 423/423; 
NODE_960_length_1281_cov_1.480069; 821..1243], aac(6')-Ib-cr [100; 
552/600; NODE_2021_length_601_cov_2.879747; 50.601], oqxA [96.51; 
1176/1176; NODE_203_length_16405_cov_12.260167; 11870..13045], 
oqxB [97.84; 3153/3153; NODE_203_length_16405_cov_12.260167; 
















RLH/ 13C 597 
IncL/M(pOXA-48) [100; 661/661; 
NODE_48_length_40735_cov_47




blaLEN16 [99.88; 861/861; NODE_65_length_29446_cov_5.646407; 
2126..2986], blaOXA-48 [100; 798/798; 
NODE_131_length_2231_cov_50.799406; 1409..2206], oqxA [96.52; 
1176/1176; NODE_61_length_31271_cov_5.067718; 3342..4517], 
oqxB [97.84; 3153/3153; NODE_61_length_31271_cov_5.067718; 
4541..7693], fosA [93.33; 420/420; 
NODE_1_length_374273_cov_5.180876; 348876..349295], fosA7 











IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.18
8581; 6065..6624], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_16_length_40780_cov_55




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 












IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.18
8581; 6065..6624], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_16_length_40780_cov_55




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 












IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.18
8581; 6065..6624], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_16_length_40780_cov_55




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 

















IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.18
8581; 6065..6624], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_16_length_40780_cov_55




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 












IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.18
8581; 6065..6624], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_16_length_40780_cov_55




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 












IncFIB(K) [98.93; 560/560; 
NODE_length_10828_cov_24.18
8581; 6065..6624], 
IncL/M(pOXA-48) [100; 661/661; 
NODE_16_length_40780_cov_55




blaOXA-48 [100; 798/798; NODE_27_length_2231_cov_59.179813], fosA 
[100; 412/420; NODE_4_length_369297_cov_14.817052; 14063..14474], 
oqxA [99.41; 1176/1176; NODE_9_length_194205_cov_14.128505; 






















IncL/M(pOXA-48) [100; 661/661; 
NODE_4_length_58177_cov_130
.322550; 49268..49928], 
IncFIB(K) [98.93; 560/560; 
NODE_7_length_37899_cov_10.02




blaOXA-48  [100; 798/798; NODE_1087_length_2231_cov_151.101781; 
1409..2206], sul1 [100; 840/840; 
NODE_249_length_7201_cov_9.939355; 751..1590], oqxA [96.65; 
1177/1176; NODE_190_length_8705_cov_3.221562; 4475..5650], 
oqxB [99.02; 3153/3153; NODE_190_length_8705_cov_3.221562; 
1299.4451], aadA2b [99.87; 780/780; 
NODE_249_length_7201_cov_9.939355; 2095..2874], fosA [96.95; 
426/426; NODE_2109_length_1027_cov_2.451111; 68..493], blaACT-15 
[99.65; 1146/1146; NODE_440_length_4766_cov_2.460228; 
2517..3662] 
 
COM; community study, PPS; point prevalence study, OUT; outbreak study, N/AL Not applicable; CITF; Citrobacter freundii, ENTC; Enterobacter cloacae, 
PSEA; Pseudomonas aeruginosa; PROM; Proteus mirabilis, KLEP; Klebsiella pneumoniae, ESSC; Escherichia coli, RLH, Royal London; Barts, St 
Bartholomew’s Hospital; ITU, Intensive care unit; NUH, Newham University Hospital; WX, Whipps Cross University Hospital 
OUT5, OUT6 were both Enterobacter cloacae, OUT7 was an Escherichia coli, all other OUT isolates were Klebsiella pneumoniae  
 
The Royal London Hospital was sampled between the 1st to 30th September 2017 and then again from the 2nd to 9th April 2018. Intensive Care Units across 
all sites were sampled between 19 to 25th February 2018. Newham University hospital was sampled between 7th- 21st May 2018, St Bartholomews from 




6.4.4 Dominant strains 
K. pneumoniae was the most prevalent species recovered, with ST17 the most frequently detected (n = 10) sequence type. The other K. pneumoniae 
isolates (n = 14) comprised 11 individual sequence types.  
 
From Table 14, it is evident that the isolates from the prevalence study were highly varied. However, individual trees for the K. pneumoniae (figure 11), E. 






Figure 11: Phylogenetic tree of all carbapenemase-producing K. pneumoniae isolates from the point prevalence study. 




The amount of genetic change corresponds to the length of the branch; the longer the branch, the more change has occurred and the further away the 
species were from their ancestor. The scale, labelled 0.03, indicates the amount of genetic change observed, illustrated by the branches. They are 
measured in substitutions per site. All phylogenetic trees were produced using CSI Phylogeny and are based on single nucleotide polymorphism (SNP) 
analysis. 
 
Five K. pneumoniae isolates comprised 2 distinct clusters, with KLEP12 and KLEP13 in one cluster and KLEP3, KLEP4 and KLEP5 in the second cluster. 
Comparison of their data in table 14 reveals that the isolates within each cluster belonged to the same MLST group, carried the same plasmids and shared 
the same resistance genes, bar one. Also of note, KLEP3, KLEP4 and KLEP5 were recovered from patients on the same ward, as were KLEP 12 and 

















Figure 12: Phylogenetic tree of all carbapenemase-producing E. coli isolates from the point prevalence study. 
Branches marked in the same colour, correspond to patients on the same ward. 
 
Similarly to the identified K. pneumoniae clusters, ESCC2, ESCC4 and ESCC10 appeared highly related (Figure 12) and carried the same plasmids and 
resistance genes (Table 14). Though their sequence type was unknown, it is presumed that all three belonged to the same ST grouping. Based on these 




Figure 13: Phylogenetic tree of all carbapenemase-producing E. cloacae isolates from the point prevalence study. 
Isolates marked in the same colour, correspond to patients on the same ward. 
 
The highly related isolate cluster of ENTC3/ ENTC4 and ENTC6/8, bore identical plasmids, resistance genes and sequence type, therefore, were 





Figure 14: Phylogenetic tree of all CPO positive isolates associated with suspected outbreaks at BHT 
Branches marked in the same colour correspond to patients on the same ward. 
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Isolates OUT10-OUT15 (K. pneumoniae) belonged to the same MLST group and carried the same 
plasmids and resistance genes (Table 14), with their relatedness clearly evident in figure 14. The 
remaining OUT isolates do not appear as highly related, however, OUT2 and OUT4 cluster 
together with just a short distance from OUT3, all three of which bear similar plasmids (Table 14), 
therefore could be considered a clade. Despite some relatedness among these isolates from 
patients on the same outbreak ward, Table 14 and Figure 14 clearly display the variability within 
these isolates also.  
 
6.5 Discussion  
 
As well as the phylogenetic trees for each species, the STs identified and the range of resistance 
markers detected, illustrate the diversity among the CPOs described here. However, it is important 
to note that specific plasmids were shared among the study isolates, specifically IncL/M, which was 
identified in the large majority of OXA-48-producing organisms. IncHI2A was widely detected in 
isolates which tested positive for NDM-1 (88%), suggesting these are linked.  This is supported by 
many reports in the literature, which have identified OXA-48 on IncL/M plasmids and NDM alleles 
on IncH12A plasmids (Alousi et al., 2018; Cai et al., 2019; Solgi et al., 2017). 
 
6.5.1 Sequence type 
Multiple isolates belonged to the same sequence type, including E. cloacae ST245 (n=2), K. 
pneumoniae ST17 (n=10) and K. pneumoniae ST502 (n=2). An unknown sequence type was 
identified in four E. coli isolates, recovered from inpatients at WX hospital, three of which appeared 
highly related (Figure 12). The locus, alignment length and allele length of the alleles identified 
within these isolates were identical, indicating they did belong to the same sequence type.  
Phylogenetic trees revealed several, small, isolate clusters that appeared highly related, with the 
same genetic content (Table 14), indicating transmission of the same strain between different 
patients, such as ENTC3 and ENTC4 (ST245) (Figure 13 and Table 14). These isolates were 
recovered from inpatients on adjoining renal wards at WX Hospital, indicating that this transmission 
likely arose from shared equipment, bathrooms and/or healthcare professionals. This demonstrates 
a geographical and temporal link, in conjunction with the microbiological data (Dancer, 2014; Irfan 
et al., 2019). 
 
There are no reports in the literature of E. cloacae ST245. However, other reported 
carbapenemase-producing E. cloacae include ST89, ST78, ST105 and ST108 (Majewski et al., 
2014; Annavajhala et al., 2019). Similarly, there were two K. pneumoniae clusters that appeared 
equally highly related in genetic content and were recovered from patients on the same ward: 
KLEP3 - 5 (ST17), blaOXA-48, IncL/M plasmid, elderly care ward and KLEP 12 - 13 (ST502), blaNDM, 
IncH12A plasmid, thoracic surgery ward. K. pneumoniae ST502 has not been reported in the 
literature, therefore, it is possibly novel to the carbapenemase field as well. All three of these 
isolate clusters were from WX hospital, which was built in the early 1900s and has a symmetrical, 
open plan layout (i.e. Nightingale wards) that is no longer considered ideal from an IPC perspective 
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(Cummins and Ready, 2016). Therefore, it is possible that the patients from which these isolates 
were recovered may have been transferred between wards, had direct contact and/or shared 
equipment, although, contamination of the environment and transmission via healthcare staff 
should also be considered. The identification of these clusters at WX hospital highlights the 
requirement for efficient and effective cleaning of the environment, decontamination of equipment 
and hand washing of all staff, as it is highly likely that one of these transfer pathways was 
responsible for the cross-transmission between patients indicated here (Dancer, 2014). This is of 
particular importance when the healthcare setting layout (Nightingale wards) is sub-optimal for IPC. 
 
Many published studies have utilised WGS to determine the relatedness of bacteria associated 
with an outbreak. One study used WGS to determine the differences in SNPs and MLST between 
outbreak isolates and identified two strains in both environmental reservoirs and clinical samples 
(Enterobacter cloacae, ST24; Citrobacter freundii, ST8).  Horizontal transmission of blaIMP was 
confirmed as the reason for this outbreak (Marmor et al., 2020). A number of K. pneumoniae 
strains have also been linked with CPE outbreaks, including ST258, ST661, ST101 and ST11 with 
ST258 being the most commonly detected (Kwong et al., 2018; Martin et al., 2017; Palmieri et al., 
2020; Sheppard et al., 2016; Voulgari et al., 2013). 
 
The blaOXA-48 carried on the IncL/M plasmid in this study has also been reported to be present on 
IncHI1 and IncF plasmids (Findlay et al., 2017b). A UK study over a 7-year period reported that 
ST14, ST231, ST147, ST101, ST11 and ST16 were the most commonly encountered strains of K. 
pneumoniae carrying OXA-48 carbapenemase. Similarly, ST38 and ST410 were the most 
frequently isolated E. coli harbouring an OXA-48 enzyme and ST108 in E. cloacae (Findlay et al., 
2017b). None of the strains detected in this project were among these sequence types.  
K. pneumoniae ST17, reported in both the PPS and the outbreak isolates, has also been 
documented as a CPE producer worldwide, demonstrating the universal transmission of this clone 
(Argente et al., 2019; Liapis et al., 2014; Strydom et al., 2020; Vargas et al., 2019). 
 
6.5.2 Plasmids and resistance genes  
Despite K. pneumoniae ST258 being frequently linked to clonal transmission of OXA-48 
carbapenemases, other studies also suggest specific transposons and/or plasmids are responsible 
for this transmission (e.g. Tn4401 and IncL/M plasmid) (Espedido et al., 2013; Mathers et al., 2015; 
Sheppard et al., 2016). 
 
A variety of plasmids and resistance genes were detected in this study, which mirrors reports of 
multiple plasmids encoding carbapenemase genes, ESBLs and aminoglycoside modifying 
enzymes, among others (Bitar et al., 2020; Partridge et al., 2018). Often these genetic elements 
are common to multiple strains, despite other genotypic differences. Conversely, E. cloacae 
isolates ENTC1, ENTC5 and ENTC7 all belonged to different STs and contained a variety of 
plasmids, but they all possessed IncHI2 and IncH12A with 100% identity. Similarly, three isolates of 
E. coli (ESCC6, ESCC8 and ESCC11) also harboured IncHI2 and IncHI2A plasmids and had 
similar resistance profiles towards beta-lactams, colistin, macrolides, sulphonamides and 
aminoglycosides. Together, this suggests that there may have been horizontal transfer of these 
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plasmids between these isolates, which all tested positive for the NDM-1 gene. The IncHI2 and 
IncHI2A plasmids were also located in one of the Proteus species, which harboured an NDM 
carbapenemase. These large plasmids have been widely detected in the Enterobacterales and 
associated with carbapenemase possession, as well as being easily transmitted by conjugation, 
thereby facilitating the transmission of genes conferring resistance to aminoglycosides, 
tetracyclines, sulphonamides and beta-lactams also (Cai et al., 2019; Rozwandowicz et al., 2018).  
Also of note, IncHI2 and IncHI2A were always detected together within the same isolate and have 
also been reported together in the literature (Samuelsen et al., 2018). This was also noted with 
plasmids IncFIB(pECLA) and IncFII(pECLA), however this was not reported in literature and likely 
to be novel to this study.  
 
K. pneumoniae was the most frequently detected organism in this study, of which 64% possessed 
OXA-48 on an IncL/M plasmid and 36% possessed an NDM, which was likely present on IncHI2 or 
IncHI2A in the majority. One isolate, KLEP6, possessed a blaNDM-5 alongside five other plasmids. 
Therefore, it cannot be determined which plasmid, if any, this gene is present on, but reports in the 
literature suggest IncFII and IncX3 most likely encode the NDM-5 (Li et al., 2018; Tian et al., 2020; 
Yang et al., 2014; Xu et al., 2019; Yang et al., 2020). Several E. coli isolates carried blaOXA-48 also 
on the IncL/M plasmid. Interestingly, ESCC1 and ESCC5 were from patients on the same ward, 
therefore, it is possible that horizontal transmission had taken place here. In ESCC7 blaNDM was 
identified on an IncFII(pAMA1167-NDM-5) plasmid, which has also been reported in literature 
(Overballe-Petersen et al., 2018; Roer et al., 2018). 
 
IncL plasmids have been reported worldwide, to harbour the blaOXA-48 gene. One German study 
also detected the same IncL plasmid in all 35 OXA-48-producing E. coli and K. pneumoniae 
isolates, all of which belonged to various STs. They concluded that this plasmid was highly stable 
and transmissible via horizontal gene transfer (Hamprecht et al., 2019). As with this current study, 
where blaOXA-48 was detected on an IncL/M plasmid, Solgi et al. (2017) also detected this plasmid-
carbapenemase combination in E. coli.  IncHI2 and IncHI2A were the other dominant plasmids in 
this study and detected within the NDM-producing isolates. This genetic combination has also been 
reported previously, along with blaNDM on IncFII plasmids, which was detected in one isolate here 
(Cai et al., 2019; Fiett et al., 2014).  
 
Just one P. aeruginosa (PSEA) was included in this study and it encoded three different NDM 
alleles (blaNDM-1, blaNDM-2 and blaNDM-18), along with several other beta-lactamases. Carriage of 
several carbapenemase alleles has been documented, although is uncommon (Barguigua et al., 
2013a; Khalifa et al., 2016).   
  
In addition to the carbapenemases, there was a variety of resistance genes detected in this study, 
with beta-lactamases and aminoglycoside modifying enzymes comprising the greatest proportion.  
As with many other studies, CTX-M-15, blaTEM-1b and aac(6’)-Ib-cr were the most frequently detected 
here (Abrar et al., 2019; Bajpai et al., 2017; Bevan et al., 2017; Eftekhar and Seyedpour, 2015). 
Like the blaOXA-48 and blaNDM genes in this study, these genes were also plasmid-encoded and often 
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linked to IncI1, IncFI, IncFII and pK319 (Barguigua et al., 2013b; Mshana et al., 2009; Upadhyay et 
al., 2015).  
 
The mcr-9 (mobilised colistin-resistance) gene was detected in 66.7% of all NDM-producing 
strains, including 66.7% of E. cloacae, 80% K. pneumoniae and 75% of E. coli. Similar plasmids in 
all isolates were IncHI2 and IncHI2A, which have also been linked to carrying the blaNDM gene. The 
mcr-9 gene is a newly identified variant described worldwide, found in various species of 
Enterobacterales and reported to be located on IncH12 plasmids (Li et al., 2020). Several studies 
have reported the co-production of mcr and blaNDM genes (Delgado-Blas et al., 2016; Liu et al., 
2017; Feng et al 2018; Lin et al 2020). Colistin is one of the treatments of choice for infections 
caused by MDR bacteria and, therefore when present with NDM producers, will make these strains 
even more challenging to treat. 
 
6.5.3 Outbreak isolates  
A selection of isolates from suspected outbreaks across BHT were analysed by WGS to determine 
whether the individual cases were linked or sporadic in nature. Isolates OUT1-9 were recovered 
from the Surgical Care ward at RLH, while isolates OUT10-16 were recovered from two wards at 
WX and it was clear that those from RLH were much more varied than those at WX (Table 14). 
This was even more evident when reviewing the phylogenetic tree, where isolates OUT10 – 15 
appeared highly related (Figure 14). The only exception was OUT16, where despite possessing 
identical plasmids as OUT10-15, it appeared to cluster within the RLH isolates, indicating possible 
inter-hospital transmission. However, there is no further patient information to confirm this 
hypothesis. Comparison of the RLH and WX outbreak isolates also indicated that these were likely 
two separate outbreaks. Despite the fact that all isolates shared the same IncL/M plasmid, with 
100% identity, the majority of isolates from WX belonged to the same clone (species, ST17) and 
were highly related in plasmid and resistance gene content, indicating this is likely one fit strain that 
has transferred between patients at this site. It could be that the IncL/M plasmid associated with the 
OXA-48 transmission was responsible for both suspected outbreaks, with the plasmid being 
acquired by the ST17 clone at WX, which allowed successful transmission between patients. 
Cases of K. pneumoniae ST17 have been documented in the literature, both in outbreak and non-
outbreak settings, and involved both NDM and OXA-48 (Argente et al., 2019; Jin et al., 2015; Liapis 
et al., 2014; Strydom et al., 2020; Vargas et al., 2019). The diversity of the isolates from patients at 
RLH indicates that transmission of the same strain between patients was unlikely; however, 
horizontal transfer via the IncL/M plasmid seems plausible given the evidence presented here. To 
determine this fully, future work should focus on further analysis of the plasmids.  
 
In contrast to the isolates that appeared related and highly similar in genetic characteristics, some 
isolates of the same sequence type varied. OUT2 and OUT4, for example, belonged to ST45 but 
varied greatly in their resistance genes. This is possibly due to the additional plasmid, IncQ1, 
detected in OUT4, providing additional resistance genes. Similar findings have been demonstrated 
with OUT8 and OUT9 also, potentially caused by possession of the IncFII(K) plasmid. Therefore, 
when proposing an outbreak is associated with the isolates possessing a particular plasmid (e.g. 
IncL/M with OXA-48), it is important to determine the genetic content of each plasmid to identify the 
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common denominator in outbreak isolates. This was a limitation of this study, which would be 
resolved by analysing each plasmid sequence as part of future work. 
 
6.5.4 Susceptibilities in relation to resistant markers 
Antibiotic susceptibility testing of the 38 isolates from the PPS described here was performed 
against a limited number of antibiotics, meaning it was difficult to determine the true impact of many 
of the antibiotic resistance genes detected by WGS (Table 14). Though all isolates possessed a 
carbapenemase gene and the majority were resistant to meropenem (n = 36/37), just 21/37 were 
resistant to ertapenem. This, however, corresponds with the OXA-48-producing isolates, an 
association which has been reported on several occasions to be carbapenem-susceptible (Cubero 
et al., 2015; Machuca et al., 2019; Nazik et al., 2012). It is also for this reason that BHT uses the 
algorithm described in chapter 3 (Ciesielczuk et al., 2018). On a similar note, all isolates possessed 
at least one beta-lactamase gene (e.g. blaCTX-M-15, blaDHA-1, blaNDM-1, blaOXA-1, blaTEM-1B), yet 
resistance to beta-lactams tested (piperacillin-tazobactam and temocillin) was observed in just 
23/37 and 15/37 isolates, respectively. However, it is not known which precise resistance genes 
encode resistance to the antibiotics tested here. Therefore, the presence of a resistance gene did 
not automatically lead to phenotypic resistance.  
 
Many other resistance genes detected (e.g. fosA, fosB, sul1, mcr-9) did not have a phenotypic 
result for comparison. However, various studies have identified these genes in carbapenemase-
producing isolates and reported phenotypic resistance (Doi et al., 2016; Mathys et al., 2018; Osei 
Sekyere and Amoako, 2017). In addition, reports describing the plasmids encoding 
carbapenemase genes also identified many of these genes, such as blaCTX-M-14 and aadA2 present 
on IncL/M (Adamczuk et al., 2015). Therefore, it is plausible that many of the additional genes 
detected here (e.g. blaCTX-M-15, blaOXA-1 and blaTEM-1B) do confer antibiotic resistance in the study 
isolates. This would result in these isolates being multi-drug resistant and difficult to treat if they 
were to cause infection. One phenotypic-genotypic combination that did correspond was 
susceptibility to fosfomycin for all E. coli isolates, which was supported by the lack of corresponding 
resistance genes (fosA). 
 
Given the variety of species recovered from the patients within all studies described here, including 
the outbreaks, it is highly likely that the IncL/M plasmid was responsible for the large number of 
OXA-48-producers at BHT. As well as the isolate transmitting between patients, this plasmid also 
jumped between organisms within the same patient (e.g. CITF1 and ESCC5). However, it cannot 
be determined accurately from this study where the NDM originates, though this is also likely to be 
present on a plasmid, as demonstrated by various reports (Li et al., 2018; Tian et al., 2020; Xu et 
al., 2019; Yang et al., 2014; Yang et al., 2020). 
 
6.5.5 Limitations  
Though extensive data has been presented here indicating the link between an IncL/M plasmid and 
OXA-48 possession, this data would be improved by determining the specific plasmid content and 
comparing these sequences/integrons/transposons between isolates. This would provide a 
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definitive answer as to whether horizontal transfer did occur and confirm whether the RLH isolates 
were indeed part of a plasmid-mediated outbreak. However, this could also be thrown into 
question, as plasmids can be highly diverse and even those which are deemed the same type (e.g. 
IncL/M) may not share all core genes, as plasmids can lose, gain and rearrange their genetic 
contents frequently over time (Gillings, 2014; Orlek et al., 2017; Turner et al., 2014). A further 
limitation is the lack of patient data for inferring patient to patient transmission. The information 
provided within this analysis strongly suggests that isolates from WX were highly related and likely 
spread between patients, but further patient information, such as date of admission, any indwelling 
devices and movement between wards, was not provided.  
Sequencing a greater number of isolates for the outbreak study would lead to more representative 
results and determine how widespread the IncL/M plasmid was within the Trust. However, this 
would require a WGS-specific bioinformatician for accurate data analysis and interpretation, which 
was not available for this study. WGS comes with its own limitations. Although it can be used to 
identify previously unknown genetic characteristics, identify antibiotic resistance conferring genes 
and mutations and form epidemiological links, it also generates a large amount of data, which 
requires specialist processes and analysis. Analytic validity in WGS is the term given to the 
accuracy of predication of the presence of a nucleotide base. The more times the nucleotide base 
is read, the higher the accuracy. This therefore needs to be taken into account when discussing the 
limitations of WGS, as it is important that the sequencing performed has passed the threshold for 
statistical accuracy prior to data interpretation (Lin, 2019). Finally, for data completion, this study 
would have benefited from extended antibiotic susceptibility testing so that more comparisons 
between phenotypic and genotypic resistance could be made. Although the literature has reported 
on this subject, it would enable a more accurate analysis of the isolates investigated here (Bardet 
and Rolain, 2018; Gupta et al., 2018). 
 
6.6 Conclusion  
 
In conclusion, from the WGS data analysed here, it is highly likely that the IncL/M plasmid identified 
in OXA-48-producing isolates was responsible for the rapid transmission of blaOXA-48 at BHT and the 
associated outbreaks. Isolates possessing NDM, on plasmids IncHI2 or IncHI2A, did not appear as 
readily transferable, as they were recovered far less frequently than OXA-48-producers, and 
indicate a possible community source (chapter 5). Occasional CPO transmission can also be linked 
to transfer of virulent strains between patients, including the K. pneumoniae ST17 strain observed 
in this study. However, this strain also encoded the IncL/M plasmid responsible for the OXA-48 
transmission, indicating this species-ST-plasmid combination might represent a “superbug” within 
BHT.  With this plasmid spread, novel IPC measures are required to prevent onward transmission 







Chapter 7: Overall Discussion 
 
CPOs are a worldwide problem and are detected in hospitals, the community and the environment 
(Kelly et al., 2017). Patients are routinely screened to ensure optimal patient management and 
avoid intra-hospital and patient transmission (Richter and Marchaim, 2017). This project’s overall 
aim was to gain a better understanding of CPOs at BHT in order to inform best practice on patient 
screening. This was achieved through the following objectives: review of published engagement 
with the PHE toolkit for managing CPEs, optimising detection of the “big five” carbapenemases, 
evaluation of CPO screening and prevalence in different patient populations across BHT, and 
carrying out phylogenetic analyses of isolates from outbreak, community and inpatient sources. 
Prior to this project, BHT did not actively screen specific target groups, other than those previously 
positive for a CPO. Even though the Trust’s IPC policy states that specific groups should be 
screened, which was in alignment with those published in the PHE toolkit, this was not enforced or 
routinely practised. Taking data from both the inpatient PPS and community study performed, at-
risk groups were identified, specific to BHT’s own population. This enabled a business case to be 
put forward for enhanced screening of these patient groups. In addition, WGS of various CPOs 
recovered from patients at BHT identified the likely cause of a previously suspected OXA-48-
producer outbreak as isolates with an IncL/M plasmid, and also determined whether transient 
versus established carriage could be differentiated. 
 
7.1 Laboratory methods 
There are a variety of laboratory methods used to detect CPOs which include various media, 
antibiotic disk combinations or hydrolysis tests, lateral flow devices and PCR assays (Berry et al., 
2019; Maurya et al., 2019; PHE, 2019; Simner et al., 2018; Wareham and Abdul Momin; 2017). 
CPO epidemiology can vary geographically, meaning some laboratories require a low-throughput 
test for just the most common CPOs, whereas other laboratories will require a high-throughput test 
which includes the less frequently encountered carbapenemases. 
 
As part of this project (chapter 3) a published PCR was modified and then verified against 
reference laboratory results to confirm accuracy. Surprisingly, verification results revealed the in-
house PCR to be superior to that of the reference laboratory, as it identified additional enzymes in 
isolates, as well as proving a number of isolates were VIM-negative. Both of these discrepancies 
were confirmed by a third external laboratory. Similar findings were reported by Smiljanic et al. 
(2017), as their in-house PCR was specifically superior at detecting OXA-like carbapenemases, 
compared with a commercial assay (Smiljanic et al., 2017). AMRHAI (PHE) was the reference 
laboratory used for verifying the results of this in-house PCR evaluation. Although their initial 
validation correctly identified all 402 isolates harbouring carbapenemases, it appears their methods 
now need updating, as a number of new carbapenemase alleles have been described since this 
publication (Ellington et al., 2016; Hishinuma et al., 2019; Liu et al., 2017). 
 
Implementation of the boil extraction method with the in-house PCR, into routine use, would be 
both cost and time effective, compared with current methods. Similar findings have been reported 
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in other PCR-based studies, as well as comparable sensitivity (Oueslati et al., 2018; Singh-
Moodley and Perovic 2016; Sweeney et al., 2006; Yamagishi et al., 2016). The boil extraction 
method appears to be a commonly used alternative to the more expensive automated platforms, 
with one study comparing outputs from both methods and determining the boil method to have the 
same sensitivity (Oueslati et al., 2018). The in-house PCR was also significantly more affordable 
than both the available commercial lateral flow devices for the “big five”, as well as the GeneXpert 
test. Both these tests, however, are far simpler to perform and the GeneXpert (Cepheid) has the 
advantage of being validated for direct testing of swabs for CPO detection. Future work could 
include validating the in-house PCR for direct testing from the swab also and adapting the assay to 
be more in line with TATs currently offered by commercial platforms (Tato et al., 2016).  
 
7.2 Patient screening 
National guidelines and literature recommend the use of a rectal swab or stool sample for the 
detection of a CPO (Lerner et al., 2013; PHE, 2013). Guidelines also stipulate the presence of 
visible faecal material on rectal swabs, however, one study disputes this, but the reason was not 
disclosed (Otter et al., 2016). Presence of faecal material is thought to increase the likelihood of 
detecting a CPO and it highlights that a high-quality rectal swab is taken. However, this project did 
not note the presence or absence of faecal material on swabs. Perineal and peri-anal swabs have 
also been proposed as alternatives to the more intrusive rectal swab, but both have demonstrated 
reduced sensitivity for CPO detection (Currie et al., 2018; Dyakova et al., 2017; Soria Segarra et 
al., 2018; Van der Zee et al., 2014). The systematic review (chapter 2) illustrated that all 
laboratories (n=5), followed these guidelines and tested rectal swabs, with one study even 
excluding perineal swabs from the analysis (Mookerjee et al., 2018). All currently available 
commercial kits have been evaluated for testing of direct bacterial colonies and the majority (8/13) 
for rectal swabs. Only three of thirteen were validated for testing from blood cultures and the 
remainder of sample types (peri-rectal swabs, bronchial specimens, urine and stool) only being 
evaluated by one kit (PHE, 2019). One study looked at 7,504 urine samples to determine the CPE 
prevalence in urine, which was reported to be low (0.13%). Despite this low prevalence, urine has 
demonstrated to be a valuable sample type for both CPO and CPE detection (Woodford et al., 
2018). Other studies have also determined urine as a possible sample type for the detection of 
CPOs (Collins et al., 2016; Eshetie et al., 2015). However, urine cannot replace the need for a 
rectal swab, as this specimen type relies on either a badly taken sample (contaminated with faecal 
flora) or an infection to be present. Therefore, additional sample types other than those 
recommended by the PHE toolkit, should only be collected if a CPO infection is suspected.  
 
The hospitals detailed in chapter 2 gathered risk factor-based questionnaires prior to screening 
(Carter et al., 2015; Poole et al., 2016; Wilson et al., 2018; Otter et al., 2016; Mookerjee et al., 
2018). A multitude of risk factors have been reported including foreign travel, hospitalisation and 
treatment in the UK and abroad, various forms of immunosuppression, use of mechanical and/or 
indwelling devices, admission to ITU, prior antimicrobial use and patient mobility (Carter et al., 
2015; ECDC, 2011; Madueno et al., 2017; Mariappan et al., 2017). Due to the frequency of reports, 
many of these risk factors have been included in the National guidelines (PHE, 2013). Patient 
126 
 
groups identified in this project, which were identified as having a higher risk of possessing a CPO, 
included several of the factors documented above, as well as admission to care of the elderly 
wards, renal wards and admission to WX hospital. Therefore, this data supports the 
recommendations set out in the National guidelines, but also reveals risk factors specific to BHT. 
Highlighting the importance of each UK Trust conducting their own PPS to determine additional risk 
factors associated with their patient groups (Carter et al., 2015; Poole et al., 2016; Wilson et al., 
2018; Otter et al., 2016; Mookerjee et al., 2018). 
 
PHE Guidelines state that an at-risk patient should be isolated upon admission and three rectal 
swabs, testing negative for a CPO, taken 48 hours apart, are recommended prior to removing the 
patient from isolation (PHE, 2013). If this recommendation was followed entirely, it would be a 
significant cost to the Trust in terms of inpatient management, staffing and laboratory testing, plus 
the majority do not have sufficient isolation facilities. This also relies on staff following the 
guidelines accurately, however, from the PPS conducted in BHT, it is clear that this does not 
happen. This recommendation also suggests test results should be available within 48 hours in 
order for the next test to be conducted, if needed. However, as discussed above, many CPO tests 
rely on culture, leading to an overall TAT of 2-3 days, sometimes more (Ratnayake et al., 2020). In 
2009, the first CPE was detected in the UK and in 2011 the then Health Protection Agency (HPA) 
released the first guidelines on their control, followed by the PHE toolkit in late 2013. Numbers of 
CPEs confirmed by the reference laboratory went from <500 cases between 2009-2011, up to 
around 1500 in 2014, 2500 in 2016 and 4028 in 2018 (PHE, 2019). Perhaps, most tellingly, when 
the PHE toolkit was published, the prevalence of CPOs was not as well documented, with fewer 
CPO reports than published today and when isolation of all suspected carriers may have been 
more feasible (unpublished data from the antimicrobial resistant workbooks-PHE, 2018). Therefore, 
it is imperative that this toolkit is updated to include risk factors, data and recommendations that 
have been published since 2013. In the meantime, hospitals should use this toolkit as a basic 
guideline, while also referring to international legislation and local prevalence, to formulate trust-
specific policies.  
 
Sequential screening has the potential to differentiate between established versus transient 
carriage (D'Andrea et al., 2011). The PHE toolkit states that a confirmed CPO carrier should be 
considered as such for their lifetime, despite subsequent negative screens. However, if the CPO 
was confirmed as transient carriage, it may eradicate the need for strict IPC measures, which are 
costly to the hospital, and would be better for the patient’s well-being, as being isolated can have 
an impact on a patient’s mental health. Both methicillin-resistant Staphylococcus aureus (MRSA) 
and Clostridioides difficile have both been involved in outbreaks worldwide and screening and 
isolation practises vary for each organism (Berger et al., 2019; Gateau et al., 2019; Poole et al., 
2016; Beukers et al., 2020). In the UK, all inpatients are screened for MRSA prior to admission, 
preferably by PCR, but culture on selective media remains commonly practised. This is with the 
aim to isolate the patient and implement IPC measures to prevent further transmission and 
outbreaks (Hubner et al., 2015). Upon confirmation of a positive result, treatment to eradicate 
carriage typically includes topical mupirocin with chlorhexidine washing (Lindgren et al., 2018). 
Patients are not considered a positive carrier for life, as with CPE, despite decolonisation only 
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being effective long term in 50-60% of cases, nor are three consecutive negative screens 
recommended (Department of Health, 2006). C. difficile is another example of a bacterium which 
colonises the gut. When toxin production is present, infection is associated with high morbidity and 
mortality. Routine screening is not performed, patients are isolated only when symptomatic and 
upon testing positive for the toxin producing C. difficile. Once the patient no longer has diarrhoea, 
and the risk of transmission greatly reduced, the patient is removed from isolation and no more 
screening tests are required (PHE, 2013).  
 
Not only are follow-up screens required to monitor CPO status, a negative screen does not allow 
the patient to be removed from isolation, which differs greatly from the guidance formulated for the 
management of C. difficile. It could be recommended that unless the previously positive patient 
presents with diarrhoea, the patient could be removed from isolation, provided they have a current 
negative status.   
 
The relevance of sequential screening was evaluated in chapter 5 and demonstrated that CPO 
carriage within a patient varied and several patients did alternate from positive to negative status 
and then remained negative. The normal flora of the gut is extremely diverse and constantly 
changing with diet, antibiotic treatment and gastrointestinal infection, among others (Dudek-Wicher 
et al., 2018). Therefore, the PHE toolkit recommendation to maintain IPC measures despite a 
negative screen is somewhat understandable, where these factors are unknown. However, if the 
CPO becomes undetectable, the argument could be made that this is no longer an infection control 
risk and unlikely to be passed between patients or the environment. Therefore, the patient could be 
de-isolated, with weekly screens to determine on-going carriage status. However, a Korean study 
demonstrated that 80% of patients with KPC-producers remained positive on subsequent 
screening, compared to approximately 36.7% of patients with NDM-CPE (Lim et al., 2018). This 
demonstrates that KPC-producer carriage is less likely to be transient, when compared to NDM-
producers. Therefore, de-isolation might need to be enzyme specific. For example, the majority of 
CPOs identified in this study produced OXA-48 and sequential screening revealed 48.2% of 
patients to remain positive on subsequent screens. 
 
It was clear from the study data that the PHE toolkit was not followed when it came to sequential 
screening. Patients had anything from 1 - 9 screens, but often screening would stop once a patient 
was confirmed as CPO-positive, which was a major limitation of this study, as the value of 
subsequent screening could not be determined for all patients.  Following a positive result, patients 
remained cohorted until discharged.  
 
A total of 62% of patients tested positive for carriage within the 3-screen recommendation; the 
remaining 38% would have remained undetected (PHE, 2013). However, all NDM-carriers were 
detected within this 3-screen period. As the NDM-producer was likely to be community acquired, it 
is likely that 3 screens is sufficient to identify hospital acquired carbapenemases, such as those 




From the information gained from the sequential screening data, it is possible that patients revert 
back to negative following a positive result and stay negative, therefore, classifying patients as 
having transient, rather than established carriage, would seem to be appropriate. These patients 
could then be transferred to an open bay, with weekly screens to monitor carriage status to identify 
any that potentially become positive again or acquire a different CPO. 
 
7.3 Surveillance 
Surveillance of CPOs is performed by actively screening for carriage status or via routine infection 
diagnosis. Surveillance and antimicrobial stewardship is incredibly important to monitor the rates of 
CPO carriage, determine transmission pathways and implement IPC measures. For MRSA, 
screening is performed upon admission and/or prior to surgery (Department of Health, 2006). 
However, screening for CPOs has not yet become part of this routine screening. The PHE toolkit 
recommends isolation of all patients fitting into one of three risk categories. However, at BHT, this 
would encompass more than half of all inpatients, making it highly impractical and costly. To 
overcome this, many hospitals screen at-risk groups instead (Carter et al., 2015; Poole et al., 2016; 
Wilson et al., 2018; Otter et al., 2016; Mookerjee et al., 2018; Segagni Lusignani et al., 2020). Data 
from this project was used to determine the prevalence of CPOs in the inpatient population across 
the Trust and identify high-risk patient groups. From this, targeted screening, based on locally-
derived data was implemented. An update of the toolkit to amend recommendations due to the 
impracticality of isolating so many patients should be undertaken. By using the risk factor and 
prevalence data obtained from the PPS (chapter 4), it was possible to determine that the following 
patient groups require screening upon admission: all admissions to Whipps Cross University 
Hospital (due to the high prevalence rate), admissions to Renal Dialysis units across all sites, care 
of the elderly, any previous hospitalisation within 12 months, hospitalisation abroad within 12 
months, foreign travel in past 12 months and patients known to be positive for a carbapenemase-
producer. This is in addition to all admissions to the surgical ward associated with the OXA-48 
outbreak at BHT, admissions to intensive and critical care units, due to the increased morbidity and 
mortality associated with this group of patients, alongside difficultly in closure of these wards 
necessary for cohorting and fumigation. Chapter 6 details a suspected outbreak of OXA-48 
producing organisms at BHT. This outbreak, partly due to its long duration, reduced the credibility 
of the Trust and also made it increasingly difficult to repatriate patients, as other trusts would not 
accept patients due to the risk of CPO transmission. A business case was devised, which used 
data from the PPS, to allow for the more efficient and timely microbiological testing of at-risk 
patients.  
 
Prior to the OXA-48 outbreak and submission of the business case, few patients were screened for 
a CPO, despite regular isolation of CPOs from clinical samples, because there was no enforced 
routine screening protocol in place at this time. Confirmation of a CPO was performed by the 
reference laboratory, and took approximately 2 weeks, which was unacceptable for optimal 
isolation and management of these patients. This slow TAT also contributed to the success of the 
business case, as it allowed for increased testing in the microbiology laboratory, which reduced the 




7.4 Outbreaks and clusters 
Various clones have been linked with antibiotic resistance transmission, such as E. coli ST131 and 
CTX-M-15 and ST258 with K. pneumoniae (Chen et al., 2014; Peirano et al., 2014).  The WGS 
data from this study (chapter 6) indicated vertical transmission between patients at WX Hospital. 
This was illustrated by K. pneumoniae ST17, encoding the same plasmids and resistance genes, 
identified within a cluster of patients in this hospital (Table 14 and Figure 15). This strain of K. 
pneumoniae has been commonly reported in the literature to harbour not only OXA-48 and NDM, 
but has also been linked to CTX-M-15 and other OXA-type beta-lactamases (Argente et al., 2019; 
Jin et al., 2015; Liapis et al., 2014; Strydom et al., 2020; Vargas et al., 2019). Other isolates 
identified in the suspected OXA-48 outbreak (chapter 6) varied, however, they all had one 
characteristic in common: possession of an IncL/M(pOXA-48) plasmid. Therefore, it is proposed 
that horizontal gene transfer between isolates, with subsequent transmission between these 
patients, although further analysis would be required to confirm this, beyond the scope of this 
project. Unlike the OXA-48-producing isolates, a small number encoded blaNDM, which appeared to 
be linked with an IncHI2 or IncHI2A plasmid, but was not as widespread within the Trust, indicating 
a fitness cost to this strain on harbouring the NDM-encoding plasmid. However, further plasmid 
analysis would be required to confirm these theories.  
 
7.5 Prevalence 
Hospital trusts in the UK have reported CPO prevalence between 0-11%, with higher rates 
confined to Manchester and a prevalence in London ranging between 0.3 - 3.8% (unpublished data 
from the antimicrobial resistant workbooks-PHE, 2018; Mookerjee et al., 2018; Otter et al., 2016; 
Poole et al., 2016). Around Europe, CPO rates are far higher, with reported rates between 0% - 
64.7% (ECDC, Surveillance Atlas of Infectious Diseases). The USA, however, more closely 
resembles the UK with 11% of K. pneumoniae and 2% of E. coli resistant to carbapenems (CDC, 
2013).  
 
At BHT, the inpatient prevalence determined by the PPS was within parameters associated within 
England, at 3.1%, although at the higher end. It was felt that the suspected OXA-48 outbreak 
contributed to this higher prevalence, as well as the Nightingale-style wards of WX hospital and the 
greater elderly population treated there. Nightingale-style wards have been described to have beds 
in closer proximity, shared toilets and a reduced number of wash basins. A report studying 
norovirus outbreaks observed a significantly higher number of  norovirus outbreaks on Nightingale-
style wards, compared with non-Nightingale-style wards. This clearly demonstrates the increased 
transmission risk associated with these old-style wards and hospitals (Cummins and Ready, 2016). 
This data was also added to the CPO business case to enhance screening practises at WX and 
prevent further CPO outbreaks, where possible.  
 
On the other hand, community prevalence at BHT was low (0.5%) (Henderson et al., 2019). The 
majority of published studies refer to community samples as outpatients or inpatients samples 
collected within 3 days of admission (Coccolini et al., 2015; Miller and Johnson, 2016; Tang et al., 
2016). The majority of these studies demonstrated that community carriage mirrors that of inpatient 
carriage (van Duin et al., 2013). However, this was not a finding from the prevalence study 
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conducted at BHT (chapter 4). Community acquisition of a CPO has been reported to be caused by 
contamination of drinking water, livestock, transmission through household contacts or from 
contaminated environmental surfaces (Liu et al., 2016; Walsh et al., 2011). However, it is not 
possible to perform contact tracing or identify all reservoirs of CPOs in the community. Therefore, 
healthcare screening provides the best opportunity to identify community CPO carriage and 
epidemiology.  
 
7.6 Infection Prevention Control 
There have been many studies worldwide documenting the IPC measures in place for the 
containment of MDR bacteria, specifically CPOs (Magiorakos et al., 2017; Tacconelli et al., 2014 
Teerawattanapong et al., 2017). During a suspected outbreak the reference laboratory plays a 
crucial role in confirmation of the outbreak by providing epidemiological results of whether the 
cases are linked. However, the turnaround time to receipt of the result can be up to 2 weeks in the 
UK, which is not practical for adequate IPC management. The hospital’s role is to ensure the 
control measures are in place, and to provide both guidance and financial support in the control 
and prevention of further transmission. However, this is not the case at BHT, where the infection 
control team does not have its own budget. Therefore, during an outbreak, the laboratory is 
expected to pay for the enhanced screening. If the screening protocol was incorporated into a 
government guideline, the Trust would have to comply, and screening could take place more freely, 
with dedicated budgets, thus removing the requirement for a business case. For example, there are 
government guidelines for both C. difficile and MRSA, meaning that for each new MRSA 
bacteraemia which the Trust reports, a large fine is issued. This has ensured that adequate 
protocols, pre-admission screening, treatment and IPC measures are in place.  
 
7.7 Conclusion and recommendations 
IPC teams are crucial to help minimise the transmission of CPOs between patients and the 
environment. However, this point is only valid if the IPC team know what the CPO prevalence is 
and who the high-risk patients are. The current PHE toolkit is out of date and no longer fully fit for 
purpose. Therefore, based on evidence detailed in previous chapters together with factors reported 
in the literature since the Toolkit was published, new guidance should consider:  
1. Patient screening prior to admission. Currently this is only advised for MRSA screening, 
however knowing a patient's status immediately prior to hospitalisation would reduce 
unnecessary isolation and cohorting of new admissions. 
2. If admission is unavoidable without prior screening, at-risk patients must be identified and 
screened immediately. If isolation is not possible, these patients should be cohorted until 
carriage status is known.  
3. Each Trust should perform a PPS to determine their own at-risk groups and take into 
account international, national, published and locally gathered data to devise internal 




4. Traditional culture-based methods could be recommended for patients undergoing 
screening prior to admission to reduce cost, while rapid techniques could be used for those 
screened on admission, where a quick TAT is required, and for outbreaks.  
5. Immediate isolation for confirmed positive carriers, not just all those deemed “high risk”, 
with en-suite facilities and efficient IPC measures may reduce the transmission further, with 
effective communication between staff and the patient.  
6. Screening of positive carriers should continue, to establish transient versus established 
carriage, with the aim to remove patients from isolation if negative carriage persists 
(transient).  
7. Three CPO screens are sufficient for identifying community CPOs, while subsequent 
screens that later become positive likely represent hospital-based acquisition. The total 














































Isolate number Resistance 
mechanism 
Organism OXA48 KPC VIM IMP NDM In-house 
Result 
1 ESBL Escherichia coli    ND    ND    ND    ND    ND NEG 
2 NEG Enterobacter cloacae    ND    ND    ND    ND    ND NEG 
3 ESBL Escherichia coli    ND    ND    ND    ND    ND NEG 
4 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
5 ESBL Escherichia coli    ND    ND    ND    ND    ND NEG 
6 ESBL Escherichia coli    ND    ND    ND    ND    ND NEG 
7 ESBL Klebsiella pneumoniae    ND    ND    ND    ND    ND NEG 
8 ESBL Escherichia coli    ND     ND     ND     ND     ND  NEG 
9 ESBL Escherichia coli    ND      ND      ND      ND      ND   NEG 
10 ESBL Escherichia coli    ND    ND    ND    ND    ND NEG 
11 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
12 NEG Acinetobacter baumannii    ND    ND    ND    ND    ND NEG 
13 NEG Morganella morganii    ND    ND    ND    ND    ND NEG 
14 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
15 NEG Proteus mirabilis    ND    ND    ND    ND    ND NEG 
16 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
17 NEG Klebsiella oxytoca    ND    ND    ND    ND    ND NEG 
18 NEG Enterobacter cloacae    ND    ND    ND    ND    ND NEG 
19 NEG Acinetobacter spp    ND    ND    ND    ND    ND NEG 
20 NEG Serratia marcescens     ND    ND    ND    ND    ND NEG 
21 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
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22 NEG Enterobacter species    ND    ND    ND    ND    ND NEG 
23 ESBL Enterobacter cloacae    ND    ND    ND    ND    ND NEG 
24 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
25 NEG Escherichia coli   ND    ND    ND    ND    ND  NEG 
26 NEG Enterobacter aerogenes    ND    ND    ND    ND    ND NEG 
27 NEG Enterobacter cloacae    ND    ND    ND    ND    ND NEG 
28 NEG Klebsiella pneumoniae    ND    ND    ND    ND    ND NEG 
29 OXA51/23 Acinetobacter baumannii    ND    ND    ND    ND    ND NEG 
30 NEG Escherichia coli    ND    ND    ND    ND    ND NEG 
31 OXA23 Acinetobacter baumannii    ND    ND    ND    ND    ND NEG 
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Isolate number Gene Organism OXA-48 KPC VIM IMP NDM In-house 
Result 
32 KPC Klebsiella 
pneumoniae 
 ND 15.35  ND  ND  ND KPC 
33 KPC Enterobacter 
cloacae 
 ND 15.41  ND  ND  ND KPC 
34 KPC Klebsiella 
pneumoniae 
 ND 19.33  ND  ND  ND KPC 
35 KPC Escherichia coli  ND 17.44  ND  ND  ND KPC 
36 KPC Escherichia coli  ND 18.16  ND  ND  ND KPC 
37 KPC Escherichia coli  ND 18.06  ND  ND  ND KPC 
38 KPC Klebsiella 
pneumoniae 
 ND 15.36  ND  ND  ND KPC 
39 KPC Klebsiella 
pneumoniae 
 ND 18.92  ND  ND  ND KPC 
40 KPC Escherichia coli  ND 17.92  ND  ND  ND KPC 
41 KPC Escherichia coli  ND 17.68  ND  ND  ND KPC 
42 KPC Escherichia coli  ND 17.72  ND  ND  ND KPC 































Isolate number Gene Organism OXA-48 KPC VIM IMP NDM In-house 
Result 
43 IMP Klebsiella 
pneumoniae 
ND  ND  ND  25.36 ND  IMP 
44 IMP Klebsiella 
pneumoniae 
 ND  ND  ND 24.27  ND IMP 
45 IMP Klebsiella 
pneumoniae 
 ND  ND  ND 28.43  ND IMP 
46 IMP Klebsiella 
pneumoniae 
 ND  ND  ND 28.07  ND IMP 
47 IMP Enterobacter 
cloacae 
ND ND ND 16.66 ND IMP 
48 IMP Enterobacter 
cloacae 

































Gene Organism OXA-48 KPC VIM IMP NDM In-house Result 
49 OXA-48 Enterobacter cloacae 12.17 ND ND ND ND OXA48 
50 OXA-48 Escherichia coli 12.29 ND ND ND ND OXA48 
51 OXA-48 Escherichia coli 20.39 ND ND ND ND OXA48 
52 OXA-48 Escherichia coli 17.56 ND ND ND ND OXA48 
53 OXA-48 Escherichia coli 15.65 ND ND ND ND OXA48 
54 OXA-48 Escherichia coli 15.41 ND ND ND ND OXA48 
55 OXA-48 Klebsiella 
pneumoniae 
15.51 ND ND ND 22.39 OXA48 and NDM 
56 OXA-48 Escherichia coli 15.78 ND ND ND ND OXA48 
57 OXA-48 Escherichia coli 16.15 ND ND ND ND OXA48 
58 OXA-48 Escherichia coli 15.26 ND ND ND ND OXA48 
59 OXA-48 Escherichia coli  16.61 ND ND ND ND OXA48 
60 OXA-48 Escherichia coli 15.57 ND ND ND ND OXA48 
61 OXA-48 Escherichia coli 14.89 ND ND ND ND OXA48 
62 OXA-48 Escherichia coli 14.81 ND ND ND ND OXA48 
63 OXA-48 Escherichia coli 13.02 ND ND ND ND OXA48 
64 OXA-48 + 
KPC 

































Gene Organism OXA-48 KPC VIM IMP NDM  In-house  
 Result 
65 NDM Escherichia coli  ND  ND ND  ND 17.07 NDM 
66 NDM Escherichia coli  ND  ND ND  ND 20.96 NDM 
67 NDM Enterobacter cloacae  ND  ND ND  ND 20.78 NDM 
68 NDM Klebsiella pneumoniae  ND  ND ND  ND 19.85 NDM 
69 NDM Acinetobacter 
baumannii 
 ND  ND ND  ND 20.86 NDM 
70 NDM Klebsiella pneumoniae  ND  ND ND  ND 20 NDM 
71 NDM Escherichia coli  ND  ND ND  ND 19.65 NDM 
72 NDM Enterobacter spp  ND  ND ND  ND 19.17 NDM 
73 NDM Citrobacter freundii  ND  ND ND  ND 18.94 NDM 








Gene Organism OXA-48 KPC VIM IMP NDM In-house Result 
75 VIM Pseudomonas 
aeruginosa 
ND ND 16.24 ND ND VIM 
76 VIM Escherichia coli ND ND ND ND ND NEG 
77 VIM Pseudomonas 
aeruginosa 
ND ND 17.08 ND ND VIM 
78 VIM Klebsiella pneumoniae ND ND 17.35 ND ND VIM 
79 VIM Klebsiella oxytoca ND ND ND ND ND NEG 
80 VIM Pseudomonas putida ND ND 16.14 ND ND VIM 
81 VIM Escherichia coli ND ND 17.17 ND ND VIM 
82 VIM Escherichia coli ND ND ND ND ND NEG 
83 VIM Pseudomonas 
aeruginosa 
ND ND 17.09 ND ND VIM 
84 VIM Klebsiella oxytoca ND ND 17.42 ND ND VIM 
85 VIM Escherichia coli ND ND 15.59 ND ND VIM 
86 VIM Citrobacter freundii ND ND 18.44 ND ND VIM 




ND ND 18.2 ND 7.07 VIM + NDM 
88 VIM Citrobacter freundii ND ND 17.96 ND ND VIM 
89 VIM Citrobacter freundii ND ND 17.46 ND ND VIM 
90 VIM Pseudomonas 
aeruginosa 




Appendix 6: Continued 
91 VIM Pseudomonas 
aeruginosa 
ND ND 17.35 ND ND VIM 
92 VIM Pseudomonas 
aeruginosa 
ND ND 17.58 ND ND VIM 
93 VIM Pseudomonas 
aeruginosa 
ND ND 17.18 ND ND VIM 
94 VIM Pseudomonas 
aeruginosa 
ND ND 20.75 ND ND VIM 
95 VIM Pseudomonas 
aeruginosa 










Appendix 7: PCR results for the DNA extraction methods  
 
Isolate number Species & carbapenemase Cq values 
Boil method  Automated method 
96 E. coli – VIM 13.89 17.42 
97 P. aeruginosa - VIM 16.82 17.09 
98 Klebsiella pneumoniae- KPC 15.37 15.36 
99 Citrobacter freundii- NDM 12.88 18.94 
100 Escherichia coli- OXA-48 15.29 12.29 
101 Escherichia coli- KPC 18.94 18.06 
102 Escherichia coli- NDM 8.56 17.19 
103 Klebsiella pneumoniae- NDM 15.59 17 
104 Enterobacter cloacae- NDM 11.72 16.88 
105 Acinetobacter baumannii- NDM 15.27 17.56 
106 Enterobacter cloacae- OXA-48 11.84 12.17 
107 Escherichia coli- KPC 16.55 18.16 
108 Escherichia coli- OXA-48 11.32 11.32 
109 Escherichia coli- KPC 17.2 17.44 
110 Escherichia coli- OXA-48 16.06 20.39 
111 Serratia marcescens- OXA-48 12.74 14.81 
112 Pseudomonas putida- VIM 12.17 16.14 
113 Klebsiella pneumoniae- IMP 22.71 24.27 
114 Klebsiella pneumoniae- IMP 22.78 25.36 




  Appendix 8: Number of CPE screens per patient associated with the OXA-48 outbreak 
 
Study 
number Number of screens Dates Organism Result 
1 2 30/10/2017 Negative   
    06/11/2017 Klebsiella pneumoniae  OXA-48 
    06/11/2017 Escherichia coli  OXA-48 
2 2 30/01/2017 Escherichia coli  OXA-48 
    06/02/2017 Escherichia coli  OXA-48 




  Appendix 8: Continued 
    14/06/2017 Negative   
4 2 27/03/2017 Escherichia coli  OXA-48 
    31/03/2017 Klebsiella oxytoca  OXA-48 
5 2 02/04/2017 Escherichia coli  OXA-48 
    08/04/2017 Klebsiella pneumoniae  NDM 
6 9 27/11/2017 Negative   
    04/12/2017 Negative   
    11/12/2017 Negative   
    18/12/2017 Negative   
    02/01/2018 Citrobacter freundii OXA-48 
    09/01/2018 Negative   
    12/02/2018 Negative   
  
  19/02/2018 Negative 
  
    26/02/2018 Negative   
7 5 16/07/2017 Negative   
    23/07/2017 Negative   
  
  14/08/2017 Negative 
  
    21/08/2017 Negative   
    29/08/2017 Enterobacter cloacae  OXA-48 
8 5 13/11/2017 Negative   
  
  20/11/2017 Negative 
  
    27/11/2017 Negative   
  
  04/12/2017 Negative 
  
    11/12/2017 Escherichia coli  OXA-48 
  
  11/12/2017 Enterobacter cloacae  
OXA-48 
9 2 14/11/2016 Escherichia coli  OXA-48 
    03/12/2017 Negative   
10 3 11/08/2017 Negative   
  
  14/08/2017 Negative 
  
    21/08/2017 Escherichia coli  OXA-48 
11 2 07/03/2017 Enterobacter aerogenes  OXA-48 
142 
 
  Appendix 8: Continued 
    13/03/2017 Enterobacter aerogenes  OXA-48 
12 
4 11/08/2017 Negative 
  
    14/08/2017 Negative   
    21/08/2017 Negative   
  
  29/08/2017 Escherichia coli  
OXA-48 
13 3 24/06/2017 Negative   
    25/06/2017 Negative   
    02/07/2017 Klebsiella pneumoniae  OXA-48 
14 3 24/10/2016 Negative   
    14/11/2016 Escherichia coli  OXA-48 
    13/01/2017 Escherichia coli  OXA-48 
15 2 19/09/2016 Escherichia coli  OXA-48 
    26/09/2016 Klebsiella pneumoniae  OXA-48 
16 2 21/11/2016 Escherichia coli  OXA-48 
    21/11/2016 Klebsiella pneumoniae  OXA-48 
    28/11/2016 Escherichia coli  OXA-48 
17 2 20/02/2017 Escherichia coli  OXA-48 
    27/03/2017 Escherichia coli  OXA-48 
    27/03/2017 Klebsiella pneumoniae  OXA-48 
18 6 23/10/2017 Negative   
    23/10/2017 Negative   
    23/10/2017 Negative   
    30/10/2017 Negative   
    06/11/2017 Negative   
    20/11/2017 Escherichia coli  OXA-48 
19 2 15/03/2018 Negative   
    19/03/2018 Escherichia coli  NDM 
20 3 10/06/2016 Negative   
    14/06/2016 Negative   
    11/06/2017 Escherichia coli  OXA-48 
21 4 20/09/2017 Negative   
    25/09/2017 Negative   
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  Appendix 8: Continued 
    02/10/2017 Negative   
    09/10/2017 Enterobacter cloacae  OXA-48 
22 2 10/04/2017 Escherichia coli  OXA-48 
    16/04/2017 Escherichia coli  OXA-48 
23 5 25/06/2017 Negative   
    10/07/2017 Negative   
    16/07/2017 Negative   
    27/08/2017 Negative   
    01/09/2017 Klebsiella pneumoniae  OXA-48 
    01/09/2017 Citrobacter freundii  OXA-48 
24 4 23/07/2017 Negative   
    30/07/2017 Negative   
    14/08/2017 Negative   
    21/08/2017 Klebsiella pneumoniae  OXA-48 
25 6 29/08/2017 Negative   
    08/09/2017 Negative   
    11/09/2017 Enterobacter cloacae  NDM 
    18/09/2017 Negative   
    15/02/2018 Negative   
    19/02/2018 Negative   
26 2 09/01/2017 Escherichia coli  OXA-48 
    28/02/2017 Escherichia coli  OXA-48 
27 2 19/09/2016 Enterobacter cloacae  OXA-48 
    19/09/2016 Escherichia coli  OXA-48 
    26/09/2016 Escherichia coli  OXA-48 
28 3 28/09/2017 Negative   
    02/10/2017 Negative   
    11/10/2017 Escherichia coli  OXA-48 
29 2 13/11/2017 Negative   
    20/11/2017 Klebsiella variicola OXA-48 
30 2 06/02/2017 Escherichia coli  OXA-48 
    22/07/2017 Escherichia coli  NDM 
    22/07/2017 Escherichia coli  
NDM/OXA-
48 
31 4 07/07/2016 Negative   
    13/09/2016 Escherichia coli  OXA-48 
    17/10/2016 Citrobacter species  OXA-48 
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    17/10/2016 Escherichia coli  OXA-48 
    21/11/2016 Escherichia coli  OXA-48 
    21/11/2016 Klebsiella pneumoniae  OXA-48 
32 2 18/09/2017 Negative   
    
31/10/2017 
 Escherichia coli  OXA-48 
33 2 16/04/2017 Escherichia coli  OXA-48 
    23/04/2017 Citrobacter freundii  OXA-48 
    23/04/2017 Escherichia coli  OXA-48 
34 2 20/02/2017 Klebsiella pneumoniae  OXA-48 
    23/03/2017 Escherichia coli  OXA-48 
35 3 23/11/2017 Negative   
    27/11/2017 Negative   
    04/12/2017 Klebsiella variicola OXA-48 
36 2 11/08/2017 Negative   
    13/03/2018 Escherichia coli  OXA-48 
    13/03/2018 Klebsiella pneumoniae  OXA-48 
37 2 16/04/2017 Escherichia coli  OXA-48 
    16/04/2017 Klebsiella pneumoniae  OXA-48 
    30/05/2017 Klebsiella pneumoniae  OXA-48 
38 2 20/03/2017 Escherichia coli  OXA-48 
    27/03/2017 Escherichia coli  OXA-48 
39 2 23/05/2016 Escherichia coli  OXA-48 
    14/06/2016 Enterobacter aerogenes  OXA-48 
40 3 07/12/2017 Klebsiella variicola OXA-48 
    11/12/2017 Negative   
    09/03/2018 Negative   
41 2 11/06/2017 Negative   
    18/06/2017 Escherichia coli  OXA-48 
42 2 16/01/2017 Escherichia coli  OXA-48 
    23/01/2017 Escherichia coli  OXA-48 
43 3 17/09/2017 Negative   
    18/09/2017 Negative   
    25/09/2017 Klebsiella pneumoniae  OXA-48 
    25/09/2017 Escherichia coli  OXA-48 
44 3 07/11/2016 Escherichia coli  OXA-48 
    07/11/2016 Klebsiella pneumoniae  OXA-48 
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    14/11/2016 Escherichia coli  OXA-48 
    14/11/2016 Klebsiella pneumoniae  OXA-48 
    21/11/2016 Escherichia coli  OXA-48 
    21/11/2016 Klebsiella pneumoniae  OXA-48 
45 2 07/11/2016 Escherichia coli  OXA-48 
    21/11/2016 Klebsiella pneumoniae  OXA-48 
46 2 19/09/2016 Escherichia coli  OXA-48 
    26/09/2016 Negative   
47 3 07/11/2016 Escherichia coli  OXA-48 
    07/11/2016 Klebsiella pneumoniae  OXA-48 
    14/11/2016 Escherichia coli  OXA-48 
    14/11/2016 Klebsiella pneumoniae  OXA-48 
    21/11/2016 Escherichia coli  OXA-48 
48 2 05/06/2017 Klebsiella pneumoniae  OXA-48 
    11/06/2017 Negative   
49 2 20/11/2017 Negative  
  18/12/2017 Enterobacter aerogenes OXA-48 
50 2 02/10/2017 Negative  
  09/10/2017 Enterobacter cloacae NDM 
   Escherichia coli NDM 
51 3 24/10/2016 Negative  
  14/11/2016 Escherichia coli OXA-48 
  13/01/2017 Escherichia coli OXA-48 
52 2 01/11/2016 Escherichia coli OXA-48 
  21/11/2016 Escherichia coli OXA-48 
53 2 01/10/2016 Klebsiella pneumoniae OXA-48 
  03/10/2016 Klebsiella pneumoniae OXA-48 
54 2 07/03/2017 Escherichia coli OXA-48 
































Appendix 10: Published paper, A point prevalence study to determine the inpatient rate of carbapenemase-
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